U.S. patent application number 10/146419 was filed with the patent office on 2003-05-08 for novel nucleic acids and polypeptides.
Invention is credited to Asundi, Vinod, Drmanac, Radoje T., Liu, Chenghua, Tang, Y. Tom, Wang, Jian-Rui, Xu, Chongjun, Xue, Aidong J., Zhang, Jie, Zhou, Ping.
Application Number | 20030087370 10/146419 |
Document ID | / |
Family ID | 27066367 |
Filed Date | 2003-05-08 |
United States Patent
Application |
20030087370 |
Kind Code |
A1 |
Tang, Y. Tom ; et
al. |
May 8, 2003 |
Novel nucleic acids and polypeptides
Abstract
The present invention provides novel nucleic acids, novel
polypeptide sequences encoded by these nucleic acids and uses
thereof.
Inventors: |
Tang, Y. Tom; (San Jose,
CA) ; Liu, Chenghua; (San Jose, CA) ; Zhou,
Ping; (San Jose, CA) ; Asundi, Vinod; (Foster
City, CA) ; Zhang, Jie; (Campbell, CA) ; Wang,
Jian-Rui; (Cupertino, CA) ; Xue, Aidong J.;
(Sunnyvale, CA) ; Xu, Chongjun; (San Jose, CA)
; Drmanac, Radoje T.; (Palo Alto, CA) |
Correspondence
Address: |
Petrina S. Hsi
HYSEQ, INC.
670 Almanor Avenue
Sunnyvale
CA
94085
US
|
Family ID: |
27066367 |
Appl. No.: |
10/146419 |
Filed: |
May 15, 2002 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10146419 |
May 15, 2002 |
|
|
|
09668680 |
Sep 22, 2000 |
|
|
|
6436703 |
|
|
|
|
09668680 |
Sep 22, 2000 |
|
|
|
09649167 |
Aug 23, 2000 |
|
|
|
09649167 |
Aug 23, 2000 |
|
|
|
09540217 |
Mar 31, 2000 |
|
|
|
Current U.S.
Class: |
435/69.1 ;
435/183; 435/320.1; 435/325; 530/350; 536/23.2 |
Current CPC
Class: |
A61K 38/00 20130101;
C07K 14/47 20130101; C07K 14/8107 20130101 |
Class at
Publication: |
435/69.1 ;
435/183; 435/320.1; 435/325; 530/350; 536/23.2 |
International
Class: |
C12P 021/02; C12N
005/06; C07K 014/435; C07H 021/04; C12N 009/00 |
Claims
What is claimed is:
1. An isolated polynucleotide comprising a nucleotide sequence
selected from the group consisting of SEQ ID NO: 1-13, a mature
protein coding portion of SEQ ID NO: 1-13, an active domain of SEQ
ID NO: 1-13, and complementary sequences thereof.
2. An isolated polynucleotide encoding a polypeptide with
biological activity, wherein said polynucleotide hybridizes to the
polynucleotide of claim 1 under stringent hybridization
conditions.
3. An isolated polynucleotide encoding a polypeptide with
biological activity, wherein said polynucleotide has greater than
about 90% sequence identity with the polynucleotide of claim 1.
4. The polynucleotide of claim 1 wherein said polynucleotide is
DNA.
5. An isolated polynucleotide of claim 1 wherein said
polynucleotide comprises the complementary sequences.
6. A vector comprising the polynucleotide of claim 1.
7. An expression vector comprising the polynucleotide of claim
1.
8. A host cell genetically engineered to comprise the
polynucleotide of claim 1.
9. A host cell genetically engineered to comprise the
polynucleotide of claim 1 operatively associated with a regulatory
sequence that modulates expression of the polynucleotide in the
host cell.
10. An isolated polypeptide, wherein the polypeptide is selected
from the group consisting of: (a) a polypeptide encoded by any one
of the polynucleotides of claim 1; and (b) a polypeptide encoded by
a polynucleotide hybridizing under stringent conditions with any
one of SEQ ID NO: 1-13.
11. A composition comprising the polypeptide of claim 10 and a
carrier.
12. An antibody directed against the polypeptide of claim 10.
13. A method for detecting the polynucleotide of claim 1 in a
sample, comprising: a) contacting the sample with a compound that
binds to and forms a complex with the polynucleotide of claim 1 for
a period sufficient to form the complex; and b) detecting the
complex, so that if a complex is detected, the polynucleotide of
claim 1 is detected.
14. A method for detecting the polynucleotide of claim 1 in a
sample, comprising: a) contacting the sample under stringent
hybridization conditions with nucleic acid primers that anneal to
the polynucleotide of claim 1 under such conditions; b) amplifying
a product comprising at least a portion of the polynucleotide of
claim 1; and c) detecting said product and thereby the
polynucleotide of claim 1 in the sample.
15. The method of claim 14, wherein the polynucleotide is an RNA
molecule and the method further comprises reverse transcribing an
annealed RNA molecule into a cDNA polynucleotide.
16. A method for detecting the polypeptide of claim 10 in a sample,
comprising: a) contacting the sample with a compound that binds to
and forms a complex with the polypeptide under conditions and for a
period sufficient to form the complex; and b) detecting formation
of the complex, so that if a complex formation is detected, the
polypeptide of claim 10 is detected.
17. A method for identifying a compound that binds to the
polypeptide of claim 10, comprising: a) contacting the compound
with the polypeptide of claim 10 under conditions sufficient to
form a polypeptide/compound complex; and b) detecting the complex,
so that if the polypeptide/compound complex is detected, a compound
that binds to the polypeptide of claim 10 is identified.
18. A method for identifying a compound that binds to the
polypeptide of claim 10, comprising: a) contacting the compound
with the polypeptide of claim 10, in a cell, under conditions
sufficient to form a polypeptide/compound complex, wherein the
complex drives expression of a reporter gene sequence in the cell;
and b) detecting the complex by detecting reporter gene sequence
expression, so that if the polypeptide/compound complex is
detected, a compound that binds to the polypeptide of claim 10 is
identified.
19. A method of producing the polypeptide of claim 10, comprising,
a) culturing a host cell comprising a polynucleotide sequence
selected from the group consisting of a polynucleotide sequence of
SEQ ID NO: 1-13, a mature protein coding portion of SEQ ID NO:
1-13, an active domain of SEQ ID NO: 1-13, complementary sequences
thereof and a polynucleotide sequence hybridizing under stringent
conditions to SEQ ID NO: 1-13, under conditions sufficient to
express the polypeptide in said cell; and b) isolating the
polypeptide from the cell culture or cells of step (a).
20. An isolated polypeptide comprising an amino acid sequence
selected from the group consisting of any one of the polypeptides
from the Sequence Listing, the mature protein portion thereof, or
the active domain thereof.
21. The polypeptide of claim 20 wherein the polypeptide is provided
on a polypeptide array.
22. A collection of polynucleotides, wherein the collection
comprising the sequence information of at least one of SEQ ID NO:
1-13.
23. The collection of claim 22, wherein the collection is provided
on a nucleic acid array.
24. The collection of claim 23, wherein the array detects
full-matches to any one of the polynucleotides in the
collection.
25. The collection of claim 23, wherein the array detects
mismatches to any one of the polynucleotides in the collection.
26. The collection of claim 22, wherein the collection is provided
in a computer-readable format.
27. A method of treatment comprising administering to a mammalian
subject in need thereof a therapeutic amount of a composition
comprising a polypeptide of claim 10 or 20 and a pharmaceutically
acceptable carrier.
28. A method of treatment comprising administering to a mammalian
subject in need thereof a therapeutic amount of a composition
comprising an antibody that specifically binds to a polypeptide of
claim 10 or 20 and a pharmaceutically acceptable carrier.
Description
1. CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part application of
U.S. application Ser. No. 09/649,167, filed Aug. 23, 2000, Attorney
Docket No. 790CIP, which in turn is a continuation-in-part
application of U.S. application Ser. No. 09/540,217, filed Mar. 31,
2000, Attorney Docket No. 790, both of which are incorporated
herein by reference in their entirety.
2. BACKGROUND OF THE INVENTION
[0002] 2.1 Technical Field
[0003] The present invention provides novel polynucleotides and
proteins encoded by such polynucleotides, along with uses for these
polynucleotides and proteins, for example in therapeutic,
diagnostic and research methods.
[0004] 2.2 Background
[0005] Technology aimed at the discovery of protein factors
(including e.g., cytokines, such as lymphokines, interferons, CSFs,
chemokines, and interleukins) has matured rapidly over the past
decade. The now routine hybridization cloning and expression
cloning techniques clone novel polynucleotides "directly" in the
sense that they rely on information directly related to the
discovered protein (i.e., partial DNA/amino acid sequence of the
protein in the case of hybridization cloning; activity of the
protein in the case of expression cloning). More recent "indirect"
cloning techniques such as signal sequence cloning, which isolates
DNA sequences based on the presence of a now well-recognized
secretory leader sequence motif, as well as various PCR-based or
low stringency hybridization-based cloning techniques, have
advanced the state of the art by making available large numbers of
DNA/amino acid sequences for proteins that are known to have
biological activity, for example, by virtue of their secreted
nature in the case of leader sequence cloning, by virtue of their
cell or tissue source in the case of PCR-based techniques, or by
virtue of structural similarity to other genes of known biological
activity.
[0006] Identified polynucleotide and polypeptide sequences have
numerous applications in, for example, diagnostics, forensics, gene
mapping; identification of mutations responsible for genetic
disorders or other traits, to assess biodiversity, and to produce
many other types of data and products dependent on DNA and amino
acid sequences.
3. SUMMARY OF THE INVENTION
[0007] The compositions of the present invention include novel
isolated polypeptides, novel isolated polynucleotides encoding such
polypeptides, including recombinant DNA molecules, cloned genes or
degenerate variants thereof, especially naturally occurring
variants such as allelic variants, antisense polynucleotide
molecules, and antibodies that specifically recognize one or more
epitopes present on such polypeptides, as well as hybridomas
producing such antibodies.
[0008] The compositions of the present invention additionally
include vectors, including expression vectors, containing the
polynucleotides of the invention, cells genetically engineered to
contain such polynucleotides and cells genetically engineered to
express such polynucleotides.
[0009] The present invention relates to a collection or library of
at least one novel nucleic acid sequence assembled from expressed
sequence tags (ESTs) isolated mainly by sequencing by hybridization
(SBH), and in some cases, sequences obtained from one or more
public databases. The invention relates also to the proteins
encoded by such polynucleotides, along with therapeutic, diagnostic
and research utilities for these polynucleotides and proteins.
These nucleic acid sequences are designated as SEQ ID NO: 1-13 and
are provided in the Sequence Listing. In the nucleic acids provided
in the Sequence Listing, A is adenosine; C is cytosine; G is
guanosine; T is thymine; and N is any of the four bases. In the
amino acids provided in the Sequence Listing, * corresponds to the
stop codon.
[0010] The nucleic acid sequences of the present invention also
include, nucleic acid sequences that hybridize to the complement of
SEQ ID NO: 1-13 under stringent hybridization conditions; nucleic
acid sequences which are allelic variants or species homologues of
any of the nucleic acid sequences recited above, or nucleic acid
sequences that encode a peptide comprising a specific domain or
truncation of the peptides encoded by SEQ ID NO: 1-13. A
polynucleotide comprising a nucleotide sequence having at least 90%
identity to an identifying sequence of SEQ ID NO: 1-13 or a
degenerate variant or fragment thereof. The identifying sequence
can be 100 base pairs in length.
[0011] The nucleic acid sequences of the present invention also
include the sequence information from the nucleic acid sequences of
SEQ ID NO: 1-13. The sequence information can be a segment of any
one of SEQ ID NO: 1-13 that uniquely identifies or represents the
sequence information of SEQ ID NO: 1-13.
[0012] A collection as used in this application can be a collection
of only one polynucleotide. The collection of sequence information
or identifying information of each sequence can be provided on a
nucleic acid array. In one embodiment, segments of sequence
information is provided on a nucleic acid array to detect the
polynucleotide that contains the segment. The array can be designed
to detect fill-match or mismatch to the polynucleotide that
contains the segment. The collection can also be provided in a
computer-readable format.
[0013] This invention also includes the reverse or direct
complement of any of the nucleic acid sequences recited above;
cloning or expression vectors containing the nucleic acid
sequences; and host cells or organisms transformed with these
expression vectors. Nucleic acid sequences (or their reverse or
direct complements) according to the invention have numerous
applications in a variety of techniques known to those skilled in
the art of molecular biology, such as use as hybridization probes,
use as primers for PCR, use in an array, use in computer-readable
media, use in sequencing full-length genes, use for chromosome and
gene mapping, use in the recombinant production of protein, and use
in the generation of anti-sense DNA or RNA, their chemical analogs
and the like.
[0014] In a preferred embodiment, the nucleic acid sequences of SEQ
ID NO: 1-13 or novel segments or parts of the nucleic acids of the
invention are used as primers in expression assays that are well
known in the art. In a particularly preferred embodiment, the
nucleic acid sequences of SEQ ID NO: 1-13 or novel segments or
parts of the nucleic acids provided herein are used in diagnostics
for identifying expressed genes or, as well known in the art and
exemplified by Vollrath et al., Science 258:52-59 (1992), as
expressed sequence tags for physical mapping of the human
genome.
[0015] The isolated polynucleotides of the invention include, but
are not limited to, a polynucleotide comprising any one of the
nucleotide sequences set forth in SEQ ID NO: 1-13; a polynucleotide
comprising any of the full length protein coding sequences of SEQ
ID NO: 1-13; and a polynucleotide comprising any of the nucleotide
sequences of the mature protein coding sequences of SEQ ID NO:
1-13. The polynucleotides of the present invention also include,
but are not limited to, a polynucleotide that hybridizes under
stringent hybridization conditions to (a) the complement of any one
of the nucleotide sequences set forth in SEQ ID NO: 1-13; (b) a
nucleotide sequence encoding any one of the amino acid sequences
set forth in the Sequence Listing; (c) a polynucleotide which is an
allelic variant of any polynucleotides recited above; (d) a
polynucleotide which encodes a species homolog (e.g. orthologs) of
any of the proteins recited above; or (e) a polynucleotide that
encodes a polypeptide comprising a specific domain or truncation of
any of the polypeptides comprising an amino acid sequence set forth
in the Sequence Listing.
[0016] The isolated polypeptides of the invention include, but are
not limited to, a polypeptide comprising any of the amino acid
sequences set forth in the Sequence Listing; or the corresponding
full length or mature protein. Polypeptides of the invention also
include polypeptides with biological activity that are encoded by
(a) any of the polynucleotides having a nucleotide sequence set
forth in SEQ ID NO: 1-13; or (b) polynucleotides that hybridize to
the complement of the polynucleotides of (a) under stringent
hybridization conditions. Biologically or immunologically active
variants of any of the polypeptide sequences in the Sequence
Listing, and "substantial equivalents" thereof (e.g., with at least
about 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% amino acid
sequence identity) that preferably retain biological activity are
also contemplated. The polypeptides of the invention may be wholly
or partially chemically synthesized but are preferably produced by
recombinant means using the genetically engineered cells (e.g. host
cells) of the invention.
[0017] The invention also provides compositions comprising a
polypeptide of the invention. Polypeptide compositions of the
invention may further comprise an acceptable carrier, such as a
hydrophilic, e.g., pharmaceutically acceptable, carrier.
[0018] The invention also provides host cells transformed or
transfected with a polynucleotide of the invention.
[0019] The invention also relates to methods for producing a
polypeptide of the invention comprising growing a culture of the
host cells of the invention in a suitable culture medium under
conditions permitting expression of the desired polypeptide, and
purifying the polypeptide from the culture or from the host cells.
Preferred embodiments include those in which the protein produced
by such process is a mature form of the protein.
[0020] Polynucleotides according to the invention have numerous
applications in a variety of techniques known to those skilled in
the art of molecular biology. These techniques include use as
hybridization probes, use as oligomers, or primers, for PCR, use
for chromosome and gene mapping, use in the recombinant production
of protein, and use in generation of anti-sense DNA or RNA, their
chemical analogs and the like. For example, when the expression of
an mRNA is largely restricted to a particular cell or tissue type,
polynucleotides of the invention can be used as hybridization
probes to detect the presence of the particular cell or tissue mRNA
in a sample using, e.g., in situ hybridization.
[0021] In other exemplary embodiments, the polynucleotides are used
in diagnostics as expressed sequence tags for identifying expressed
genes or, as well known in the art and exemplified by Vollrath et
al., Science 258:52-59 (1992), as expressed sequence tags for
physical mapping of the human genome.
[0022] The polypeptides according to the invention can be used in a
variety of conventional procedures and methods that are currently
applied to other proteins. For example, a polypeptide of the
invention can be used to generate an antibody that specifically
binds the polypeptide. Such antibodies, particularly monoclonal
antibodies, are useful for detecting or quantitating the
polypeptide in tissue. The polypeptides of the invention can also
be used as molecular weight markers, and as a food supplement.
[0023] Methods are also provided for preventing, treating, or
ameliorating a medical condition which comprises the step of
administering to a mammalian subject a therapeutically effective
amount of a composition comprising a polypeptide of the present
invention and a pharmaceutically acceptable carrier.
[0024] In particular, the polypeptides and polynucleotides of the
invention can be utilized, for example, in methods for the
prevention and/or treatment of disorders involving aberrant protein
expression or biological activity.
[0025] The present invention further relates to methods for
detecting the presence of the polynucleotides or polypeptides of
the invention in a sample. Such methods can, for example, be
utilized as part of prognostic and diagnostic evaluation of
disorders as recited herein and for the identification of subjects
exhibiting a predisposition to such conditions. The invention
provides a method for detecting the polynucleotides of the
invention in a sample, comprising contacting the sample with a
compound that binds to and forms a complex with the polynucleotide
of interest for a period sufficient to form the complex and under
conditions sufficient to form a complex and detecting the complex
such that if a complex is detected, the polynucleotide of interest
is detected. The invention also provides a method for detecting the
polypeptides of the invention in a sample comprising contacting the
sample with a compound that binds to and forms a complex with the
polypeptide under conditions and for a period sufficient to form
the complex and detecting the formation of the complex such that if
a complex is formed, the polypeptide is detected.
[0026] The invention also provides kits comprising polynucleotide
probes and/or monoclonal antibodies, and optionally quantitative
standards, for carrying out methods of the invention. Furthermore,
the invention provides methods for evaluating the efficacy of
drugs, and monitoring the progress of patients, involved in
clinical trials for the treatment of disorders as recited
above.
[0027] The invention also provides methods for the identification
of compounds that modulate (i.e., increase or decrease) the
expression or activity of the polynucleotides and/or polypeptides
of the invention. Such methods can be utilized, for example, for
the identification of compounds that can ameliorate symptoms of
disorders as recited herein. Such methods can include, but are not
limited to, assays for identifying compounds and other substances
that interact with (e.g., bind to) the polypeptides of the
invention. The invention provides a method for identifying a
compound that binds to the polypeptides of the invention comprising
contacting the compound with a polypeptide of the invention in a
cell for a time sufficient to form a polypeptide/compound complex,
wherein the complex drives expression of a reporter gene sequence
in the cell; and detecting the complex by detecting the reporter
gene sequence expression such that if expression of the reporter
gene is detected the compound the binds to a polypeptide of the
invention is identified.
[0028] The methods of the invention also provides methods for
treatment which involve the administration of the polynucleotides
or polypeptides of the invention to individuals exhibiting symptoms
or tendencies. In addition, the invention encompasses methods for
treating diseases or disorders as recited herein comprising
administering compounds and other substances that modulate the
overall activity of the target gene products. Compounds and other
substances can effect such modulation either on the level of target
gene/protein expression or target protein activity.
[0029] The polypeptides of the present invention and the
polynucleotides encoding them are also useful for the same
functions known to one of skill in the art as the polypeptides and
polynucleotides to which they have homology (set forth in Table 1);
for which they have a signature region (as set forth in Table 3);
or for which they have homology to a gene family (as set forth in
Table 4). If no homology is set forth for a sequence, then the
polypeptides and polynucleotides of the present invention are
useful for a variety of applications, as described herein,
including use in arrays for detection.
4. DETAILED DESCRIPTION OF THE INVENTION
[0030] 4.1 Definitions
[0031] It must be noted that as used herein and in the appended
claims, the singular forms "a", "an" and "the" include plural
references unless the context clearly dictates otherwise.
[0032] The term "active" refers to those forms of the polypeptide
which retain the biologic and/or immunologic activities of any
naturally occurring polypeptide. According to the invention, the
terms "biologically active" or "biological activity" refer to a
protein or peptide having structural, regulatory or biochemical
functions of a naturally occurring molecule. Likewise
"immunologically active" or "immunological activity" refers to the
capability of the natural, recombinant or synthetic polypeptide to
induce a specific immune response in appropriate animals or cells
and to bind with specific antibodies.
[0033] The term "activated cells" as used in this application are
those cells which are engaged in extracellular or intracellular
membrane trafficking, including the export of secretory or
enzymatic molecules as part of a normal or disease process.
[0034] The terms "complementary" or "complementarity" refer to the
natural binding of polynucleotides by base pairing. For example,
the sequence 5'-AGT-3' binds to the complementary sequence
3'-TCA-5'. Complementarity between two single-stranded molecules
may be "partial" such that only some of the nucleic acids bind or
it may be "complete" such that total complementarity exists between
the single stranded molecules. The degree of complementarity
between the nucleic acid strands has significant effects on the
efficiency and strength of the hybridization between the nucleic
acid strands.
[0035] The term "embryonic stem cells (ES)" refers to a cell that
can give rise to many differentiated cell types in an embryo or an
adult, including the germ cells. The term "germ line stem cells
(GSCs)" refers to stem cells derived from primordial stem cells
that provide a steady and continuous source of germ cells for the
production of gametes. The term "primordial germ cells (PGCs)"
refers to a small population of cells set aside from other cell
lineages particularly from the yolk sac, mesenteries, or gonadal
ridges during embryogenesis that have the potential to
differentiate into germ cells and other cells. PGCs are the source
from which GSCs and ES cells are derived The PGCs, the GSCs and the
ES cells are capable of self-renewal. Thus these cells not only
populate the germ line and give rise to a plurality of terminally
differentiated cells that comprise the adult specialized organs,
but are able to regenerate themselves.
[0036] The term "expression modulating fragment," EMF, means a
series of nucleotides which modulates the expression of an operably
linked ORF or another EMF.
[0037] As used herein, a sequence is said to "modulate the
expression of an operably linked sequence" when the expression of
the sequence is altered by the presence of the EMF. EMFs include,
but are not limited to, promoters, and promoter modulating
sequences (inducible elements). One class of EMFs are nucleic acid
fragments which induce the expression of an operably linked ORF in
response to a specific regulatory factor or physiological
event.
[0038] The terms "nucleotide sequence" or "nucleic acid" or
"polynucleotide" or "oligonculeotide" are used interchangeably and
refer to a heteropolymer of nucleotides or the sequence of these
nucleotides. These phrases also refer to DNA or RNA of genomic or
synthetic origin which may be single-stranded or double-stranded
and may represent the sense or the antisense strand, to peptide
nucleic acid (PNA) or to any DNA-like or RNA-like material. It is
contemplated that where the polynucleotide is RNA, the T (thymine)
in the sequences provided herein is substituted with U (uracil).
Generally, nucleic acid segments provided by this invention may be
assembled from fragments of the genome and short oligonucleotide
linkers, or from a series of oligonucleotides, or from individual
nucleotides, to provide a synthetic nucleic acid which is capable
of being expressed in a recombinant transcriptional unit comprising
regulatory elements derived from a microbial or viral operon, or a
eukaryotic gene.
[0039] The terms "oligonucleotide fragment" or a "polynucleotide
fragment", "portion," or "segment" or "probe" or "primer" are used
interchangeable and refer to a sequence of nucleotide residues
which are at least about 5 nucleotides, more preferably at least
about 7 nucleotides, more preferably at least about 9 nucleotides,
more preferably at least about 11 nucleotides and most preferably
at least about 17 nucleotides. The fragment is preferably less than
about 500 nucleotides, preferably less than about 200 nucleotides,
more preferably less than about 100 nucleotides, more preferably
less than about 50 nucleotides and most preferably less than 30
nucleotides. Preferably the probe is from about 6 nucleotides to
about 200 nucleotides, preferably from about 15 to about 50
nucleotides, more preferably from about 17 to 30 nucleotides and
most preferably from about 20 to 25 nucleotides. Preferably the
fragments can be used in polymerase chain reaction (PCR), various
hybridization procedures or microarray procedures to identify or
amplify identical or related parts of mRNA or DNA molecules. A
fragment or segment may uniquely identify each polynucleotide
sequence of the present invention. Preferably the fragment
comprises a sequence substantially similar to any one of SEQ ID
NOs:1-13.
[0040] Probes may, for example, be used to determine whether
specific mRNA molecules are present in a cell or tissue or to
isolate similar nucleic acid sequences from chromosomal DNA as
described by Walsh et al. (Walsh, P. S. et al., 1992, PCR Methods
Appl 1:241-250). They may be labeled by nick translation, Klenow
fill-in reaction, PCR, or other methods well known in the art.
Probes of the present invention, their preparation and/or labeling
are elaborated in Sambrook, J. et al., 1989, Molecular Cloning: A
Laboratory Manual, Cold Spring Harbor Laboratory, NY; or Ausubel,
F. M. et al., 1989, Current Protocols in Molecular Biology, John
Wiley & Sons, New York N.Y., both of which are incorporated
herein by reference in their entirety.
[0041] The nucleic acid sequences of the present invention also
include the sequence information from the nucleic acid sequences of
SEQ ID NOs: 1-13. The sequence information can be a segment of any
one of SEQ ID NOs: 1-13 that uniquely identifies or represents the
sequence information of that sequence of SEQ ID NO: 1-13. One such
segment can be a twenty-mer nucleic acid sequence because the
probability that a twenty-mer is fully matched in the human genome
is 1 in 300. In the human genome, there are three billion base
pairs in one set of chromosomes. Because 4.sup.20 possible
twenty-mers exist, there are 300 times more twenty-mers than there
are base pairs in a set of human chromosome. Using the same
analysis, the probability for a seventeen-mer to be fully matched
in the human genome is approximately 1 in 5. When these segments
are used in arrays for expression studies, fifteen-mer segments can
be used. The probability that the fifteen-mer is fully matched in
the expressed sequences is also approximately one in five because
expressed sequences comprise less than approximately 5% of the
entire genome sequence.
[0042] Similarly, when using sequence information for detecting a
single mismatch, a segment can be a twenty-five mer. The
probability that the twenty-five mer would appear in a human genome
with a single mismatch is calculated by multiplying the probability
for a full match (1.div.4.sup.25) times the increased probability
for mismatch at each nucleotide position (3.times.25). The
probability that an eighteen mer with a single mismatch can be
detected in an array for expression studies is approximately one in
five. The probability that a twenty-mer with a single mismatch can
be detected in a human genome is approximately one in five.
[0043] The term "open reading frame," ORF, means a series of
nucleotide triplets coding for amino acids without any termination
codons and is a sequence translatable into protein.
[0044] The terms "operably linked" or "operably associated" refer
to functionally related nucleic acid sequences. For example, a
promoter is operably associated or operably linked with a coding
sequence if the promoter controls the transcription of the coding
sequence. While operably linked nucleic acid sequences can be
contiguous and in the same reading frame, certain genetic elements
e.g. repressor genes are not contiguously linked to the coding
sequence but still control transcription/translation of the coding
sequence.
[0045] The term "pluripotent" refers to the capability of a cell to
differentiate into a number of differentiated cell types that are
present in an adult organism. A pluripotent cell is restricted in
its differentiation capability in comparison to a totipotent
cell.
[0046] The terms "polypeptide" or "peptide" or "amino acid
sequence" refer to an oligopeptide, peptide, polypeptide or protein
sequence or fragment thereof and to naturally occurring or
synthetic molecules. A polypeptide "fragment," "portion," or
"segment" is a stretch of amino acid residues of at least about 5
amino acids, preferably at least about 7 amino acids, more
preferably at least about 9 amino acids and most preferably at
least about 17 or more amino acids. The peptide preferably is not
greater than about 200 amino acids, more preferably less than 150
amino acids and most preferably less than 100 amino acids.
Preferably the peptide is from about 5 to about 200 amino acids. To
be active, any polypeptide must have sufficient length to display
biological and/or immunological activity.
[0047] The term "naturally occurring polypeptide" refers to
polypeptides produced by cells that have not been genetically
engineered and specifically contemplates various polypeptides
arising from post-translational modifications of the polypeptide
including, but not limited to, acetylation, carboxylation,
glycosylation, phosphorylation, lipidation and acylation.
[0048] The term "translated protein coding portion" means a
sequence which encodes for the full length protein which may
include any leader sequence or any processing sequence.
[0049] The term "mature protein coding sequence" means a sequence
which encodes a peptide or protein without a signal or leader
sequence. The peptide may have been produced by processing in the
cell which removes any leader/signal sequence. The peptide may be
produced synthetically or the protein may have been produced using
a polynucleotide only encoding for the mature protein coding
sequence.
[0050] The term "derivative" refers to polypeptides chemically
modified by such techniques as ubiquitination, labeling (e.g., with
radionuclides or various enzymes), covalent polymer attachment such
as pegylation (derivatization with polyethylene glycol) and
insertion or substitution by chemical synthesis of amino acids such
as omithine, which do not normally occur in human proteins.
[0051] The term "variant"(or "analog") refers to any polypeptide
differing from naturally occurring polypeptides by amino acid
insertions, deletions, and substitutions, created using, e g.,
recombinant DNA techniques. Guidance in determining which amino
acid residues may be replaced, added or deleted without abolishing
activities of interest, may be found by comparing the sequence of
the particular polypeptide with that of homologous peptides and
minimizing the number of amino acid sequence changes made in
regions of high homology (conserved regions) or by replacing amino
acids with consensus sequence.
[0052] Alternatively, recombinant variants encoding these same or
similar polypeptides may be synthesized or selected by making use
of the "redundancy" in the genetic code. Various codon
substitutions, such as the silent changes which produce various
restriction sites, may be introduced to optimize cloning into a
plasmid or viral vector or expression in a particular prokaryotic
or eukaryotic system. Mutations in the polynucleotide sequence may
be reflected in the polypeptide or domains of other peptides added
to the polypeptide to modify the properties of any part of the
polypeptide, to change characteristics such as ligand-binding
affinities, interchain affinities, or degradation/turnover
rate.
[0053] Preferably, amino acid "substitutions" are the result of
replacing one amino acid with another amino acid having similar
structural and/or chemical properties, i.e., conservative amino
acid replacements. "Conservative" amino acid substitutions may be
made on the basis of similarity in polarity, charge, solubility,
hydrophobicity, hydrophilicity, and/or the amphipathic nature of
the residues involved. For example, nonpolar (hydrophobic) amino
acids include alanine, leucine, isoleucine, valine, proline,
phenylalanine, tryptophan, and methionine; polar neutral amino
acids include glycine, serine, threonine, cysteine, tyrosine,
asparagine, and glutamine; positively charged (basic) amino acids
include arginine, lysine, and histidine; and negatively charged
(acidic) amino acids include aspartic acid and glutamic acid.
"Insertions" or "deletions" are preferably in the range of about 1
to 20 amino acids, more preferably 1 to 10 amino acids. The
variation allowed may be experimentally determined by
systematically making insertions, deletions, or substitutions of
amino acids in a polypeptide molecule using recombinant DNA
techniques and assaying the resulting recombinant variants for
activity.
[0054] Alternatively, where alteration of function is desired,
insertions, deletions or non-conservative alterations can be
engineered to produce altered polypeptides. Such alterations can,
for example, alter one or more of the biological functions or
biochemical characteristics of the polypeptides of the invention.
For example, such alterations may change polypeptide
characteristics such as ligand-binding affinities, interchain
affinities, or degradation/turnover rate. Further, such alterations
can be selected so as to generate polypeptides that are better
suited for expression, scale up and the like in the host cells
chosen for expression. For example, cysteine residues can be
deleted or substituted with another amino acid residue in order to
eliminate disulfide bridges.
[0055] The terms "purified" or "substantially purified" as used
herein denotes that the indicated nucleic acid or polypeptide is
present in the substantial absence of other biological
macromolecules, e.g., polynucleotides, proteins, and the like. In
one embodiment, the polynucleotide or polypeptide is purified such
that it constitutes at least 95% by weight, more preferably at
least 99% by weight, of the indicated biological macromolecules
present (but water, buffers, and other small molecules, especially
molecules having a molecular weight of less than 1000 daltons, can
be present).
[0056] The term "isolated" as used herein refers to a nucleic acid
or polypeptide separated from at least one other component (e.g.,
nucleic acid or polypeptide) present with the nucleic acid or
polypeptide in its natural source. In one embodiment, the nucleic
acid or polypeptide is found in the presence of (if anything) only
a solvent, buffer, ion, or other component normally present in a
solution of the same. The terms "isolated" and "purified" do not
encompass nucleic acids or polypeptides present in their natural
source.
[0057] The term "recombinant," when used herein to refer to a
polypeptide or protein, means that a polypeptide or protein is
derived from recombinant (e.g., microbial, insect, or mammalian)
expression systems. "Microbial" refers to recombinant polypeptides
or proteins made in bacterial or fungal (e.g., yeast) expression
systems. As a product, "recombinant microbial" defines a
polypeptide or protein essentially free of native endogenous
substances and unaccompanied by associated native glycosylation.
Polypeptides or proteins expressed in most bacterial cultures,
e.g., E. coli, will be free of glycosylation modifications;
polypeptides or proteins expressed in yeast will have a
glycosylation pattern in general different from those expressed in
mammalian cells.
[0058] The term "recombinant expression vehicle or vector" refers
to a plasmid or phage or virus or vector, for expressing a
polypeptide from a DNA (RNA) sequence. An expression vehicle can
comprise a transcriptional unit comprising an assembly of (1) a
genetic element or elements having a regulatory role in gene
expression, for example, promoters or enhancers, (2) a structural
or coding sequence which is transcribed into mRNA and translated
into protein, and (3) appropriate transcription initiation and
termination sequences. Structural units intended for use in yeast
or eukaryotic expression systems preferably include a leader
sequence enabling extracellular secretion of translated protein by
a host cell. Alternatively, where recombinant protein is expressed
without a leader or transport sequence, it may include an amino
terminal methionine residue. This residue may or may not be
subsequently cleaved from the expressed recombinant protein to
provide a final product.
[0059] The term "recombinant expression system" means host cells
which have stably integrated a recombinant transcriptional unit
into chromosomal DNA or carry the recombinant transcriptional unit
extrachromosomally. Recombinant expression systems as defined
herein will express heterologous polypeptides or proteins upon
induction of the regulatory elements linked to the DNA segment or
synthetic gene to be expressed. This term also means host cells
which have stably integrated a recombinant genetic element or
elements having a regulatory role in gene expression, for example,
promoters or enhancers. Recombinant expression systems as defined
herein will express polypeptides or proteins endogenous to the cell
upon induction of the regulatory elements linked to the endogenous
DNA segment or gene to be expressed. The cells can be prokaryotic
or eukaryotic.
[0060] The term "secreted" includes a protein that is transported
across or through a membrane, including transport as a result of
signal sequences in its amino acid sequence when it is expressed in
a suitable host cell. "Secreted" proteins include without
limitation proteins secreted wholly (e.g., soluble proteins) or
partially (e.g., receptors) from the cell in which they are
expressed. "Secreted" proteins also include without limitation
proteins that are transported across the membrane of the
endoplasmic reticulum. "Secreted" proteins are also intended to
include proteins containing non-typical signal sequences (e.g.
Interleukin-1 Beta, see Krasney, P. A. and Young, P. R. (1992)
Cytokine 4(2):134-143) and factors released from damaged cells
(e.g. Interleukin-1 Receptor Antagonist, see Arend, W. P. et. al.
(1998) Annu. Rev. Immunol. 16:27-55)
[0061] Where desired, an expression vector may be designed to
contain a "signal or leader sequence" which will direct the
polypeptide through the membrane of a cell. Such a sequence may be
naturally present on the polypeptides of the present invention or
provided from heterologous protein sources by recombinant DNA
techniques.
[0062] The term "stringent" is used to refer to conditions that are
commonly understood in the art as stringent. Stringent conditions
can include highly stringent conditions (i.e., hybridization to
filter-bound DNA in 0.5 M NaHPO.sub.4, 7% sodium dodecyl sulfate
(SDS), 1 mM EDTA at 65.degree. C., and washing in
0.1.times.SSC/0.1% SDS at 68.degree. C.), and moderately stringent
conditions (i.e., washing in 0.2.times.SSC/0.1% SDS at 42.degree.
C.). Other exemplary hybridization conditions are described herein
in the examples.
[0063] In instances of hybridization of deoxyoligonucleotides,
additional exemplary stringent hybridization conditions include
washing in 6.times.SSC/0.05% sodium pyrophosphate at 37.degree. C.
(for 14-base oligonucleotides), 48.degree. C. (for 17-base oligos),
55.degree. C. (for 20-base oligonucleotides), and 60.degree. C.
(for 23-base oligonucleotides).
[0064] As used herein, "substantially equivalent" can refer both to
nucleotide and amino acid sequences, for example a mutant sequence,
that varies from a reference sequence by one or more substitutions,
deletions, or additions, the net effect of which does not result in
an adverse functional dissimilarity between the reference and
subject sequences. Typically, such a substantially equivalent
sequence varies from one of those listed herein by no more than
about 35% (i.e., the number of individual residue substitutions,
additions, and/or deletions in a substantially equivalent sequence,
as compared to the corresponding reference sequence, divided by the
total number of residues in the substantially equivalent sequence
is about 0.35 or less). Such a sequence is said to have 65%
sequence identity to the listed sequence. In one embodiment, a
substantially equivalent, e.g., mutant, sequence of the invention
varies from a listed sequence by no more than 30% (70% sequence
identity); in a variation of this embodiment, by no more than 25%
(75% sequence identity); and in a further variation of this
embodiment, by no more than 20% (80% sequence identity) and in a
further variation of this embodiment, by no more than 10% (90%
sequence identity) and in a further variation of this embodiment,
by no more that 5% (95% sequence identity). Substantially
equivalent, e.g., mutant, amino acid sequences according to the
invention preferably have at least 80% sequence identity with a
listed amino acid sequence, more preferably at least 90% sequence
identity. Substantially equivalent nucleotide sequences of the
invention can have lower percent sequence identities, taking into
account, for example, the redundancy or degeneracy of the genetic
code. Preferably, nucleotide sequence has at least about 65%
identity, more preferably at least about 75% identity, and most
preferably at least about 95% identity. For the purposes of the
present invention, sequences having substantially equivalent
biological activity and substantially equivalent expression
characteristics are considered substantially equivalent. For the
purposes of determining equivalence, truncation of the mature
sequence (e.g., via a mutation which creates a spurious stop codon)
should be disregarded. Sequence identity may be determined, e.g.,
using the Jotun Hein method (Hein, J. (1990) Methods Enzymol.
183:626-645). Identity between sequences can also be determined by
other methods known in the art, e.g. by varying hybridization
conditions.
[0065] The term "totipotent" refers to the capability of a cell to
differentiate into all of the cell types of an adult organism.
[0066] The term "transformation" means introducing DNA into a
suitable host cell so that the DNA is replicable, either as an
extrachromosomal element, or by chromosomal integration. The term
"transfection" refers to the taking up of an expression vector by a
suitable host cell, whether or not any coding sequences are in fact
expressed. The term "infection" refers to the introduction of
nucleic acids into a suitable host cell by use of a virus or viral
vector.
[0067] As used herein, an "uptake modulating fragment," UMF, means
a series of nucleotides which mediate the uptake of a linked DNA
fragment into a cell. UMFs can be readily identified using known
UMFs as a target sequence or target motif with the computer-based
systems described below. The presence and activity of a UMF can be
confirmed by attaching the suspected UMF to a marker sequence. The
resulting nucleic acid molecule is then incubated with an
appropriate host under appropriate conditions and the uptake of the
marker sequence is determined. As described above, a UMF will
increase the frequency of uptake of a linked marker sequence.
[0068] Each of the above terms is meant to encompass all that is
described for each, unless the context dictates otherwise.
[0069] 4.2 Nucleic Acids of the Invention
[0070] Nucleotide sequences of the invention are set forth in the
Sequence Listing.
[0071] The isolated polynucleotides of the invention include a
polynucleotide comprising the nucleotide sequences of SEQ ID NO:
1-13; a polynucleotide encoding any one of the peptide sequences of
SEQ ID NO:1-13; and a polynucleotide comprising the nucleotide
sequence encoding the mature protein coding sequence of the
polynucleotides of any one of SEQ ID NO: 1-13. The polynucleotides
of the present invention also include, but are not limited to, a
polynucleotide that hybridizes under stringent conditions to (a)
the complement of any of the nucleotides sequences of SEQ ID NO:
1-13; (b) nucleotide sequences encoding any one of the amino acid
sequences set forth in the Sequence Listing; (c) a polynucleotide
which is an allelic variant of any polynucleotide recited above;
(d) a polynucleotide which encodes a species homolog of any of the
proteins recited above; or (e) a polynucleotide that encodes a
polypeptide comprising a specific domain or truncation of the
polypeptides of SEQ ID NO: 1-13. Domains of interest may depend on
the nature of the encoded polypeptide; e.g., domains in
receptor-like polypeptides include ligand-binding, extracellular,
transmembrane, or cytoplasmic domains, or combinations thereof;
domains in immunoglobulin-like proteins include the variable
immunoglobulin-like domains; domains in enzyme-like polypeptides
include catalytic and substrate binding domains; and domains in
ligand polypeptides include receptor-binding domains.
[0072] The polynucleotides of the invention include naturally
occurring or wholly or partially synthetic DNA, e.g., cDNA and
genomic DNA, and RNA, e.g., mRNA. The polynucleotides may include
all of the coding region of the cDNA or may represent a portion of
the coding region of the cDNA.
[0073] The present invention also provides genes corresponding to
the cDNA sequences disclosed herein. The corresponding genes can be
isolated in accordance with known methods using the sequence
information disclosed herein. Such methods include the preparation
of probes or primers from the disclosed sequence information for
identification and/or amplification of genes in appropriate genomic
libraries or other sources of genomic materials. Further 5' and 3'
sequence can be obtained using methods known in the art. For
example, full length cDNA or genomic DNA that corresponds to any of
the polynucleotides of SEQ ID NO: 1-13 can be obtained by screening
appropriate cDNA or genomic DNA libraries under suitable
hybridization conditions using any of the polynucleotides of SEQ ID
NO: 1-13 or a portion thereof as a probe. Alternatively, the
polynucleotides of SEQ ID NO: 1-13 may be used as the basis for
suitable primer(s) that allow identification and/or amplification
of genes in appropriate genomic DNA or cDNA libraries.
[0074] The nucleic acid sequences of the invention can be assembled
from ESTs and sequences (including cDNA and genomic sequences)
obtained from one or more public databases, such as dbEST, gbpri,
and UniGene. The EST sequences can provide identifying sequence
information, representative fragment or segment information, or
novel segment information for the full-length gene.
[0075] The polynucleotides of the invention also provide
polynucleotides including nucleotide sequences that are
substantially equivalent to the polynucleotides recited above.
Polynucleotides according to the invention can have, e.g., at least
about 65%, at least about 70%, at least about 75%, at least about
80%, more typically at least about 90%, and even more typically at
least about 95%, sequence identity to a polynucleotide recited
above.
[0076] Included within the scope of the nucleic acid sequences of
the invention are nucleic acid sequence fragments that hybridize
under stringent conditions to any of the nucleotide sequences of
SEQ ID NO: 1-13, or complements thereof, which fragment is greater
than about 5 nucleotides, preferably 7 nucleotides, more preferably
greater than 9 nucleotides and most preferably greater than 17
nucleotides. Fragments of, e.g. 15, 17, or 20 nucleotides or more
that are selective for (i.e. specifically hybridize to any one of
the polynucleotides of the invention) are contemplated. Probes
capable of specifically hybridizing to a polynucleotide can
differentiate polynucleotide sequences of the invention from other
polynucleotide sequences in the same family of genes or can
differentiate human genes from genes of other species, and are
preferably based on unique nucleotide sequences.
[0077] The sequences falling within the scope of the present
invention are not limited to these specific sequences, but also
include allelic and species variations thereof. Allelic and species
variations can be routinely determined by comparing the sequence
provided in SEQ ID NO: 1-13, a representative fragment thereof, or
a nucleotide sequence at least 90% identical, preferably 95%
identical, to SEQ ID NOs: 1-13 with a sequence from another isolate
of the same species. Furthermore, to accommodate codon variability,
the invention includes nucleic acid molecules coding for the same
amino acid sequences as do the specific ORFs disclosed herein. In
other words, in the coding region of an ORF, substitution of one
codon for another codon that encodes the same amino acid is
expressly contemplated.
[0078] The nearest neighbor or homology result for the nucleic
acids of the present invention, including SEQ ID NOs: 1-13, can be
obtained by searching a database using an algorithm or a program.
Preferably, a BLAST which stands for Basic Local Alignment Search
Tool is used to search for local sequence alignments (Altshul, S.
F. J Mol. Evol. 36 290-300 (1993) and Altschul S. F. et al. J. Mol.
Biol. 21:403-410 (1990)). Alternatively a FASTA version 3 search
against Genpept, using Fastxy algorithm.
[0079] Species homologs (or orthologs) of the disclosed
polynucleotides and proteins are also provided by the present
invention. Species homologs may be isolated and identified by
making suitable probes or primers from the sequences provided
herein and screening a suitable nucleic acid source from the
desired species.
[0080] The invention also encompasses allelic variants of the
disclosed polynucleotides or proteins; that is, naturally-occurring
alternative forms of the isolated polynucleotide which also encode
proteins which are identical, homologous or related to that encoded
by the polynucleotides.
[0081] The nucleic acid sequences of the invention are further
directed to sequences which encode variants of the described
nucleic acids. These amino acid sequence variants may be prepared
by methods known in the art by introducing appropriate nucleotide
changes into a native or variant polynucleotide. There are two
variables in the construction of amino acid sequence variants: the
location of the mutation and the nature of the mutation. Nucleic
acids encoding the amino acid sequence variants are preferably
constructed by mutating the polynucleotide to encode an amino acid
sequence that does not occur in nature. These nucleic acid
alterations can be made at sites that differ in the nucleic acids
from different species (variable positions) or in highly conserved
regions (constant regions). Sites at such locations will typically
be modified in series, e.g., by substituting first with
conservative choices (e.g., hydrophobic amino acid to a different
hydrophobic amino acid) and then with more distant choices (e.g.,
hydrophobic amino acid to a charged amino acid), and then deletions
or insertions may be made at the target site. Amino acid sequence
deletions generally range from about 1 to 30 residues, preferably
about 1 to 10 residues, and are typically contiguous. Amino acid
insertions include amino- and/or carboxyl-terminal fusions ranging
in length from one to one hundred or more residues, as well as
intrasequence insertions of single or multiple amino acid residues.
Intrasequence insertions may range generally from about 1 to 10
amino residues, preferably from 1 to 5 residues. Examples of
terminal insertions include the heterologous signal sequences
necessary for secretion or for intracellular targeting in different
host cells and sequences such as FLAG or poly-histidine sequences
useful for purifying the expressed protein.
[0082] In a preferred method, polynucleotides encoding the novel
amino acid sequences are changed via site-directed mutagenesis.
This method uses oligonucleotide sequences to alter a
polynucleotide to encode the desired amino acid variant, as well as
sufficient adjacent nucleotides on both sides of the changed amino
acid to form a stable duplex on either side of the site of being
changed. In general, the techniques of site-directed mutagenesis
are well known to those of skill in the art and this technique is
exemplified by publications such as, Edelman et al., DNA 2:183
(1983). A versatile and efficient method for producing
site-specific changes in a polynucleotide sequence was published by
Zoller and Smith, Nucleic Acids Res. 10:6487-6500 (1982). PCR may
also be used to create amino acid sequence variants of the novel
nucleic acids. When small amounts of template DNA are used as
starting material, primer(s) that differs slightly in sequence from
the corresponding region in the template DNA can generate the
desired amino acid variant. PCR amplification results in a
population of product DNA fragments that differ from the
polynucleotide template encoding the polypeptide at the position
specified by the primer. The product DNA fragments replace the
corresponding region in the plasmid and this gives a polynucleotide
encoding the desired amino acid variant.
[0083] A further technique for generating amino acid variants is
the cassette mutagenesis technique described in Wells et al., Gene
34:315 (1985); and other mutagenesis techniques well known in the
art, such as, for example, the techniques in Sambrook et al.,
supra, and Current Protocols in Molecular Biology, Ausubel et al.
Due to the inherent degeneracy of the genetic code, other DNA
sequences which encode substantially the same or a functionally
equivalent amino acid sequence may be used in the practice of the
invention for the cloning and expression of these novel nucleic
acids. Such DNA sequences include those which are capable of
hybridizing to the appropriate novel nucleic acid sequence under
stringent conditions.
[0084] Polynucleotides encoding preferred polypeptide truncations
of the invention can be used to generate polynucleotides encoding
chimeric or fusion proteins comprising one or more domains of the
invention and heterologous protein sequences.
[0085] The polynucleotides of the invention additionally include
the complement of any of the polynucleotides recited above. The
polynucleotide can be DNA (genomic, cDNA, amplified, or synthetic)
or RNA. Methods and algorithms for obtaining such polynucleotides
are well known to those of skill in the art and can include, for
example, methods for determining hybridization conditions that can
routinely isolate polynucleotides of the desired sequence
identities.
[0086] In accordance with the invention, polynucleotide sequences
comprising the mature protein coding sequences corresponding to any
one of SEQ ID NO: 1-13, or functional equivalents thereof, may be
used to generate recombinant DNA molecules that direct the
expression of that nucleic acid, or a functional equivalent
thereof, in appropriate host cells. Also included are the cDNA
inserts of any of the clones identified herein.
[0087] A polynucleotide according to the invention can be joined to
any of a variety of other nucleotide sequences by well-established
recombinant DNA techniques (see Sambrook J et al. (1989) Molecular
Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, NY).
Useful nucleotide sequences for joining to polynucleotides include
an assortment of vectors, e.g., plasmids, cosmids, lambda phage
derivatives, phagemids, and the like, that are well known in the
art. Accordingly, the invention also provides a vector including a
polynucleotide of the invention and a host cell containing the
polynucleotide. In general, the vector contains an origin of
replication functional in at least one organism, convenient
restriction endonuclease sites, and a selectable marker for the
host cell. Vectors according to the invention include expression
vectors, replication vectors, probe generation vectors, and
sequencing vectors. A host cell according to the invention can be a
prokaryotic or eukaryotic cell and can be a unicellular organism or
part of a multicellular organism.
[0088] The present invention further provides recombinant
constructs comprising a nucleic acid having any of the nucleotide
sequences of SEQ ID NOs: 1-13 or a fragment thereof or any other
polynucleotides of the invention. In one embodiment, the
recombinant constructs of the present invention comprise a vector,
such as a plasmid or viral vector, into which a nucleic acid having
any of the nucleotide sequences of SEQ ID NOs: 1-13 or a fragment
thereof is inserted, in a forward or reverse orientation. In the
case of a vector comprising one of the ORFs of the present
invention, the vector may further comprise regulatory sequences,
including for example, a promoter, operably linked to the ORF.
Large numbers of suitable vectors and promoters are known to those
of skill in the art and are commercially available for generating
the recombinant constructs of the present invention. The following
vectors are provided by way of example. Bacterial: pBs,
phagescript, PsiX174, pBluescript SK, pBs KS, pNH8a, pNH16a,
pNH18a, pNH46a (Stratagene); pTrc99A, pKK223-3, pKK233-3, pDR540,
pRIT5 (Pharmacia). Eukaryotic: pWLneo, pSV2cat, pOG44, PXTI, pSG
(Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia).
[0089] The isolated polynucleotide of the invention may be operably
linked to an expression control sequence such as the pMT2 or pED
expression vectors disclosed in Kaufman et al., Nucleic Acids Res.
19, 4485-4490 (1991), in order to produce the protein
recombinantly. Many suitable expression control sequences are known
in the art. General methods of expressing recombinant proteins are
also known and are exemplified in R. Kaufman, Methods in Enzymology
185, 537-566 (1990). As defined herein "operably linked" means that
the isolated polynucleotide of the invention and an expression
control sequence are situated within a vector or cell in such a way
that the protein is expressed by a host cell which has been
transformed (transfected) with the ligated
polynucleotide/expression control sequence.
[0090] Promoter regions can be selected from any desired gene using
CAT (chloramphenicol transferase) vectors or other vectors with
selectable markers. Two appropriate vectors are pKK232-8 and pCM7.
Particular named bacterial promoters include lac, lacZ, T3, T7,
gpt, lambda PR, and trc. Eukaryotic promoters include CMV immediate
early, HSV thymidine kinase, early and late SV40, LTRs from
retrovirus, and mouse metallothionein-I. Selection of the
appropriate vector and promoter is well within the level of
ordinary skill in the art. Generally, recombinant expression
vectors will include origins of replication and selectable markers
permitting transformation of the host cell, e.g., the ampicillin
resistance gene of E. coli and S. cerevisiae TRP1 gene, and a
promoter derived from a highly-expressed gene to direct
transcription of a downstream structural sequence. Such promoters
can be derived from operons encoding glycolytic enzymes such as
3-phosphoglycerate kinase (PGK), a-factor, acid phosphatase, or
heat shock proteins, among others. The heterologous structural
sequence is assembled in appropriate phase with translation
initiation and termination sequences, and preferably, a leader
sequence capable of directing secretion of translated protein into
the periplasmic space or extracellular medium. Optionally, the
heterologous sequence can encode a fusion protein including an
amino terminal identification peptide imparting desired
characteristics, e.g., stabilization or simplified purification of
expressed recombinant product. Useful expression vectors for
bacterial use are constructed by inserting a structural DNA
sequence encoding a desired protein together with suitable
translation initiation and termination signals in operable reading
phase with a functional promoter. The vector will comprise one or
more phenotypic selectable markers and an origin of replication to
ensure maintenance of the vector and to, if desirable, provide
amplification within the host. Suitable prokaryotic hosts for
transformation include E. coli, Bacillus subtilis, Salmonella
typhimurium and various species within the genera Pseudomonas,
Streptomyces, and Staphylococcus, although others may also be
employed as a matter of choice.
[0091] As a representative but non-limiting example, useful
expression vectors for bacterial use can comprise a selectable
marker and bacterial origin of replication derived from
commercially available plasmids comprising genetic elements of the
well known cloning vector pBR322 (ATCC 37017). Such commercial
vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals,
Uppsala, Sweden) and GEM 1 (Promega Biotech, Madison, Wis., USA).
These pBR322 "backbone" sections are combined with an appropriate
promoter and the structural sequence to be expressed. Following
transformation of a suitable host strain and growth of the host
strain to an appropriate cell density, the selected promoter is
induced or derepressed by appropriate means (e.g., temperature
shift or chemical induction) and cells are cultured for an
additional period. Cells are typically harvested by centrifugation,
disrupted by physical or chemical means, and the resulting crude
extract retained for further purification.
[0092] Polynucleotides of the invention can also be used to induce
immune responses. For example, as described in Fan et al., Nat.
Biotech. 17:870-872 (1999), incorporated herein by reference,
nucleic acid sequences encoding a polypeptide may be used to
generate antibodies against the encoded polypeptide following
topical administration of naked plasmid DNA or following injection,
and preferably intramuscular injection of the DNA. The nucleic acid
sequences are preferably inserted in a recombinant expression
vector and may be in the form of naked DNA.
[0093] 4.3 Hosts
[0094] The present invention further provides host cells
genetically engineered to contain the polynucleotides of the
invention. For example, such host cells may contain nucleic acids
of the invention introduced into the host cell using known
transformation, transfection or infection methods. The present
invention still further provides host cells genetically engineered
to express the polynucleotides of the invention, wherein such
polynucleotides are in operative association with a regulatory
sequence heterologous to the host cell which drives expression of
the polynucleotides in the cell.
[0095] Knowledge of nucleic acid sequences allows for modification
of cells to permit, or increase, expression of endogenous
polypeptide. Cells can be modified (e.g., by homologous
recombination) to provide increased polypeptide expression by
replacing, in whole or in part, the naturally occurring promoter
with all or part of a heterologous promoter so that the cells
express the polypeptide at higher levels. The heterologous promoter
is inserted in such a manner that it is operatively linked to the
encoding sequences. See, for example, PCT International Publication
No. WO94/12650, PCT International Publication No. WO92/20808, and
PCT International Publication No. WO91/09955. It is also
contemplated that, in addition to heterologous promoter DNA,
amplifiable marker DNA (e.g., ada, dhfr, and the multifunctional
CAD gene which encodes carbamyl phosphate synthase, aspartate
transcarbamylase, and dihydroorotase) and/or intron DNA may be
inserted along with the heterologous promoter DNA. If linked to the
coding sequence, amplification of the marker DNA by standard
selection methods results in co-amplification of the desired
protein coding sequences in the cells.
[0096] The host cell can be a higher eukaryotic host cell, such as
a mammalian cell, a lower eukaryotic host cell, such as a yeast
cell, or the host cell can be a prokaryotic cell, such as a
bacterial cell. Introduction of the recombinant construct into the
host cell can be effected by calcium phosphate transfection, DEAE,
dextran mediated transfection, or electroporation (Davis, L. et
al., Basic Methods in Molecular Biology (1986)). The host cells
containing one of the polynucleotides of the invention, can be used
in conventional manners to produce the gene product encoded by the
isolated fragment (in the case of an ORF) or can be used to produce
a heterologous protein under the control of the EMF.
[0097] Any host/vector system can be used to express one or more of
the ORFs of the present invention. These include, but are not
limited to, eukaryotic hosts such as HeLa cells, Cv-1 cell, COS
cells, 293 cells, and Sf9 cells, as well as prokaryotic host such
as E. coli and B. subtilis. The most preferred cells are those
which do not normally express the particular polypeptide or protein
or which expresses the polypeptide or protein at low natural level.
Mature proteins can be expressed in mammalian cells, yeast,
bacteria, or other cells under the control of appropriate
promoters. Cell-free translation systems can also be employed to
produce such proteins using RNAs derived from the DNA constructs of
the present invention. Appropriate cloning and expression vectors
for use with prokaryotic and eukaryotic hosts are described by
Sambrook, et al., in Molecular Cloning: A Laboratory Manual, Second
Edition, Cold Spring Harbor, N.Y. (1989), the disclosure of which
is hereby incorporated by reference.
[0098] Various mammalian cell culture systems can also be employed
to express recombinant protein. Examples of mammalian expression
systems include the COS-7 lines of monkey kidney fibroblasts,
described by Gluzman, Cell 23:175 (1981). Other cell lines capable
of expressing a compatible vector are, for example, the C127,
monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney
293 cells, human epidermal A431 cells, human Colo205 cells, 3T3
cells, CV-1 cells, other transformed primate cell lines, normal
diploid cells, cell strains derived from in vitro culture of
primary tissue, primary explants, HeLa cells, mouse L cells, BHK,
HL-60, U937, HaK or Jurkat cells. Mammalian expression vectors will
comprise an origin of replication, a suitable promoter and also any
necessary ribosome binding sites, polyadenylation site, splice
donor and acceptor sites, transcriptional termination sequences,
and 5' flanking nontranscribed sequences. DNA sequences derived
from the SV40 viral genome, for example, SV40 origin, early
promoter, enhancer, splice, and polyadenylation sites may be used
to provide the required nontranscribed genetic elements.
Recombinant polypeptides and proteins produced in bacterial culture
are usually isolated by initial extraction from cell pellets,
followed by one or more salting-out, aqueous ion exchange or size
exclusion chromatography steps. Protein refolding steps can be
used, as necessary, in completing configuration of the mature
protein. Finally, high performance liquid chromatography (HPLC) can
be employed for final purification steps. Microbial cells employed
in expression of proteins can be disrupted by any convenient
method, including freeze-thaw cycling, sonication, mechanical
disruption, or use of cell lysing agents.
[0099] Alternatively, it may be possible to produce the protein in
lower eukaryotes such as yeast or insects or in prokaryotes such as
bacteria. Potentially suitable yeast strains include Saccharomyces
cerevisiae, Schizosaccharomyces pombe, Kluyveromyces strains,
Candida, or any yeast strain capable of expressing heterologous
proteins. Potentially suitable bacterial strains include
Escherichia coli, Bacillus subtilis, Salmonella typhimurium, or any
bacterial strain capable of expressing heterologous proteins. If
the protein is made in yeast or bacteria, it may be necessary to
modify the protein produced therein, for example by phosphorylation
or glycosylation of the appropriate sites, in order to obtain the
functional protein. Such covalent attachments may be accomplished
using known chemical or enzymatic methods.
[0100] In another embodiment of the present invention, cells and
tissues may be engineered to express an endogenous gene comprising
the polynucleotides of the invention under the control of inducible
regulatory elements, in which case the regulatory sequences of the
endogenous gene may be replaced by homologous recombination. As
described herein, gene targeting can be used to replace a gene's
existing regulatory region with a regulatory sequence isolated from
a different gene or a novel regulatory sequence synthesized by
genetic engineering methods. Such regulatory sequences may be
comprised of promoters, enhancers, scaffold-attachment regions,
negative regulatory elements, transcriptional initiation sites,
regulatory protein binding sites or combinations of said sequences.
Alternatively, sequences which affect the structure or stability of
the RNA or protein produced may be replaced, removed, added, or
otherwise modified by targeting. These sequence include
polyadenylation signals, mRNA stability elements, splice sites,
leader sequences for enhancing or modifying transport or secretion
properties of the protein, or other sequences which alter or
improve the function or stability of protein or RNA molecules.
[0101] The targeting event may be a simple insertion of the
regulatory sequence, placing the gene under the control of the new
regulatory sequence, e.g. inserting a new promoter or enhancer or
both upstream of a gene. Alternatively, the targeting event may be
a simple deletion of a regulatory element, such as the deletion of
a tissue-specific negative regulatory element. Alternatively, the
targeting event may replace an existing element; for example, a
tissue-specific enhancer can be replaced by an enhancer that has
broader or different cell-type specificity than the naturally
occurring elements. Here, the naturally occurring sequences are
deleted and new sequences are added. In all cases, the
identification of the targeting event may be facilitated by the use
of one or more selectable marker genes that are contiguous with the
targeting DNA, allowing for the selection of cells in which the
exogenous DNA has integrated into the host cell genome. The
identification of the targeting event may also be facilitated by
the use of one or more marker genes exhibiting the property of
negative selection, such that the negatively selectable marker is
linked to the exogenous DNA, but configured such that the
negatively selectable marker flanks the targeting sequence, and
such that a correct homologous recombination event with sequences
in the host cell genome does not result in the stable integration
of the negatively selectable marker. Markers useful for this
purpose include the Herpes Simplex Virus thymidine kinase (TK) gene
or the bacterial xanthine-guanine phosphoribosyl-transferase (gpt)
gene.
[0102] The gene targeting or gene activation techniques which can
be used in accordance with this aspect of the invention are more
particularly described in U.S. Pat. Nos. 5,272,071 to Chappel;
5,578,461 to Sherwin et al.; International Application No.
PCT/US92/09627 (WO93/09222) by Selden et al.; and International
Application No. PCT/US90/06436 (WO91/06667) by Skoultchi et al.,
each of which is incorporated by reference herein in its
entirety.
[0103] 4.4 Polypeptides of the Invention
[0104] The isolated polypeptides of the invention include, but are
not limited to, a polypeptide comprising: the amino acid sequences
set forth as any one of SEQ ID NO: 1-13 or an amino acid sequence
encoded by any one of the nucleotide sequences SEQ ID NOs: 1-13 or
the corresponding full length or mature protein. Polypeptides of
the invention also include polypeptides preferably with biological
or immunological activity that are encoded by: (a) a polynucleotide
having any one of the nucleotide sequences set forth in SEQ ID NOs:
1-13 or (b) polynucleotides encoding any one of the amino acid
sequences set forth as SEQ ID NO: 1-13 or (c) polynucleotides that
hybridize to the complement of the polynucleotides of either (a) or
(b) under stringent hybridization conditions. The invention also
provides biologically active or immunologically active variants of
any of the amino acid sequences set forth as SEQ ID NO: 1-13 or the
corresponding full length or mature protein; and "substantial
equivalents" thereof (e.g., with at least about 65%, at least about
70%, at least about 75%, at least about 80%, at least about 85%, at
least about 90%, typically at least about 95%, more typically at
least about 98%, or most typically at least about 99% amino acid
identity) that retain biological activity. Polypeptides encoded by
allelic variants may have a similar, increased, or decreased
activity compared to polypeptides comprising SEQ ID NO: 1-13.
[0105] Fragments of the proteins of the present invention which are
capable of exhibiting biological activity are also encompassed by
the present invention. Fragments of the protein may be in linear
form or they may be cyclized using known methods, for example, as
described in H. U. Saragovi, et al., Bio/Technology 10, 773-778
(1992) and in R. S. McDowell, et al., J. Amer. Chem. Soc. 114,
9245-9253 (1992), both of which are incorporated herein by
reference. Such fragments may be fused to carrier molecules such as
immunoglobulins for many purposes, including increasing the valency
of protein binding sites.
[0106] The present invention also provides both full-length and
mature forms (for example, without a signal sequence or precursor
sequence) of the disclosed proteins. The protein coding sequence is
identified in the sequence listing by translation of the disclosed
nucleotide sequences. The mature form of such protein may be
obtained by expression of a full-length polynucleotide in a
suitable mammalian cell or other host cell. The sequence of the
mature form of the protein is also determinable from the amino acid
sequence of the full-length form. Where proteins of the present
invention are membrane bound, soluble forms of the proteins are
also provided. In such forms, part or all of the regions causing
the proteins to be membrane bound are deleted so that the proteins
are fully secreted from the cell in which it is expressed.
[0107] Protein compositions of the present invention may further
comprise an acceptable carrier, such as a hydrophilic, e.g.,
pharmaceutically acceptable, carrier.
[0108] The present invention further provides isolated polypeptides
encoded by the nucleic acid fragments of the present invention or
by degenerate variants of the nucleic acid fragments of the present
invention. By "degenerate variant" is intended nucleotide fragments
which differ from a nucleic acid fragment of the present invention
(e.g., an ORF) by nucleotide sequence but, due to the degeneracy of
the genetic code, encode an identical polypeptide sequence.
Preferred nucleic acid fragments of the present invention are the
ORFs that encode proteins.
[0109] A variety of methodologies known in the art can be utilized
to obtain any one of the isolated polypeptides or proteins of the
present invention. At the simplest level, the amino acid sequence
can be synthesized using commercially available peptide
synthesizers. The synthetically-constructed protein sequences, by
virtue of sharing primary, secondary or tertiary structural and/or
conformational characteristics with proteins may possess biological
properties in common therewith, including protein activity. This
technique is particularly useful in producing small peptides and
fragments of larger polypeptides. Fragments are useful, for
example, in generating antibodies against the native polypeptide.
Thus, they may be employed as biologically active or immunological
substitutes for natural, purified proteins in screening of
therapeutic compounds and in immunological processes for the
development of antibodies.
[0110] The polypeptides and proteins of the present invention can
alternatively be purified from cells which have been altered to
express the desired polypeptide or protein. As used herein, a cell
is said to be altered to express a desired polypeptide or protein
when the cell, through genetic manipulation, is made to produce a
polypeptide or protein which it normally does not produce or which
the cell normally produces at a lower level. One skilled in the art
can readily adapt procedures for introducing and expressing either
recombinant or synthetic sequences into eukaryotic or prokaryotic
cells in order to generate a cell which produces one of the
polypeptides or proteins of the present invention.
[0111] The invention also relates to methods for producing a
polypeptide comprising growing a culture of host cells of the
invention in a suitable culture medium, and purifying the protein
from the cells or the culture in which the cells are grown. For
example, the methods of the invention include a process for
producing a polypeptide in which a host cell containing a suitable
expression vector that includes a polynucleotide of the invention
is cultured under conditions that allow expression of the encoded
polypeptide. The polypeptide can be recovered from the culture,
conveniently from the culture medium, or from a lysate prepared
from the host cells and further purified. Preferred embodiments
include those in which the protein produced by such process is a
full length or mature form of the protein.
[0112] In an alternative method, the polypeptide or protein is
purified from bacterial cells which naturally produce the
polypeptide or protein. One skilled in the art can readily follow
known methods for isolating polypeptides and proteins in order to
obtain one of the isolated polypeptides or proteins of the present
invention. These include, but are not limited to,
immunochromatography, HPLC, size-exclusion chromatography,
ion-exchange chromatography, and immuno-affinity chromatography.
See, e.g., Scopes, Protein Purification: Principles and Practice,
Springer-Verlag (1994); Sambrook, et al., in Molecular Cloning: A
Laboratory Manual; Ausubel et al., Current Protocols in Molecular
Biology. Polypeptide fragments that retain biological/immunological
activity include fragments comprising greater than about 100 amino
acids, or greater than about 200 amino acids, and fragments that
encode specific protein domains.
[0113] The purified polypeptides can be used in in vitro binding
assays which are well known in the art to identify molecules which
bind to the polypeptides. These molecules include but are not
limited to, for e.g., small molecules, molecules from combinatorial
libraries, antibodies or other proteins. The molecules identified
in the binding assay are then tested for antagonist or agonist
activity in in vivo tissue culture or animal models that are well
known in the art. In brief, the molecules are titrated into a
plurality of cell cultures or animals and then tested for either
cell/animal death or prolonged survival of the animal/cells.
[0114] In addition, the peptides of the invention or molecules
capable of binding to the peptides may be complexed with toxins,
e.g., ricin or cholera, or with other compounds that are toxic to
cells. The toxin-binding molecule complex is then targeted to a
tumor or other cell by the specificity of the binding molecule for
SEQ ID NO: 1-13.
[0115] The protein of the invention may also be expressed as a
product of transgenic animals, e.g., as a component of the milk of
transgenic cows, goats, pigs, or sheep which are characterized by
somatic or germ cells containing a nucleotide sequence encoding the
protein.
[0116] The proteins provided herein also include proteins
characterized by amino acid sequences similar to those of purified
proteins but into which modification are naturally provided or
deliberately engineered. For example, modifications, in the peptide
or DNA sequence, can be made by those skilled in the art using
known techniques. Modifications of interest in the protein
sequences may include the alteration, substitution, replacement,
insertion or deletion of a selected amino acid residue in the
coding sequence. For example, one or more of the cysteine residues
may be deleted or replaced with another amino acid to alter the
conformation of the molecule. Techniques for such alteration,
substitution, replacement, insertion or deletion are well known to
those skilled in the art (see, e.g., U.S. Pat. No. 4,518,584).
Preferably, such alteration, substitution, replacement, insertion
or deletion retains the desired activity of the protein. Regions of
the protein that are important for the protein function can be
determined by various methods known in the art including the
alanine-scanning method which involved systematic substitution of
single or strings of amino acids with alanine, followed by testing
the resulting alanine-containing variant for biological activity.
This type of analysis determines the importance of the substituted
amino acid(s) in biological activity. Regions of the protein that
are important for protein function may be determined by the eMATRIX
program.
[0117] Other fragments and derivatives of the sequences of proteins
which would be expected to retain protein activity in whole or in
part and are useful for screening or other immunological
methodologies may also be easily made by those skilled in the art
given the disclosures herein. Such modifications are encompassed by
the present invention.
[0118] The protein may also be produced by operably linking the
isolated polynucleotide of the invention to suitable control
sequences in one or more insect expression vectors, and employing
an insect expression system. Materials and methods for
baculovirus/insect cell expression systems are commercially
available in kit form from, e.g., Invitrogen, San Diego, Calif.,
U.S.A. (the MaxBat.TM. kit), and such methods are well known in the
art, as described in Summers and Smith, Texas Agricultural
Experiment Station Bulletin No. 1555 (1987), incorporated herein by
reference. As used herein, an insect cell capable of expressing a
polynucleotide of the present invention is "transformed."
[0119] The protein of the invention may be prepared by culturing
transformed host cells under culture conditions suitable to express
the recombinant protein. The resulting expressed protein may then
be purified from such culture (i.e., from culture medium or cell
extracts) using known purification processes, such as gel
filtration and ion exchange chromatography. The purification of the
protein may also include an affinity column containing agents which
will bind to the protein; one or more column steps over such
affinity resins as concanavalin A-agarose, heparin-toyopearl.TM. or
Cibacrom blue 3GA Sepharose.TM.; one or more steps involving
hydrophobic interaction chromatography using such resins as phenyl
ether, butyl ether, or propyl ether; or immunoaffinity
chromatography.
[0120] Alternatively, the protein of the invention may also be
expressed in a form which will facilitate purification. For
example, it may be expressed as a fusion protein, such as those of
maltose binding protein (MBP), glutathione-S-transferase (GST) or
thioredoxin (TRX), or as a His tag. Kits for expression and
purification of such fusion proteins are commercially available
from New England BioLab (Beverly, Mass.), Pharmacia (Piscataway,
N.J.) and Invitrogen, respectively. The protein can also be tagged
with an epitope and subsequently purified by using a specific
antibody directed to such epitope. One such epitope ("FLAG.RTM.")
is commercially available from Kodak (New Haven, Conn.).
[0121] Finally, one or more reverse-phase high performance liquid
chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media,
e.g., silica gel having pendant methyl or other aliphatic groups,
can be employed to further purify the protein. Some or all of the
foregoing purification steps, in various combinations, can also be
employed to provide a substantially homogeneous isolated
recombinant protein. The protein thus purified is substantially
free of other mammalian proteins and is defined in accordance with
the present invention as an "isolated protein."
[0122] The polypeptides of the invention include analogs
(variants). This embraces fragments, as well as peptides in which
one or more amino acids has been deleted, inserted, or substituted.
Also, analogs of the polypeptides of the invention embrace fusions
of the polypeptides or modifications of the polypeptides of the
invention, wherein the polypeptide or analog is fused to another
moiety or moieties, e.g., targeting moiety or another therapeutic
agent. Such analogs may exhibit improved properties such as
activity and/or stability. Examples of moieties which may be fused
to the polypeptide or an analog include, for example, targeting
moieties which provide for the delivery of polypeptide to
pancreatic cells, e.g., antibodies to pancreatic cells, antibodies
to immune cells such as T-cells, monocytes, dendritic cells,
granulocytes, etc., as well as receptor and ligands expressed on
pancreatic or immune cells. Other moieties which may be fused to
the polypeptide include therapeutic agents which are used for
treatment, for example, immunosuppressive drugs such as
cyclosporin, SK506, azathioprine, CD3 antibodies and steroids.
Also, polypeptides may be fused to immune modulators, and other
cytokines such as alpha or beta interferon.
[0123] 4.4.1 Determining Polypeptide and Polynucleotide Identity
and Similarity
[0124] Preferred identity and/or similarity are designed to give
the largest match between the sequences tested. Methods to
determine identity and similarity are codified in computer programs
including, but are not limited to, the GCG program package,
including GAP (Devereux, J., et al., Nucleic Acids Research
12(1):387 (1984); Genetics Computer Group, University of Wisconsin,
Madison, Wis.), BLASTP, BLASTN, BLASTX, FASTA (Altschul, S. F. et
al., J. Molec. Biol. 215:403-410 (1990), PSI-BLAST (Altschul S. F.
et al., Nucleic Acids Res. vol. 25, pp. 3389-3402, herein
incorporated by reference), eMatrix software (Wu et al., J. Comp.
Biol., Vol. 6, pp. 219-235 (1999), herein incorporated by
reference), eMotif software (Nevill-Manning et al, ISMB-97, Vol. 4,
pp. 202-209, herein incorporated by reference), pFam software
(Sonnhammer et al., Nucleic Acids Res., Vol. 26(1), pp. 320-322
(1998), herein incorporated by reference) and the Kyte-Doolittle
hydrophobocity prediction algorithm (J. Mol Biol, 157, pp. 105-31
(1982), incorporated herein by reference). The BLAST programs are
publicly available from the National Center for Biotechnology
Information (NCBI) and other sources (BLAST Manual, Altschul, S.,
et al. NCB NLM NIH Bethesda, Md. 20894; Altschul, S., et al., J.
Mol. Biol. 215:403-410 (1990).
[0125] 4.5 Gene Therapy
[0126] Mutations in the polynucleotides of the invention gene may
result in loss of normal function of the encoded protein. The
invention thus provides gene therapy to restore normal activity of
the polypeptides of the invention; or to treat disease states
involving polypeptides of the invention. Delivery of a functional
gene encoding polypeptides of the invention to appropriate cells is
effected ex vivo, in situ, or in vivo by use of vectors, and more
particularly viral vectors (e.g., adenovirus, adeno-associated
virus, or a retrovirus), or ex vivo by use of physical DNA transfer
methods (e.g., liposomes or chemical treatments). See, for example,
Anderson, Nature, supplement to vol. 392, no. 6679, pp.25-20
(1998). For additional reviews of gene therapy technology see
Friedmann, Science, 244: 1275-1281 (1989); Verma, Scientific
American: 68-84 (1990); and Miller, Nature, 357: 455-460 (1992).
Introduction of any one of the nucleotides of the present invention
or a gene encoding the polypeptides of the present invention can
also be accomplished with extrachromosomal substrates (transient
expression) or artificial chromosomes (stable expression). Cells
may also be cultured ex vivo in the presence of proteins of the
present invention in order to proliferate or to produce a desired
effect on or activity in such cells. Treated cells can then be
introduced in vivo for therapeutic purposes. Alternatively, it is
contemplated that in other human disease states, preventing the
expression of or inhibiting the activity of polypeptides of the
invention will be useful in treating the disease states. It is
contemplated that antisense therapy or gene therapy could be
applied to negatively regulate the expression of polypeptides of
the invention.
[0127] Other methods inhibiting expression of a protein include the
introduction of antisense molecules to the nucleic acids of the
present invention, their complements, or their translated RNA
sequences, by methods known in the art. Further, the polypeptides
of the present invention can be inhibited by using targeted
deletion methods, or the insertion of a negative regulatory element
such as a silencer, which is tissue specific.
[0128] The present invention still further provides cells
genetically engineered in vivo to express the polynucleotides of
the invention, wherein such polynucleotides are in operative
association with a regulatory sequence heterologous to the host
cell which drives expression of the polynucleotides in the cell.
These methods can be used to increase or decrease the expression of
the polynucleotides of the present invention.
[0129] Knowledge of DNA sequences provided by the invention allows
for modification of cells to permit, increase, or decrease,
expression of endogenous polypeptide. Cells can be modified (e.g.,
by homologous recombination) to provide increased polypeptide
expression by replacing, in whole or in part, the naturally
occurring promoter with all or part of a heterologous promoter so
that the cells express the protein at higher levels. The
heterologous promoter is inserted in such a manner that it is
operatively linked to the desired protein encoding sequences. See,
for example, PCT International Publication No. WO 94/12650, PCT
International Publication No. WO 92/20808, and PCT International
Publication No. WO 91/09955. It is also contemplated that, in
addition to heterologous promoter DNA, amplifiable marker DNA
(e.g., ada, dhfr, and the multifunctional CAD gene which encodes
carbamyl phosphate synthase, aspartate transcarbamylase, and
dihydroorotase) and/or intron DNA may be inserted along with the
heterologous promoter DNA. If linked to the desired protein coding
sequence, amplification of the marker DNA by standard selection
methods results in co-amplification of the desired protein coding
sequences in the cells.
[0130] In another embodiment of the present invention, cells and
tissues may be engineered to express an endogenous gene comprising
the polynucleotides of the invention under the control of inducible
regulatory elements, in which case the regulatory sequences of the
endogenous gene may be replaced by homologous recombination. As
described herein, gene targeting can be used to replace a gene's
existing regulatory region with a regulatory sequence isolated from
a different gene or a novel regulatory sequence synthesized by
genetic engineering methods. Such regulatory sequences may be
comprised of promoters, enhancers, scaffold-attachment regions,
negative regulatory elements, transcriptional initiation sites,
regulatory protein binding sites or combinations of said sequences.
Alternatively, sequences which affect the structure or stability of
the RNA or protein produced may be replaced, removed, added, or
otherwise modified by targeting. These sequences include
polyadenylation signals, mRNA stability elements, splice sites,
leader sequences for enhancing or modifying transport or secretion
properties of the protein, or other sequences which alter or
improve the function or stability of protein or RNA molecules.
[0131] The targeting event may be a simple insertion of the
regulatory sequence, placing the gene under the control of the new
regulatory sequence, e.g. inserting a new promoter or enhancer or
both upstream of a gene. Alternatively, the targeting event may be
a simple deletion of a regulatory element, such as the deletion of
a tissue-specific negative regulatory element. Alternatively, the
targeting event may replace an existing element; for example, a
tissue-specific enhancer can be replaced by an enhancer that has
broader or different cell-type specificity than the naturally
occurring elements. Here, the naturally occurring sequences are
deleted and new sequences are added. In all cases, the
identification of the targeting event may be facilitated by the use
of one or more selectable marker genes that are contiguous with the
targeting DNA, allowing for the selection of cells in which the
exogenous DNA has integrated into the cell genome. The
identification of the targeting event may also be facilitated by
the use of one or more marker genes exhibiting the property of
negative selection, such that the negatively selectable marker is
linked to the exogenous DNA, but configured such that the
negatively selectable marker flanks the targeting sequence, and
such that a correct homologous recombination event with sequences
in the host cell genome does hot result in the stable integration
of the negatively selectable marker. Markers useful for this
purpose include the Herpes Simplex Virus thymidine kinase (TK) gene
or the bacterial xanthine-guanine phosphoribosyl-transferase (gpt)
gene.
[0132] The gene targeting or gene activation techniques which can
be used in accordance with this aspect of the invention are more
particularly described in U.S. Pat. No. 5,272,071 to Chappel; U.S.
Pat. No. 5,578,461 to Sherwin et al.; International Application No.
PCT/US92/09627 (WO93/09222) by Selden et al.; and International
Application No. PCT/US90/06436 (WO91/06667) by Skoultchi et al.,
each of which is incorporated by reference herein in its
entirety.
[0133] 4.6 Transgenic Animals
[0134] In preferred methods to determine biological functions of
the polypeptides of the invention in vivo, one or more genes
provided by the invention are either over expressed or inactivated
in the germ line of animals using homologous recombination
[Capecchi, Science 244:1288-1292 (1989)]. Animals in which the gene
is over expressed, under the regulatory control of exogenous or
endogenous promoter elements, are known as transgenic animals.
Animals in which an endogenous gene has been inactivated by
homologous recombination are referred to as "knockout" animals.
Knockout animals, preferably non-human mammals, can be prepared as
described in U.S. Pat. No. 5,557,032, incorporated herein by
reference. Transgenic animals are useful to determine the roles
polypeptides of the invention play in biological processes, and
preferably in disease states. Transgenic animals are useful as
model systems to identify compounds that modulate lipid metabolism.
Transgenic animals, preferably non-human mammals, are produced
using methods as described in U.S. Pat. No. 5,489,743 and PCT
Publication No. WO94/28122, incorporated herein by reference.
[0135] Transgenic animals can be prepared wherein all or part of a
promoter of the polynucleotides of the invention is either
activated or inactivated to alter the level of expression of the
polypeptides of the invention. Inactivation can be carried out
using homologous recombination methods described above. Activation
can be achieved by supplementing or even replacing the homologous
promoter to provide for increased protein expression. The
homologous promoter can be supplemented by insertion of one or more
heterologous enhancer elements known to confer promoter activation
in a particular tissue.
[0136] The polynucleotides of the present invention also make
possible the development, through, e.g., homologous recombination
or knock out strategies, of animals that fail to express
polypeptides of the invention or that express a variant
polypeptide. Such animals are useful as models for studying the in
vivo activities of polypeptide as well as for studying modulators
of the polypeptides of the invention.
[0137] In preferred methods to determine biological functions of
the polypeptides of the invention in vivo, one or more genes
provided by the invention are either over expressed or inactivated
in the germ line of animals using homologous recombination
[Capecchi, Science 244:1288-1292 (1989)]. Animals in which the gene
is over expressed, under the regulatory control of exogenous or
endogenous promoter elements, are known as transgenic animals.
Animals in which an endogenous gene has been inactivated by
homologous recombination are referred to as "knockout" animals.
Knockout animals, preferably non-human mammals, can be prepared as
described in U.S. Pat. No. 5,557,032, incorporated herein by
reference. Transgenic animals are useful to determine the roles
polypeptides of the invention play in biological processes, and
preferably in disease states. Transgenic animals are useful as
model systems to identify compounds that modulate lipid metabolism.
Transgenic animals, preferably non-human mammals, are produced
using methods as described in U.S. Pat. No. 5,489,743 and PCT
Publication No. WO94/28122, incorporated herein by reference.
[0138] Transgenic animals can be prepared wherein all or part of
the polynucleotides of the invention promoter is either activated
or inactivated to alter the level of expression of the polypeptides
of the invention. Inactivation can be carried out using homologous
recombination methods described above. Activation can be achieved
by supplementing or even replacing the homologous promoter to
provide for increased protein expression. The homologous promoter
can be supplemented by insertion of one or more heterologous
enhancer elements known to confer promoter activation in a
particular tissue.
[0139] 4.7 Uses and Biological Activity
[0140] The polynucleotides and proteins of the present invention
are expected to exhibit one or more of the uses or biological
activities (including those associated with assays cited herein)
identified herein. Uses or activities described for proteins of the
present invention may be provided by administration or use of such
proteins or of polynucleotides encoding such proteins (such as, for
example, in gene therapies or vectors suitable for introduction of
DNA). The mechanism underlying the particular condition or
pathology will dictate whether the polypeptides of the invention,
the polynucleotides of the invention or modulators (activators or
inhibitors) thereof would be beneficial to the subject in need of
treatment. Thus, "therapeutic compositions of the invention"
include compositions comprising isolated polynucleotides (including
recombinant DNA molecules, cloned genes and degenerate variants
thereof) or polypeptides of the invention (including full length
protein, mature protein and truncations or domains thereof), or
compounds and other substances that modulate the overall activity
of the target gene products, either at the level of target
gene/protein expression or target protein activity. Such modulators
include polypeptides, analogs, (variants), including fragments and
fusion proteins, antibodies and other binding proteins; chemical
compounds that directly or indirectly activate or inhibit the
polypeptides of the invention (identified, e.g., via drug screening
assays as described herein); antisense polynucleotides and
polynucleotides suitable for triple helix formation; and in
particular antibodies or other binding partners that specifically
recognize one or more epitopes of the polypeptides of the
invention.
[0141] The polypeptides of the present invention may likewise be
involved in cellular activation or in one of the other
physiological pathways described herein.
[0142] 4.7.1 Research Uses and Utilities
[0143] The polynucleotides provided by the present invention can be
used by the research community for various purposes. The
polynucleotides can be used to express recombinant protein for
analysis, characterization or therapeutic use; as markers for
tissues in which the corresponding protein is preferentially
expressed (either constitutively or at a particular stage of tissue
differentiation or development or in disease states); as molecular
weight markers on gels; as chromosome markers or tags (when
labeled) to identify chromosomes or to map related gene positions;
to compare with endogenous DNA sequences in patients to identify
potential genetic disorders; as probes to hybridize and thus
discover novel, related DNA sequences; as a source of information
to derive PCR primers for genetic fingerprinting; as a probe to
"subtract-out" known sequences in the process of discovering other
novel polynucleotides; for selecting and making oligomers for
attachment to a "gene chip" or other support, including for
examination of expression patterns; to raise anti-protein
antibodies using DNA immunization techniques; and as an antigen to
raise anti-DNA antibodies or elicit another immune response. Where
the polynucleotide encodes a protein which binds or potentially
binds to another protein (such as, for example, in a
receptor-ligand interaction), the polynucleotide can also be used
in interaction trap assays (such as, for example, that described in
Gyuris et al., Cell 75:791-803 (1993)) to identify polynucleotides
encoding the other protein with which binding occurs or to identify
inhibitors of the binding interaction.
[0144] The polypeptides provided by the present invention can
similarly be used in assays to determine biological activity,
including in a panel of multiple proteins for high-throughput
screening; to raise antibodies or to elicit another immune
response; as a reagent (including the labeled reagent) in assays
designed to quantitatively determine levels of the protein (or its
receptor) in biological fluids; as markers for tissues in which the
corresponding polypeptide is preferentially expressed (either
constitutively or at a particular stage of tissue differentiation
or development or in a disease state); and, of course, to isolate
correlative receptors or ligands. Proteins involved in these
binding interactions can also be used to screen for peptide or
small molecule inhibitors or agonists of the binding
interaction.
[0145] Any or all of these research utilities are capable of being
developed into reagent grade or kit format for commercialization as
research products.
[0146] Methods for performing the uses listed above are well known
to those skilled in the art. References disclosing such methods
include without limitation "Molecular Cloning: A Laboratory
Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J.,
E. F. Fritsch and T. Maniatis eds., 1989, and "Methods in
Enzymology: Guide to Molecular Cloning Techniques", Academic Press,
Berger, S. L. and A. R. Kimmel eds., 1987.
[0147] 4.7.2 Nutritional Uses
[0148] Polynucleotides and polypeptides of the present invention
can also be used as nutritional sources or supplements. Such uses
include without limitation use as a protein or amino acid
supplement, use as a carbon source, use as a nitrogen source and
use as a source of carbohydrate. In such cases the polypeptide or
polynucleotide of the invention can be added to the feed of a
particular organism or can be administered as a separate solid or
liquid preparation, such as in the form of powder, pills,
solutions, suspensions or capsules. In the case of microorganisms,
the polypeptide or polynucleotide of the invention can be added to
the medium in or on which the microorganism is cultured.
[0149] 4.7.3 Cytokine and Cell Proliferation/Differentiation
Activity
[0150] A polypeptide of the present invention may exhibit activity
relating to cytokine, cell proliferation (either inducing or
inhibiting) or cell differentiation (either inducing or inhibiting)
activity or may induce production of other cytokines in certain
cell populations. A polynucleotide of the invention can encode a
polypeptide exhibiting such attributes. Many protein factors
discovered to date, including all known cytokines, have exhibited
activity in one or more factor-dependent cell proliferation assays,
and hence the assays serve as a convenient confirmation of cytokine
activity. The activity of therapeutic compositions of the present
invention is evidenced by any one of a number of routine factor
dependent cell proliferation assays for cell lines including,
without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G,
M+(preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e,
CMK, HUVEC, and Caco. Therapeutic compositions of the invention can
be used in the following:
[0151] Assays for T-cell or thymocyte proliferation include without
limitation those described in: Current Protocols in Immunology, Ed
by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach,
W. Strober, Pub. Greene Publishing Associates and
Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte
Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai
et al., J. Immunol. 137:3494-3500, 1986; Bertagnolli et al., J.
Immunol. 145:1706-1712, 1990; Bertagnolli et al., Cellular
Immunology 133:327-341, 1991; Bertagnolli, et al., I. Immunol.
149:3778-3783, 1992; Bowman et al., I. Immunol. 152:1756-1761,
1994.
[0152] Assays for cytokine production and/or proliferation of
spleen cells, lymph node cells or thymocytes include, without
limitation, those described in: Polyclonal T cell stimulation,
Kruisbeek, A. M. and Shevach, E. M. In Current Protocols in
Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John
Wiley and Sons, Toronto. 1994; and Measurement of mouse and human
interleukin- , Schreiber, R. D. In Current Protocols in Immunology.
J. E. e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons,
Toronto. 1994.
[0153] Assays for proliferation and differentiation of
hematopoietic and lymphopoietic cells include, without limitation,
those described in: Measurement of Human and Murine Interleukin 2
and Interleukin 4, Bottomly, K., Davis, L. S. and Lipsky, P. E. In
Current Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp.
6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al.,
J. Exp. Med. 173:1205-1211, 1991; Moreau et al., Nature
336:690-692, 1988; Greenberger et al., Proc. Natl. Acad. Sci.
U.S.A. 80:2931-2938, 1983; Measurement of mouse and human
interleukin 6--Nordan, R. In Current Protocols in Immunology. J. E.
Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto.
1991; Smith et al., Proc. Natl. Aced. Sci. U.S.A. 83:1857-1861,
1986; Measurement of human Interleukin 11--Bennett, F., Giannotti,
J., Clark, S. C. and Turner, K. J. In Current Protocols in
Immunology. J. E. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and
Sons, Toronto. 1991; Measurement of mouse and human Interleukin
9--Ciarletta, A., Giannotti, J., Clark, S. C. and Turner, K. J. In
Current Protocols in Immunology. J. E. Coligan eds. Vol 1 pp.
6.13.1, John Wiley and Sons, Toronto. 1991.
[0154] Assays for T-cell clone responses to antigens (which will
identify, among others, proteins that affect APC-T cell
interactions as well as direct T-cell effects by measuring
proliferation and cytokine production) include, without limitation,
those described in: Current Protocols in Immunology, Ed by J. E.
Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W
Strober, Pub. Greene Publishing Associates and Wiley-Interscience
(Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter
6, Cytokines and their cellular receptors; Chapter 7, Immunologic
studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA
77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411,
1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al.,
J. Immunol. 140:508-512, 1988.
[0155] 4.7.4 Stem Cell Growth Factor Activity
[0156] A polypeptide of the present invention may exhibit stem cell
growth factor activity and be involved in the proliferation,
differentiation and survival of pluripotent and totipotent stem
cells including primordial germ cells, embryonic stem cells,
hematopoietic stem cells and/or germ line stem cells.
Administration of the polypeptide of the invention to stem cells in
vivo or ex vivo is expected to maintain and expand cell populations
in a totipotential or pluripotential state which would be useful
for re-engineering damaged or diseased tissues, transplantation,
manufacture of bio-pharmaceuticals and the development of
bio-sensors. The ability to produce large quantities of human cells
has important working applications for the production of human
proteins which currently must be obtained from non-human sources or
donors, implantation of cells to treat diseases such as
Parkinson's, Alzheimer's and other neurodegenerative diseases;
tissues for grafting such as bone marrow, skin, cartilage, tendons,
bone, muscle (including cardiac muscle), blood vessels, cornea,
neural cells, gastrointestinal cells and others; and organs for
transplantation such as kidney, liver, pancreas (including islet
cells), heart and lung.
[0157] It is contemplated that multiple different exogenous growth
factors and/or cytokines may be administered in combination with
the polypeptide of the invention to achieve the desired effect,
including any of the growth factors listed herein, other stern cell
maintenance factors, and specifically including stem cell factor
(SCF), leukemia inhibitory factor (LIF), Flt-3 ligand (Flt-3L), any
of the interleukins, recombinant soluble IL-6 receptor fused to
IL-6, macrophage inflammatory protein 1-alpha (MIP-1-alpha), G-CSF,
GM-CSF, thrombopoietin (TPO), platelet factor 4 (PF-4),
platelet-derived growth factor (PDGF), neural growth factors and
basic fibroblast growth factor (bFGF).
[0158] Since totipotent stem cells can give rise to virtually any
mature cell type, expansion of these cells in culture will
facilitate the production of large quantities of mature cells.
Techniques for culturing stem cells are known in the art and
administration of polypeptides of the invention, optionally with
other growth factors and/or cytokines, is expected to enhance the
survival and proliferation of the stem cell populations. This can
be accomplished by direct administration of the polypeptide of the
invention to the culture medium. Alternatively, stroma cells
transfected with a polynucleotide that encodes for the polypeptide
of the invention can be used as a feeder layer for the stem cell
populations in culture or in vivo. Stromal support cells for feeder
layers may include embryonic bone marrow fibroblasts, bone marrow
stromal cells, fetal liver cells, or cultured embryonic fibroblasts
(see U.S. Pat. No. 5,690,926).
[0159] Stem cells themselves can be transfected with a
polynucleotide of the invention to induce autocrine expression of
the polypeptide of the invention. This will allow for generation of
undifferentiated totipotential/pluripotential stem cell lines that
are useful as is or that can then be differentiated into the
desired mature cell types. These stable cell lines can also serve
as a source of undifferentiated totipotential/pluripotential mRNA
to create cDNA libraries and templates for polymerase chain
reaction experiments. These studies would allow for the isolation
and identification of differentially expressed genes in stem cell
populations that regulate stem cell proliferation and/or
maintenance.
[0160] Expansion and maintenance of totipotent stem cell
populations will be useful in the treatment of many pathological
conditions. For example, polypeptides of the present invention may
be used to manipulate stem cells in culture to give rise to
neuroepithelial cells that can be used to augment or replace cells
damaged by illness, autoimmune disease, accidental damage or
genetic disorders. The polypeptide of the invention may be useful
for inducing the proliferation of neural cells and for the
regeneration of nerve and brain tissue, i.e. for the treatment of
central and peripheral nervous system diseases and neuropathies, as
well as mechanical and traumatic disorders which involve
degeneration, death or trauma to neural cells or nerve tissue. In
addition, the expanded stem cell populations can also be
genetically altered for gene therapy purposes and to decrease host
rejection of replacement tissues after grafting or
implantation.
[0161] Expression of the polypeptide of the invention and its
effect on stem cells can also be manipulated to achieve controlled
differentiation of the stem cells into more differentiated cell
types. A broadly applicable method of obtaining pure populations of
a specific differentiated cell type from undifferentiated stem cell
populations involves the use of a cell-type specific promoter
driving a selectable marker. The selectable marker allows only
cells of the desired type to survive. For example, stem cells can
be induced to differentiate into cardiomyocytes (Wobus et al.,
Differentiation, 48: 173-182, (1991); Klug et al., J. Clin.
Invest., 98(1): 216-224, (1998)) or skeletal muscle cells (Browder,
L. W. In: Principles of Tissue Engineering eds. Lanza et al.,
Academic Press (1997)). Alternatively, directed differentiation of
stem cells can be accomplished by culturing the stem cells in the
presence of a differentiation factor such as retinoic acid and an
antagonist of the polypeptide of the invention which would inhibit
the effects of endogenous stem cell factor activity and allow
differentiation to proceed.
[0162] In vitro cultures of stem cells can be used to determine if
the polypeptide of the invention exhibits stem cell growth factor
activity. Stem cells are isolated from any one of various cell
sources (including hematopoietic stem cells and embryonic stem
cells) and cultured on a feeder layer, as described by Thompson et
al. Proc. Natl. Acad. Sci, U.S.A., 92: 7844-7848 (1995), in the
presence of the polypeptide of the invention alone or in
combination with other growth factors or cytokines. The ability of
the polypeptide of the invention to induce stem cells proliferation
is determined by colony formation on semi-solid support e.g. as
described by Bernstein et al., Blood, 77: 2316-2321 (1991).
[0163] 4.7.5 Hematopoiesis Regulating Activity
[0164] A polypeptide of the present invention may be involved in
regulation of hematopoiesis and, consequently, in the treatment of
myeloid or lymphoid cell disorders. Even marginal biological
activity in support of colony forming cells or of factor-dependent
cell lines indicates involvement in regulating hematopoiesis, e.g.
in supporting the growth and proliferation of erythroid progenitor
cells alone or in combination with other cytokines, thereby
indicating utility, for example, in treating various anemias or for
use in conjunction with irradiation/chemotherapy to stimulate the
production of erythroid precursors and/or erythroid cells; in
supporting the growth and proliferation of myeloid cells such as
granulocytes and monocytes/macrophages (i.e., traditional CSF
activity) useful, for example, in conjunction with chemotherapy to
prevent or treat consequent myelo-suppression; in supporting the
growth and proliferation of megakaryocytes and consequently of
platelets thereby allowing prevention or treatment of various
platelet disorders such as thrombocytopenia, and generally for use
in place of or complimentary to platelet transfusions; and/or in
supporting the growth and proliferation of hematopoietic stem cells
which are capable of maturing to any and all of the above-mentioned
hematopoietic cells and therefore find therapeutic utility in
various stem cell disorders (such as those usually treated with
transplantation, including, without limitation, aplastic anemia and
paroxysmal nocturnal hemoglobinuria), as well as in repopulating
the stem cell compartment post irradiation/chemotherapy, either
in-vivo or ex-vivo (i.e., in conjunction with bone marrow
transplantation or with peripheral progenitor cell transplantation
(homologous or heterologous)) as normal cells or genetically
manipulated for gene therapy.
[0165] Therapeutic compositions of the invention can be used in the
following:
[0166] Suitable assays for proliferation and differentiation of
various hematopoietic lines are cited above.
[0167] Assays for embryonic stem cell differentiation (which will
identify, among others, proteins that influence embryonic
differentiation hematopoiesis) include, without limitation, those
described in: Johansson et al. Cellular Biology 15:141-151, 1995;
Keller et al., Molecular and Cellular Biology 13:473-486, 1993;
McClanahan et al., Blood 81:2903-2915, 1993.
[0168] Assays for stem cell survival and differentiation (which
will identify, among others, proteins that regulate
lympho-hematopoiesis) include, without limitation, those described
in: Methylcellulose colony forming assays, Freshney, M. G. In
Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp.
265-268, Wiley-Liss, Inc., New York, N.Y. 1994; Hirayama et al.,
Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; Primitive
hematopoietic colony forming cells with high proliferative
potential, McNiece, I. K. and Briddell, R. A. In Culture of
Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 23-39,
Wiley-Liss, Inc., New York, N.Y. 1994; Neben et al., Experimental
Hematology 22:353-359, 1994; Cobblestone area forming cell assay,
Ploemacher, R. E. In Culture of Hematopoietic Cells. R. I.
Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York,
N.Y. 1994; Long term bone marrow cultures in the presence of
stromal cells, Spooncer, E., Dexter, M. and Allen, T. In Culture of
Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 163-179,
Wiley-Liss, Inc., New York, N.Y. 1994; Long term culture initiating
cell assay, Sutherland, H. J. In Culture of Hematopoietic Cells. R.
I. Freshney, et al. eds. Vol pp. 139-162, Wiley-Liss, Inc., New
York, N.Y. 1994.
[0169] 4.7.6 Tissue Growth Activity
[0170] A polypeptide of the present invention also may be involved
in bone, cartilage, tendon, ligament and/or nerve tissue growth or
regeneration, as well as in wound healing and tissue repair and
replacement, and in healing of burns, incisions and ulcers.
[0171] A polypeptide of the present invention which induces
cartilage and/or bone growth in circumstances where bone is not
normally formed, has application in the healing of bone fractures
and cartilage damage or defects in humans and other animals.
Compositions of a polypeptide, antibody, binding partner, or other
modulator of the invention may have prophylactic use in closed as
well as open fracture reduction and also in the improved fixation
of artificial joints. De novo bone formation induced by an
osteogenic agent contributes to the repair of congenital, trauma
induced, or oncologic resection induced craniofacial defects, and
also is useful in cosmetic plastic surgery.
[0172] A polypeptide of this invention may also be involved in
attracting bone-forming cells, stimulating growth of bone-forming
cells, or inducing differentiation of progenitors of bone-forming
cells. Treatment of osteoporosis, ostcoarthritis, bone degenerative
disorders, or periodontal disease, such as through stimulation of
bone and/or cartilage repair or by blocking inflammation or
processes of tissue destruction (collagenase activity, osteoclast
activity, etc.) mediated by inflammatory processes may also be
possible using the composition of the invention.
[0173] Another category of tissue regeneration activity that may
involve the polypeptide of the present invention is tendon/ligament
formation. Induction of tendon/ligament-like tissue or other tissue
formation in circumstances where such tissue is not normally
formed, has application in the healing of tendon or ligament tears,
deformities and other tendon or ligament defects in humans and
other animals. Such a preparation employing a tendon/ligament-like
tissue inducing protein may have prophylactic use in preventing
damage to tendon or ligament tissue, as well as use in the improved
fixation of tendon or ligament to bone or other tissues, and in
repairing defects to tendon or ligament tissue. De novo
tendon/ligament-like tissue formation induced by a composition of
the present invention contributes to the repair of congenital,
trauma induced, or other tendon or ligament defects of other
origin, and is also useful in cosmetic plastic surgery for
attachment or repair of tendons or ligaments. The compositions of
the present invention may provide environment to attract tendon- or
ligament-forming cells, stimulate growth of tendon- or
ligament-forming cells, induce differentiation of progenitors of
tendon- or ligament-forming cells, or induce growth of
tendon/ligament cells or progenitors ex vivo for return in vivo to
effect tissue repair. The compositions of the invention may also be
useful in the treatment of tendinitis, carpal tunnel syndrome and
other tendon or ligament defects. The compositions may also include
an appropriate matrix and/or sequestering agent as a carrier as is
well known in the art.
[0174] The compositions of the present invention may also be useful
for proliferation of neural cells and for regeneration of nerve and
brain tissue, i.e. for the treatment of central and peripheral
nervous system diseases and neuropathies, as well as mechanical and
traumatic disorders, which involve degeneration, death or trauma to
neural cells or nerve tissue. More specifically, a composition may
be used in the treatment of diseases of the peripheral nervous
system, such as peripheral nerve injuries, peripheral neuropathy
and localized neuropathies, and central nervous system diseases,
such as Alzheimer's, Parkinson's disease, Huntington's disease,
amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further
conditions which may be treated in accordance with the present
invention include mechanical and traumatic disorders, such as
spinal cord disorders, head trauma and cerebrovascular diseases
such as stroke. Peripheral neuropathies resulting from chemotherapy
or other medical therapies may also be treatable using a
composition of the invention.
[0175] Compositions of the invention may also be useful to promote
better or faster closure of non-healing wounds, including without
limitation pressure ulcers, ulcers associated with vascular
insufficiency, surgical and traumatic wounds, and the like.
[0176] Compositions of the present invention may also be involved
in the generation or regeneration of other tissues, such as organs
(including, for example, pancreas, liver, intestine, kidney, skin,
endothelium), muscle (smooth, skeletal or cardiac) and vascular
(including vascular endothelium) tissue, or for promoting the
growth of cells comprising such tissues. Part of the desired
effects may be by inhibition or modulation of fibrotic scarring may
allow normal tissue to regenerate. A polypeptide of the present
invention may also exhibit angiogenic activity.
[0177] A composition of the present invention may also be useful
for gut protection or regeneration and treatment of lung or liver
fibrosis, reperfusion injury in various tissues, and conditions
resulting from systemic cytokine damage.
[0178] A composition of the present invention may also be useful
for promoting or inhibiting differentiation of tissues described
above from precursor tissues or cells; or for inhibiting the growth
of tissues described above.
[0179] Therapeutic compositions of the invention can be used in the
following:
[0180] Assays for tissue generation activity include, without
limitation, those described in: International Patent Publication
No. WO95/16035 (bone, cartilage, tendon); International Patent
Publication No. WO95/05846 (nerve, neuronal); International Patent
Publication No. WO91/07491 (skin, endothelium).
[0181] Assays for wound healing activity include, without
limitation, those described in: Winter, Epidermal Wound Healing,
pps. 71-112 (Maibach, H. I. and Rovee, D. T., eds.), Year Book
Medical Publishers, Inc., Chicago, as modified by Eaglstein and
Mertz, J. Invest. Dermatol 71:382-84 (1978).
[0182] 4.7.7 Immune Stimulating or Suppressing Activity
[0183] A polypeptide of the present invention may also exhibit
immune stimulating or immune suppressing activity, including
without limitation the activities for which assays are described
herein. A polynucleotide of the invention can encode a polypeptide
exhibiting such activities. A protein may be useful in the
treatment of various immune deficiencies and disorders (including
severe combined immunodeficiency (SCID)), e.g., in regulating (up
or down) growth and proliferation of T and/or B lymphocytes, as
well as effecting the cytolytic activity of NK cells and other cell
populations. These immune deficiencies may be genetic or be caused
by viral (e.g., HIV) as well as bacterial or fungal infections, or
may result from autoimmune disorders. More specifically, infectious
diseases causes by viral, bacterial, fungal or other infection may
be treatable using a protein of the present invention, including
infections by HIV, hepatitis viruses, herpes viruses, mycobacteria,
Leishmania spp., malaria spp. and various fungal infections such as
candidiasis. Of course, in this regard, proteins of the present
invention may also be useful where a boost to the immune system
generally may be desirable, i.e., in the treatment of cancer.
[0184] Autoimmune disorders which may be treated using a protein of
the present invention include, for example, connective tissue
disease, multiple sclerosis, systemic lupus erythematosus,
rheumatoid arthritis, autoimmune pulmonary inflammation,
Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent
diabetes mellitis, myasthenia gravis, graft-versus-host disease and
autoimmune inflammatory eye disease. Such a protein (or antagonists
thereof, including antibodies) of the present invention may also to
be useful in the treatment of allergic reactions and conditions
(e.g., anaphylaxis, serum sickness, drug reactions, food allergies,
insect venom allergies, mastocytosis, allergic rhinitis,
hypersensitivity pneumonitis, urticaria, angioedema, eczema, atopic
dermatitis, allergic contact dermatitis, erythema multiforme,
Stevens-Johnson syndrome, allergic conjunctivitis, atopic
keratoconjunctivitis, venereal keratoconjunctivitis, giant
papillary conjunctivitis and contact allergies), such as asthma
(particularly allergic asthma) or other respiratory problems. Other
conditions, in which immune suppression is desired (including, for
example, organ transplantation), may also be treatable using a
protein (or antagonists thereof) of the present invention. The
therapeutic effects of the polypeptides or antagonists thereof on
allergic reactions can be evaluated by in vivo animals models such
as the cumulative contact enhancement test (Lastbom et al.,
Toxicology 125: 59-66, 1998), skin prick test (Hoffmann et al.,
Allergy 54: 446-54, 1999), guinea pig skin sensitization test (Vohr
et al., Arch. Toxocol. 73: 501-9), and murine local lymph node
assay (Kimber et al., J. Toxicol. Environ. Health 53: 563-79).
[0185] Using the proteins of the invention it may also be possible
to modulate immune responses, in a number of ways. Down regulation
may be in the form of inhibiting or blocking an immune response
already in progress or may involve preventing the induction of an
immune response. The functions of activated T cells may be
inhibited by suppressing T cell responses or by inducing specific
tolerance in T cells, or both. Immunosuppression of T cell
responses is generally an active, non-antigen-specific, process
which requires continuous exposure of the T cells to the
suppressive agent. Tolerance, which involves inducing
non-responsiveness or anergy in T cells, is distinguishable from
immunosuppression in that it is generally antigen-specific and
persists after exposure to the tolerizing agent has ceased.
Operationally, tolerance can be demonstrated by the lack of a T
cell response upon reexposure to specific antigen in the absence of
the tolerizing agent.
[0186] Down regulating or preventing one or more antigen functions
(including without limitation B lymphocyte antigen functions (such
as, for example, B7)), e.g., preventing high level lymphokine
synthesis by activated T cells, will be useful in situations of
tissue, skin and organ transplantation and in graft-versus-host
disease (GVHD). For example, blockage of T cell function should
result in reduced tissue destruction in tissue transplantation.
Typically, in tissue transplants, rejection of the transplant is
initiated through its recognition as foreign by T cells, followed
by an immune reaction that destroys the transplant. The
administration of a therapeutic composition of the invention may
prevent cytokine synthesis by immune cells, such as T cells, and
thus acts as an immunosuppressant. Moreover, a lack of
costimulation may also be sufficient to anergize the T cells,
thereby inducing tolerance in a subject. Induction of long-term
tolerance by B lymphocyte antigen-blocking reagents may avoid the
necessity of repeated administration of these blocking reagents. To
achieve sufficient immunosuppression or tolerance in a subject, it
may also be necessary to block the function of a combination of B
lymphocyte antigens.
[0187] The efficacy of particular therapeutic compositions in
preventing organ transplant rejection or GVHD can be assessed using
animal models that are predictive of efficacy in humans. Examples
of appropriate systems which can be used include allogeneic cardiac
grafts in rats and xenogeneic pancreatic islet cell grafts in mice,
both of which have been used to examine the immunosuppressive
effects of CTLA4Ig fusion proteins in vivo as described in Lenschow
et al., Science 257:789-792 (1992) and Turka et al., Proc. Natl.
Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of
GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York,
1989, pp. 846-847) can be used to determine the effect of
therapeutic compositions of the invention on the development of
that disease.
[0188] Blocking antigen function may also be therapeutically useful
for treating autoimmune diseases. Many autoimmune disorders are the
result of inappropriate activation of T cells that are reactive
against self tissue and which promote the production of cytokines
and autoantibodies involved in the pathology of the diseases.
Preventing the activation of autoreactive T cells may reduce or
eliminate disease symptoms. Administration of reagents which block
stimulation of T cells can be used to inhibit T cell activation and
prevent production of autoantibodies or T cell-derived cytokines
which may be involved in the disease process. Additionally,
blocking reagents may induce antigen-specific tolerance of
autoreactive T cells which could lead to long-term relief from the
disease. The efficacy of blocking reagents in preventing or
alleviating autoimmune disorders can be determined using a number
of well-characterized animal models of human autoimmune diseases.
Examples include murine experimental autoimmune encephalitis,
systemic lupus erythmatosis in MRL/lpr/lpr mice or NZB hybrid mice,
murine autoimmune collagen arthritis, diabetes mellitus in NOD mice
and BB rats, and murine experimental myasthenia gravis (see Paul
ed., Fundamental Immunology, Raven Press, New York, 1989, pp.
840-856).
[0189] Upregulation of an antigen function (e.g., a B lymphocyte
antigen function), as a means of up regulating immune responses,
may also be useful in therapy. Upregulation of immune responses may
be in the form of enhancing an existing immune response or
eliciting an initial immune response. For example, enhancing an
immune response may be useful in cases of viral infection,
including systemic viral diseases such as influenza, the common
cold, and encephalitis.
[0190] Alternatively, anti-viral immune responses may be enhanced
in an infected patient by removing T cells from the patient,
costimulating the T cells in vitro with viral antigen-pulsed APCs
either expressing a peptide of the present invention or together
with a stimulatory form of a soluble peptide of the present
invention and reintroducing the in vitro activated T cells into the
patient. Another method of enhancing anti-viral immune responses
would be to isolate infected cells from a patient, transfect them
with a nucleic acid encoding a protein of the present invention as
described herein such that the cells express all or a portion of
the protein on their surface, and reintroduce the transfected cells
into the patient. The infected cells would now be capable of
delivering a costimulatory signal to, and thereby activate, T cells
in vivo.
[0191] A polypeptide of the present invention may provide the
necessary stimulation signal to T cells to induce a T cell mediated
immune response against the transfected tumor cells. In addition,
tumor cells which lack MHC class I or MHC class H molecules, or
which fail to reexpress sufficient mounts of MHC class I or MHC
class II molecules, can be transfected with nucleic acid encoding
all or a portion of (e.g., a cytoplasmic-domain truncated portion)
of an MHC class I alpha chain protein and .beta..sub.2
microglobulin protein or an MHC class II alpha chain protein and an
MHC class II beta chain protein to thereby express MHC class I or
MHC class II proteins on the cell surface. Expression of the
appropriate class I or class II MHC in conjunction with a peptide
having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2,
B7-3) induces a T cell mediated immune response against the
transfected tumor cell. Optionally, a gene encoding an antisense
construct which blocks expression of an MHC class II associated
protein, such as the invariant chain, can also be cotransfected
with a DNA encoding a peptide having the activity of a B lymphocyte
antigen to promote presentation of tumor associated antigens and
induce tumor specific immunity. Thus, the induction of a T cell
mediated immune response in a human subject may be sufficient to
overcome tumor-specific tolerance in the subject.
[0192] The activity of a protein of the invention may, among other
means, be measured by the following methods:
[0193] Suitable assays for thymocyte or splenocyte cytotoxicity
include, without limitation, those described in: Current Protocols
in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H.
Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing
Associates and Wiley-Interscience (Chapter 3, In Vitro assays for
Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies
in Humans); Herrmann et al., Proc. Natl. Acad. Sci. USA
78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974,
1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al.,
I. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol.
140:508-512, 1988; Bowman et al., J. Virology 61:1992-1998;
Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Brown et
al., J. Immunol. 153:3079-3092, 1994.
[0194] Assays for T-cell-dependent immunoglobulin responses and
isotype switching (which will identify, among others, proteins that
modulate T-cell dependent antibody responses and that affect
Th1/Th2 profiles) include, without limitation, those described in:
Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell
function: In vitro antibody production, Mond, J. J. and Brunswick,
M. In Current Protocols in Immunology. J. E. e.a. Coligan eds. Vol
1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.
[0195] Mixed lymphocyte reaction (MLR) assays (which will identify,
among others, proteins that generate predominantly Th1 and CTL
responses) include, without limitation, those described in: Current
Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D.
H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing
Associates and Wiley-Interscience (Chapter 3, In Vitro assays for
Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies
in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et
al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol.
149:3778-3783, 1992.
[0196] Dendritic cell-dependent assays (which will identify, among
others, proteins expressed by dendritic cells that activate naive
T-cells) include, without limitation, those described in: Guery et
al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of
Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal
of Immunology 154:5071-5079, 1995; Porgador et al., Journal of
Experimental Medicine 182:255-260, 1995; Nair et al., Journal of
Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965,
1994; Macatonia et al., Journal of Experimental Medicine
169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical
Investigation 94:797-807, 1994; and Inaba et al., Journal of
Experimental Medicine 172:631-640, 1990.
[0197] Assays for lymphocyte survival/apoptosis (which will
identify, among others, proteins that prevent apoptosis after
superantigen induction and proteins that regulate lymphocyte
homeostasis) include, without limitation, those described in:
Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al.,
Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research
53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk,
Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry
14:891-897, 1993; Gorczyca et al., International Journal of
Oncology 1:639-648, 1992.
[0198] Assays for proteins that influence early steps of T-cell
commitment and development include, without limitation, those
described in: Antica et al., Blood 84:111-117, 1994; Fine et al.,
Cellular Immunology 155:111-122, 1994; Galy et al., Blood
85:2770-2778, 1995; Toki et al., Proc. Nat. Acad Sci. USA
88:7548-7551, 1991.
[0199] 4.7.8 Activin/Inhibin Activity
[0200] A polypeptide of the present invention may also exhibit
activin- or inhibin-related activities. A polynucleotide of the
invention may encode a polypeptide exhibiting such characteristics.
Inhibins are characterized by their ability to inhibit the release
of follicle stimulating hormone (FSH), while activins and are
characterized by their ability to stimulate the release of follicle
stimulating hormone (FSH). Thus, a polypeptide of the present
invention, alone or in heterodimers with a member of the inhibin
family, may be useful as a contraceptive based on the ability of
inhibins to decrease fertility in female mammals and decrease
spermatogenesis in male mammals. Administration of sufficient
amounts of other inhibins can induce infertility in these mammals.
Alternatively, the polypeptide of the invention, as a homodimer or
as a heterodimer with other protein subunits of the inhibin group,
may be useful as a fertility inducing therapeutic, based upon the
ability of activin molecules in stimulating FSH release from cells
of the anterior pituitary. See, for example, U.S. Pat. No.
4,798,885. A polypeptide of the invention may also be useful for
advancement of the onset of fertility in sexually immature mammals,
so as to increase the lifetime reproductive performance of domestic
animals such as, but not limited to, cows, sheep and pigs.
[0201] The activity of a polypeptide of the invention may, among
other means, be measured by the following methods.
[0202] Assays for activin/inhibin activity include, without
limitation, those described in: Vale et al., Endocrinology
91:562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et
al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663,
1985; Forage et al., Proc. Natl. Acad. Sci. USA 83:3091-3095,
1986.
[0203] 4.7.9 Chemotactic/Chemokinetic Activity
[0204] A polypeptide of the present invention may be involved in
chemotactic or chemokinetic activity for mammalian cells,
including, for example, monocytes, fibroblasts, neutrophils,
T-cells, mast cells, eosinophils, epithelial and/or endothelial
cells. A polynucleotide of the invention can encode a polypeptide
exhibiting such attributes. Chemotactic and chemokinetic receptor
activation can be used to mobilize or attract a desired cell
population to a desired site of action. Chemotactic or chemokinetic
compositions (e.g. proteins, antibodies, binding partners, or
modulators of the invention) provide particular advantages in
treatment of wounds and other trauma to tissues, as well as in
treatment of localized infections. For example, attraction of
lymphocytes, monocytes or neutrophils to tumors or sites of
infection may result in improved immune responses against the tumor
or infecting agent.
[0205] A protein or peptide has chemotactic activity for a
particular cell population if it can stimulate, directly or
indirectly, the directed orientation or movement of such cell
population. Preferably, the protein or peptide has the ability to
directly stimulate directed movement of cells. Whether a particular
protein has chemotactic activity for a population of cells can be
readily determined by employing such protein or peptide in any
known assay for cell chemotaxis.
[0206] Therapeutic compositions of the invention can be used in the
following:
[0207] Assays for chemotactic activity (which will identify
proteins that induce or prevent chemotaxis) consist of assays that
measure the ability of a protein to induce the migration of cells
across a membrane as well as the ability of a protein to induce the
adhesion of one cell population to another cell population.
Suitable assays for movement and adhesion include, without
limitation, those described in: Current Protocols in Immunology, Ed
by J. E. Coligan, A. M. Kruisbeek, D. H. Marguiles, E. M. Shevach,
W. Strober, Pub. Greene Publishing Associates and
Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta
Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest.
95:1370-1376, 1995; Lind et al. APMIS 103:140-146, 1995; Muller et
al Eur. J. Immunol. 25:1744-1748; Gruber et al. J. of Immunol.
152:5860-5867, 1994; Johnston et al. J. of Immunol. 153:1762-1768,
1994.
[0208] 4.7.10 Hemostatic and Thrombolytic Activity
[0209] A polypeptide of the invention may also be involved in
hemostatis or thrombolysis or thrombosis. A polynucleotide of the
invention can encode a polypeptide exhibiting such attributes.
Compositions may be useful in treatment of various coagulation
disorders (including hereditary disorders, such as hemophilias) or
to enhance coagulation and other hemostatic events in treating
wounds resulting from trauma, surgery or other causes. A
composition of the invention may also be useful for dissolving or
inhibiting formation of thromboses and for treatment and prevention
of conditions resulting therefrom (such as, for example, infarction
of cardiac and central nervous system vessels (e.g., stroke).
[0210] Therapeutic compositions of the invention can be used in the
following:
[0211] Assay for hemostatic and thrombolytic activity include,
without limitation, those described in: Linet et al., J. Clin.
Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res.
45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991);
Schaub, Prostaglandins 35:467-474, 1988.
[0212] 4.7.11 Cancer Diagnosis and Therapy
[0213] Polypeptides of the invention may be involved in cancer cell
generation, proliferation or metastasis. Detection of the presence
or amount of polynucleotides or polypeptides of the invention may
be useful for the diagnosis and/or prognosis of one or more types
of cancer. For example, the presence or increased expression of a
polynucleotide/polypeptide of the invention may indicate a
hereditary risk of cancer, a precancerous condition, or an ongoing
malignancy. Conversely, a defect in the gene or absence of the
polypeptide may be associated with a cancer condition.
Identification of single nucleotide polymorphisms associated with
cancer or a predisposition to cancer may also be useful for
diagnosis or prognosis.
[0214] Cancer treatments promote tumor regression by inhibiting
tumor cell proliferation, inhibiting angiogenesis (growth of new
blood vessels that is necessary to support tumor growth) and/or
prohibiting metastasis by reducing tumor cell motility or
invasiveness. Therapeutic compositions of the invention may be
effective in adult and pediatric oncology including in solid phase
tumors/malignancies, locally advanced tumors, human soft tissue
sarcomas, metastatic cancer, including lymphatic metastases, blood
cell malignancies including multiple myeloma, acute and chronic
leukemias, and lymphomas, head and neck cancers including mouth
cancer, larynx cancer and thyroid cancer, lung cancers including
small cell carcinoma and non-small cell cancers, breast cancers
including small cell carcinoma and ductal carcinoma,
gastrointestinal cancers including esophageal cancer, stomach
cancer, colon cancer, colorectal cancer and polyps associated with
colorectal neoplasia, pancreatic cancers, liver cancer, urologic
cancers including bladder cancer and prostate cancer, malignancies
of the female genital tract including ovarian carcinoma, uterine
(including endometrial) cancers, and solid tumor in the ovarian
follicle, kidney cancers including renal cell carcinoma, brain
cancers including intrinsic brain tumors, neuroblastoma, astrocytic
brain tumors, gliomas, metastatic tumor cell invasion in the
central nervous system, bone cancers including osteomas, skin
cancers including malignant melanoma, tumor progression of human
skin keratinocytes, squamous cell carcinoma, basal cell carcinoma,
hemangiopericytoma and Karposi's sarcoma.
[0215] Polypeptides, polynucleotides, or modulators of polypeptides
of the invention (including inhibitors and stimulators of the
biological activity of the polypeptide of the invention) may be
administered to treat cancer. Therapeutic compositions can be
administered in therapeutically effective dosages alone or in
combination with adjuvant cancer therapy such as surgery,
chemotherapy, radiotherapy, thermotherapy, and laser therapy, and
may provide a beneficial effect, e.g. reducing tumor size, slowing
rate of tumor growth, inhibiting metastasis, or otherwise improving
overall clinical condition, without necessarily eradicating the
cancer.
[0216] The composition can also be administered in therapeutically
effective amounts as a portion of an anti-cancer cocktail. An
anti-cancer cocktail is a mixture of the polypeptide or modulator
of the invention with one or more anti-cancer drugs in addition to
a pharmaceutically acceptable carrier for delivery. The use of
anti-cancer cocktails as a cancer treatment is routine. Anti-cancer
drugs that are well known in the art and can be used as a treatment
in combination with the polypeptide or modulator of the invention
include: Actinomycin D, Aminoglutethimide, Asparaginase, Bleomycin,
Busulfan, Carboplatin, Carmustine, Chlorambucil, Cisplatin
(cis-DDP), Cyclophosphamide, Cytarabine HCl (Cytosine arabinoside),
Dacarbazine, Dactinomycin, Daunorubicin HCl, Doxorubicin HCl,
Estramustine phosphate sodium, Etoposide (V16-213), Floxuridine,
5-Fluorouracil (5-Fu), Flutamide, Hydroxyurea (hydroxycarbamide),
Ifosfamide, Interferon Alpha-2a, Interferon Alpha-2b, Leuprolide
acetate (LHRH-releasing factor analog), Lomustine, Mechlorethamine
HCl (nitrogen mustard), Melphalan, Mercaptopurine, Mesna,
Methotrexate (MTX), Mitomycin, Mitoxantrone HCl, Octreotide,
Plicamycin, Procarbazine HCl, Streptozocin, Tamoxifen citrate,
Thioguanine, Thiotepa, Vinblastine sulfate, Vincristine sulfate,
Amsacrine, Azacitidine, Hexamethylmelamine, Interleukin-2,
Mitoguazone, Pentostatin, Semustine, Teniposide, and Vindesine
sulfate.
[0217] In addition, therapeutic compositions of the invention may
be used for prophylactic treatment of cancer. There are hereditary
conditions and/or environmental situations (e.g. exposure to
carcinogens) known in the art that predispose an individual to
developing cancers. Under these circumstances, it may be beneficial
to treat these individuals with therapeutically effective doses of
the polypeptide of the invention to reduce the risk of developing
cancers.
[0218] In vitro models can be used to determine the effective doses
of the polypeptide of the invention as a potential cancer
treatment. These in vitro models include proliferation assays of
cultured tumor cells, growth of cultured tumor cells in soft agar
(see Freshney, (1987) Culture of Animal Cells: A Manual of Basic
Technique, Wily-Liss, New York, N.Y. Ch 18 and Ch 21), tumor
systems in nude mice as described in Giovanella et al., J. Natl.
Can. Inst., 52: 921-30 (1974), mobility and invasive potential of
tumor cells in Boyden Chamber assays as described in Pilkington et
al., Anticancer Res., 17: 4107-9 (1997), and angiogenesis assays
such as induction of vascularization of the chick chorioallantoic
membrane or induction of vascular endothelial cell migration as
described in Ribatta et al., Intl. J. Dev. Biol., 40: 1189-97
(1999) and Li et al., Clin. Exp. Metastasis, 17:423-9 (1999),
respectively. Suitable tumor cells lines are available, e.g. from
American Type Tissue Culture Collection catalogs.
[0219] 4.7.12 Receptor/Ligand Activity
[0220] A polypeptide of the present invention may also demonstrate
activity as receptor, receptor ligand or inhibitor or agonist of
receptor/ligand interactions. A polynucleotide of the invention can
encode a polypeptide exhibiting such characteristics. Examples of
such receptors and ligands include, without limitation, cytokine
receptors and their ligands, receptor kinases and their ligands,
receptor phosphatases and their ligands, receptors involved in
cell-cell interactions and their ligands (including without
limitation, cellular adhesion molecules (such as selectins,
integrins and their ligands) and receptor/ligand pairs involved in
antigen presentation, antigen recognition and development of
cellular and humoral immune responses. Receptors and ligands are
also useful for screening of potential peptide or small molecule
inhibitors of the relevant receptor/ligand interaction. A protein
of the present invention (including, without limitation, fragments
of receptors and ligands) may themselves be useful as inhibitors of
receptor/ligand interactions.
[0221] The activity of a polypeptide of the invention may, among
other means, be measured by the following methods:
[0222] Suitable assays for receptor-ligand activity include without
limitation those described in: Current Protocols in Immunology, Ed
by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach,
W. Strober, Pub. Greene Publishing Associates and
Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion
under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl.
Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med.
168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160
1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994;
Stitt et al., Cell 80:661-670, 1995.
[0223] By way of example, the polypeptides of the invention may be
used as a receptor for a ligand(s) thereby transmitting the
biological activity of that ligand(s). Ligands may be identified
through binding assays, affinity chromatography, dihybrid screening
assays, BIAcore assays, gel overlay assays, or other methods known
in the art.
[0224] Studies characterizing drugs or proteins as agonist or
antagonist or partial agonists or a partial antagonist require the
use of other proteins as competing ligands. The polypeptides of the
present invention or ligand(s) thereof may be labeled by being
coupled to radioisotopes, colorimetric molecules or a toxin
molecules by conventional methods. ("Guide to Protein Purification"
Murray P. Deutscher (ed) Methods in Enzymology Vol. 182 (1990)
Academic Press, Inc. San Diego). Examples of radioisotopes include,
but are not limited to, tritium and carbon-14. Examples of
colorimetric molecules include, but are not limited to, fluorescent
molecules such as fluorescamine, or rhodamine or other colorimetric
molecules. Examples of toxins include, but are not limited, to
ricin.
[0225] 4.7.13 Drug Screening
[0226] This invention is particularly useful for screening chemical
compounds by using the novel polypeptides or binding fragments
thereof in any of a variety of drug screening techniques. The
polypeptides or fragments employed in such a test may either be
free in solution, affixed to a solid support, borne on a cell
surface or located intracellularly. One method of drug screening
utilizes eukaryotic or prokaryotic host cells which are stably
transformed with recombinant nucleic acids expressing the
polypeptide or a fragment thereof. Drugs are screened against such
transformed cells in competitive binding assays. Such cells, either
in viable or fixed form, can be used for standard binding assays.
One may measure, for example, the formation of complexes between
polypeptides of the invention or fragments and the agent being
tested or examine the diminution in complex formation between the
novel polypeptides and an appropriate cell line, which are well
known in the art.
[0227] Sources for test compounds that may be screened for ability
to bind to or modulate (i.e., increase or decrease) the activity of
polypeptides of the invention include (1) inorganic and organic
chemical libraries, (2) natural product libraries, and (3)
combinatorial libraries comprised of either random or mimetic
peptides, oligonucleotides or organic molecules.
[0228] Chemical libraries may be readily synthesized or purchased
from a number of commercial sources, and may include structural
analogs of known compounds or compounds that are identified as
"hits" or "leads" via natural product screening.
[0229] The sources of natural product libraries are microorganisms
(including bacteria and fungi), animals, plants or other
vegetation, or marine organisms, and libraries of mixtures for
screening may be created by: (1) fermentation and extraction of
broths from soil, plant or marine microorganisms or (2) extraction
of the organisms themselves. Natural product libraries include
polyketides, non-ribosomal peptides, and (non-naturally occurring)
variants thereof. For a review, see Science 282:63-68 (1998).
[0230] Combinatorial libraries are composed of large numbers of
peptides, oligonucleotides or organic compounds and can be readily
prepared by traditional automated synthesis methods, PCR, cloning
or proprietary synthetic methods. Of particular interest are
peptide and oligonucleotide combinatorial libraries. Still other
libraries of interest include peptide, protein, peptidomimetic,
multiparallel synthetic collection, recombinatorial, and
polypeptide libraries. For a review of combinatorial chemistry and
libraries created therefrom, see Myers, Curr. Opin. Biotechnol.
8:701-707 (1997). For reviews and examples of peptidomimetic
libraries, see Al-Obeidi et al., Mol. Biotechnol, 9(3):205-23
(1998); Hruby et al., Curr Opin Chem Biol, 1(1):114-19 (1997);
Dorner et al., Bioorg Med Chem, 4(5):709-15 (1996) (alkylated
dipeptides).
[0231] Identification of modulators through use of the various
libraries described herein permits modification of the candidate
"hit" (or "lead") to optimize the capacity of the "hit" to bind a
polypeptide of the invention. The molecules identified in the
binding assay are then tested for antagonist or agonist activity in
in vivo tissue culture or animal models that are well known in the
art. In brief, the molecules are titrated into a plurality of cell
cultures or animals and then tested for either cell/animal death or
prolonged survival of the animal/cells.
[0232] The binding molecules thus identified may be complexed with
toxins, e.g., ricin or cholera, or with other compounds that are
toxic to cells such as radioisotopes. The toxin-binding molecule
complex is then targeted to a tumor or other cell by the
specificity of the binding molecule for a polypeptide of the
invention. Alternatively, the binding molecules may be complexed
with imaging agents for targeting and imaging purposes.
[0233] 4.7.14 Assay for Receptor Activity
[0234] The invention also provides methods to detect specific
binding of a polypeptide e.g. a ligand or a receptor. The art
provides numerous assays particularly useful for identifying
previously unknown binding partners for receptor polypeptides of
the invention. For example, expression cloning using mammalian or
bacterial cells, or dihybrid screening assays can be used to
identify polynucleotides encoding binding partners. As another
example, affinity chromatography with the appropriate immobilized
polypeptide of the invention can be used to isolate polypeptides
that recognize and bind polypeptides of the invention. There are a
number of different libraries used for the identification of
compounds, and in particular small molecules, that modulate (i.e.,
increase or decrease) biological activity of a polypeptide of the
invention. Ligands for receptor polypeptides of the invention can
also be identified by adding exogenous ligands, or cocktails of
ligands to two cells populations that are genetically identical
except for the expression of the receptor of the invention: one
cell population expresses the receptor of the invention whereas the
other does not. The response of the two cell populations to the
addition of ligands(s) are then compared. Alternatively, an
expression library can be co-expressed with the polypeptide of the
invention in cells, and assayed for an autocrine response to
identify potential ligand(s). As still another example, BIAcore
assays, gel overlay assays, or other methods known in the art can
be used to identify binding partner polypeptides, including, (1)
organic and inorganic chemical libraries, (2) natural product
libraries, and (3) combinatorial libraries comprised of random
peptides, oligonucleotides or organic molecules.
[0235] The role of downstream intracellular signaling molecules in
the signaling cascade of the polypeptide of the invention can be
determined. For example, a chimeric protein in which the
cytoplasmic domain of the polypeptide of the invention is fused to
the extracellular portion of a protein, whose ligand has been
identified, is produced in a host cell. The cell is then incubated
with the ligand specific for the extracellular portion of the
chimeric protein, thereby activating the chimeric receptor. Known
downstream proteins involved in intracellular signaling can then be
assayed for expected modifications i.e. phosphorylation. Other
methods known to those in the art can also be used to identify
signaling molecules involved in receptor activity.
[0236] 4.7.15 Anti-Inflammatory Activity
[0237] Compositions of the present invention may also exhibit
anti-inflammatory activity. The anti-inflammatory activity may be
achieved by providing a stimulus to cells involved in the
inflammatory response, by inhibiting or promoting cell-cell
interactions (such as, for example, cell adhesion), by inhibiting
or promoting chemotaxis of cells involved in the inflammatory
process, inhibiting or promoting cell extravasation, or by
stimulating or suppressing production of other factors which more
directly inhibit or promote an inflammatory response. Compositions
with such activities can be used to treat inflammatory conditions
including chronic or acute conditions), including without
limitation intimation associated with infection (such as septic
shock, sepsis or systemic inflammatory response syndrome (SIRS)),
ischemia-reperfusion injury, endotoxin lethality, arthritis,
complement-mediated hyperacute rejection, nephritis, cytokine or
chemokine-induced lung injury, inflammatory bowel disease, Crohn's
disease or resulting from over production of cytokines such as TNF
or IL-1. Compositions of the invention may also be useful to treat
anaphylaxis and hypersensitivity to an antigenic substance or
material. Compositions of this invention may be utilized to prevent
or treat conditions such as, but not limited to, sepsis, acute
pancreatitis, endotoxin shock, cytokine induced shock, rheumatoid
arthritis, chronic inflammatory arthritis, pancreatic cell damage
from diabetes mellitus type 1, graft versus host disease,
inflammatory bowel disease, inflamation associated with pulmonary
disease, other autoimmune disease or inflammatory disease, an
antiproliferative agent such as for acute or chronic mylegenous
leukemia or in the prevention of premature labor secondary to
intrauterine infections.
[0238] 4.7.16 Leukemias
[0239] Leukemias and related disorders may be treated or prevented
by administration of a therapeutic that promotes or inhibits
function of the polynucleotides and/or polypeptides of the
invention. Such leukemias and related disorders include but are not
limited to acute leukemia, acute lymphocytic leukemia, acute
myelocytic leukemia, myeloblastic, promyelocytic, myelomonocytic,
monocytic, erythroleukemia, chronic leukemia, chronic myelocytic
(granulocytic) leukemia and chronic lymphocytic leukemia (for a
review of such disorders, see Fishman et al., 1985, Medicine, 2d
Ed., J. B. Lippincott Co., Philadelphia).
[0240] 4.7.17 Nervous System Disorders
[0241] Nervous system disorders, involving cell types which can be
tested for efficacy of intervention with compounds that modulate
the activity of the polynucleotides and/or polypeptides of the
invention, and which can be treated upon thus observing an
indication of therapeutic utility, include but are not limited to
nervous system injuries, and diseases or disorders which result in
either a disconnection of axons, a diminution or degeneration of
neurons, or demyelination. Nervous system lesions which may be
treated in a patient (including human and non-human mammalian
patients) according to the invention include but are not limited to
the following lesions of either the central (including spinal cord,
brain) or peripheral nervous systems:
[0242] (i) traumatic lesions, including lesions caused by physical
injury or associated with surgery, for example, lesions which sever
a portion of the nervous system, or compression injuries;
[0243] (ii) ischemic lesions, in which a lack of oxygen in a
portion of the nervous system results in neuronal injury or death,
including cerebral infarction or ischemia, or spinal cord
infarction or ischemia;
[0244] (iii) infectious lesions, in which a portion of the nervous
system is destroyed or injured as a result of infection, for
example, by an abscess or associated with infection by human
immunodeficiency virus, herpes zoster, or herpes simplex virus or
with Lyme disease, tuberculosis, syphilis;
[0245] (iv) degenerative lesions, in which a portion of the nervous
system is destroyed or injured as a result of a degenerative
process including but not limited to degeneration associated with
Parkinson's disease, Alzheimer's disease, Huntington's chorea, or
amyotrophic lateral sclerosis;
[0246] (v) lesions associated with nutritional diseases or
disorders, in which a portion of the nervous system is destroyed or
injured by a nutritional disorder or disorder of metabolism
including but not limited to, vitamin B12 deficiency, folic acid
deficiency, Wernicke disease, tobacco-alcohol amblyopia,
Marchiafava-Bignami disease (primary degeneration of the corpus
callosum), and alcoholic cerebellar degeneration;
[0247] (vi) neurological lesions associated with systemic diseases
including but not limited to diabetes (diabetic neuropathy, Bell's
palsy), systemic lupus erythematosus, carcinoma, or
sarcoidosis;
[0248] (vii) lesions caused by toxic substances including alcohol,
lead, or particular neurotoxins; and
[0249] (viii) demyelinated lesions in which a portion of the
nervous system is destroyed or injured by a demyelinating disease
including but not limited to multiple sclerosis, human
immunodeficiency virus-associated myelopathy, transverse myelopathy
or various etiologies, progressive multifocal leukoencephalopathy,
and central pontine myelinolysis.
[0250] Therapeutics which are useful according to the invention for
treatment of a nervous system disorder may be selected by testing
for biological activity in promoting the survival or
differentiation of neurons. For example, and not by way of
limitation, therapeutics which elicit any of the following effects
may be useful according to the invention:
[0251] (i) increased survival time of neurons in culture;
[0252] (ii) increased sprouting of neurons in culture or in
vivo;
[0253] (iii) increased production of a neuron-associated molecule
in culture or in vivo, e.g., choline acetyltransferase or
acetylcholinesterase with respect to motor neurons; or
[0254] (iv) decreased symptoms of neuron dysfunction in vivo.
[0255] Such effects may be measured by any method known in the art.
In preferred, non-limiting embodiments, increased survival of
neurons may be measured by the method set forth in Arakawa et al.
(1990, J. Neurosci. 10:3507-3515); increased sprouting of neurons
may be detected by methods set forth in Pestronk et al. (1980, Exp.
Neurol. 70:65-82) or Brown et al. (1981, Ann. Rev. Neurosci.
4:17-42); increased production of neuron-associated molecules may
be measured by bioassay, enzymatic assay, antibody binding,
Northern blot assay, etc., depending on the molecule to be
measured; and motor neuron dysfunction may be measured by assessing
the physical manifestation of motor neuron disorder, e.g.,
weakness, motor neuron conduction velocity, or functional
disability.
[0256] In specific embodiments, motor neuron disorders that may be
treated according to the invention include but are not limited to
disorders such as infarction, infection, exposure to toxin, trauma,
surgical damage, degenerative disease or malignancy that may affect
motor neurons as well as other components of the nervous system, as
well as disorders that selectively affect neurons such as
amyotrophic lateral sclerosis, and including but not limited to
progressive spinal muscular atrophy, progressive bulbar palsy,
primary lateral sclerosis, infantile and juvenile muscular atrophy,
progressive bulbar paralysis of childhood (Fazio-Londe syndrome),
poliomyelitis and the post polio syndrome, and Hereditary
Motorsensory Neuropathy (Charcot-Marie-Tooth Disease).
[0257] 4.7.18 Other Activities
[0258] A polypeptide of the invention may also exhibit one or more
of the following additional activities or effects: inhibiting the
growth, infection or function of, or killing, infectious agents,
including, without limitation, bacteria, viruses, fungi and other
parasites; effecting (suppressing or enhancing) bodily
characteristics, including, without limitation, height, weight,
hair color, eye color, skin, fat to lean ratio or other tissue
pigmentation, or organ or body part size or shape (such as, for
example, breast augmentation or diminution, change in bone form or
shape); effecting biorhythms or circadian cycles or rhythms;
effecting the fertility of male or female subjects; effecting the
metabolism, catabolism, anabolism, processing, utilization, storage
or elimination of dietary fat, lipid, protein, carbohydrate,
vitamins, minerals, co-factors or other nutritional factors or
component(s); effecting behavioral characteristics, including,
without limitation, appetite, libido, stress, cognition (including
cognitive disorders), depression (including depressive disorders)
and violent behaviors; providing analgesic effects or other pain
reducing effects; promoting differentiation and growth of embryonic
stem cells in lineages other than hematopoietic lineages; hormonal
or endocrine activity; in the case of enzymes, correcting
deficiencies of the enzyme and treating deficiency-related
diseases; treatment of hyperproliferative disorders (such as, for
example, psoriasis); immunoglobulin-like activity (such as, for
example, the ability to bind antigens or complement); and the
ability to act as an antigen in a vaccine composition to raise an
immune response against such protein or another material or entity
which is cross-reactive with such protein.
[0259] 4.7.19 Identification of Polymorphisms
[0260] The demonstration of polymorphisms makes possible the
identification of such polymorphisms in human subjects and the
pharmacogenetic use of this information for diagnosis and
treatment. Such polymorphisms may be associated with, e.g.,
differential predisposition or susceptibility to various disease
states (such as disorders involving inflammation or immune
response) or a differential response to drug administration, and
this genetic information can be used to tailor preventive or
therapeutic treatment appropriately. For example, the existence of
a polymorphism associated with a predisposition to inflammation or
autoimmune disease makes possible the diagnosis of this condition
in humans by identifying the presence of the polymorphism.
[0261] Polymorphisms can be identified in a variety of ways known
in the art which all generally involve obtaining a sample from a
patient, analyzing DNA from the sample, optionally involving
isolation or amplification of the DNA, and identifying the presence
of the polymorphism in the DNA. For example, PCR may be used to
amplify an appropriate fragment of genomic DNA which may then be
sequenced. Alternatively, the DNA may be subjected to
allele-specific oligonucleotide hybridization (in which appropriate
oligonucleotides are hybridized to the DNA under conditions
permitting detection of a single base mismatch) or to a single
nucleotide extension assay (in which an oligonucleotide that
hybridizes immediately adjacent to the position of the polymorphism
is extended with one or more labeled nucleotides). In addition,
traditional restriction fragment length polymorphism analysis
(using restriction enzymes that provide differential digestion of
the genomic DNA depending on the presence or absence of the
polymorphism) may be performed. Arrays with nucleotide sequences of
the present invention can be used to detect polymorphisms. The
array can comprise modified nucleotide sequences of the present
invention in order to detect the nucleotide sequences of the
present invention. In the alternative, any one of the nucleotide
sequences of the present invention can be placed on the array to
detect changes from those sequences.
[0262] Alternatively a polymorphism resulting in a change in the
amino acid sequence could also be detected by detecting a
corresponding change in amino acid sequence of the protein, e.g.,
by an antibody specific to the variant sequence.
[0263] 4.7.20 Arthritis and Inflammation
[0264] The immunosuppressive effects of the compositions of the
invention against rheumatoid arthritis is determined in an
experimental animal model system. The experimental model system is
adjuvant induced arthritis in rats, and the protocol is described
by J. Holoshitz, et at., 1983, Science, 219:56, or by B. Waksman et
al., 1963, Int. Arch. Allergy Appl. Immunol., 23:129. Induction of
the disease can be caused by a single injection, generally
intradermally, of a suspension of killed Mycobacterium tuberculosis
in complete Freund's adjuvant (CFA). The route of injection can
vary, but rats may be injected at the base of the tail with an
adjuvant mixture. The polypeptide is administered in phosphate
buffered solution (PBS) at a dose of about 1-5 mg/kg. The control
consists of administering PBS only.
[0265] The procedure for testing the effects of the test compound
would consist of intradermally injecting killed Mycobacterium
tuberculosis in CFA followed by immediately administering the test
compound and subsequent treatment every other day until day 24. At
14, 15, 18, 20, 22, and 24 days after injection of Mycobacterium
CFA, an overall arthritis score may be obtained as described by J.
Holoskitz above. An analysis of the data would reveal that the test
compound would have a dramatic affect on the swelling of the joints
as measured by a decrease of the arthritis score.
[0266] 4.8 Therapeutic Methods
[0267] The compositions (including polypeptide fragments, analogs,
variants and antibodies or other binding partners or modulators
including antisense polynucleotides) of the invention have numerous
applications in a variety of therapeutic methods. Examples of
therapeutic applications include, but are not limited to, those
exemplified herein.
[0268] 4.8.1 Example
[0269] One embodiment of the invention is the administration of an
effective amount of the polypeptides or other composition of the
invention to individuals affected by a disease or disorder that can
be modulated by regulating the peptides of the invention. While the
mode of administration is not particularly important, parenteral
administration is preferred. An exemplary mode of administration is
to deliver an intravenous bolus. The dosage of the polypeptides or
other composition of the invention will normally be determined by
the prescribing physician. It is to be expected that the dosage
will vary according to the age, weight, condition and response of
the individual patient. Typically, the amount of polypeptide
administered per dose will be in the range of about 0.011 g/kg to
100 mg/kg of body weight, with the preferred dose being about 0.1
kg/kg to 10 mg/kg of patient body weight. For parenteral
administration, polypeptides of the invention will be formulated in
an injectable form combined with a pharmaceutically acceptable
parenteral vehicle. Such vehicles are well known in the art and
examples include water, saline, Ringer's solution, dextrose
solution, and solutions consisting of small amounts of the human
serum albumin. The vehicle may contain minor amounts of additives
that maintain the isotonicity and stability of the polypeptide or
other active ingredient. The preparation of such solutions is
within the skill of the art.
[0270] 4.9 Pharmaceutical Formulations and Routes of
Administration
[0271] A protein or other composition of the present invention
(from whatever source derived, including without limitation from
recombinant and non-recombinant sources and including antibodies
and other binding partners of the polypeptides of the invention)
may be administered to a patient in need, by itself, or in
pharmaceutical compositions where it is mixed with suitable
carriers or excipient(s) at doses to treat or ameliorate a variety
of disorders. Such a composition may optionally contain (in
addition to protein or other active ingredient and a carrier)
diluents, fillers, salts, buffers, stabilizers, solubilizers, and
other materials well known in the art. The term "pharmaceutically
acceptable" means a non-toxic material that does not interfere with
the effectiveness of the biological activity of the active
ingredient(s). The characteristics of the carrier will depend on
the route of administration. The pharmaceutical composition of the
invention-may also contain cytokines, lymphokines, or other
hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3,
IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13,
IL-14, IL-15, IFN, TNF0, TNF1, TNF2, G-CSF, Meg-CSF,
thrombopoietin, stem cell factor, and erythropoietin. In further
compositions, proteins of the invention may be combined with other
agents beneficial to the treatment of the disease or disorder in
question. These agents include various growth factors such as
epidermal growth factor (EGF), platelet-derived growth factor
(PDGF), transforming growth factors (TGF.alpha. and TGF-.beta.),
insulin-like growth factor (IGF), as well as cytokines described
herein.
[0272] The pharmaceutical composition may farther contain other
agents which either enhance the activity of the protein or other
active ingredient or complement its activity or use in treatment.
Such additional factors and/or agents may be included in the
pharmaceutical composition to produce a synergistic effect with
protein or other active ingredient of the invention, or to minimize
side effects. Conversely, protein or other active ingredient of the
present invention may be included in formulations of the particular
clotting factor, cytokine, lymphokine, other hematopoietic factor,
thrombolytic or anti-thrombotic factor, or anti-inflammatory agent
to minimize side effects of the clotting factor, cytokine,
lymphokine, other hematopoietic factor, thrombolytic or
anti-thrombotic factor, or anti-inflammatory agent (such as IL-1Ra,
IL-1 Hyl, IL-1 Hy2, anti-TNF, corticosteroids, immunosuppressive
agents). A protein of the present invention may be active in
multimers (e.g., heterodimers or homodimers) or complexes with
itself or other proteins. As a result, pharmaceutical compositions
of the invention may comprise a protein of the invention in such
multimeric or complexed form.
[0273] As an alternative to being included in a pharmaceutical
composition of the invention including a first protein, a second
protein or a therapeutic agent may be concurrently administered
with the first protein (e.g., at the same time, or at differing
times provided that therapeutic concentrations of the combination
of agents is achieved at the treatment site). Techniques for
formulation and administration of the compounds of the instant
application may be found in "Remington's Pharmaceutical Sciences,"
Mack Publishing Co., Easton, Pa., latest edition. A therapeutically
effective dose further refers to that amount of the compound
sufficient to result in amelioration of symptoms, e.g., treatment,
healing, prevention or amelioration of the relevant medical
condition, or an increase in rate of treatment, healing, prevention
or amelioration of such conditions. When applied to an individual
active ingredient, administered alone, a therapeutically effective
dose refers to that ingredient alone. When applied to a
combination, a therapeutically effective dose refers to combined
amounts of the active ingredients that result in the therapeutic
effect, whether administered in combination, serially or
simultaneously.
[0274] In practicing the method of treatment or use of the present
invention, a therapeutically effective amount of protein or other
active ingredient of the present invention is administered to a
mammal having a condition to be treated. Protein or other active
ingredient of the present invention may be administered in
accordance with the method of the invention either alone or in
combination with other therapies such as treatments employing
cytokines, lymphokines or other hematopoietic factors. When
co-administered with one or more cytokines, lymphokines or other
hematopoietic factors, protein or other active ingredient of the
present invention may be administered either simultaneously with
the cytokine(s), lymphokine(s), other hematopoietic factor(s),
thrombolytic or anti-thrombotic factors, or sequentially. If
administered sequentially, the attending physician will decide on
the appropriate sequence of administering protein or other active
ingredient of the present invention in combination with
cytokine(s), lymphokine(s), other hematopoietic factor(s),
thrombolytic or anti-thrombotic factors.
[0275] 4.9.1 Routes of Administration
[0276] Suitable routes of administration may, for example, include
oral, rectal, transmucosal, or intestinal-administration;
parenteral delivery, including intramuscular, subcutaneous,
intramedullary injections, as well as intrathecal, direct
intraventricular, intravenous, intraperitoneal, intranasal, or
intraocular injections. Administration of protein or other active
ingredient of the present invention used in the pharmaceutical
composition or to practice the method of the present invention can
be carried out in a variety of conventional ways, such as oral
ingestion, inhalation, topical application or cutaneous,
subcutaneous, intraperitoneal, parenteral or intravenous injection.
Intravenous administration to the patient is preferred.
[0277] Alternately, one may administer the compound in a local
rather than systemic manner, for example, via injection of the
compound directly into a arthritic joints or in fibrotic tissue,
often in a depot or sustained release formulation. In order to
prevent the scarring process frequently occurring as complication
of glaucoma surgery, the compounds may be administered topically,
for example, as eye drops. Furthermore, one may administer the drug
in a targeted drug delivery system, for example, in a liposome
coated with a specific antibody, targeting, for example, arthritic
or fibrotic tissue. The liposomes will be targeted to and taken up
selectively by the afflicted tissue.
[0278] The polypeptides of the invention are administered by any
route that delivers an effective dosage to the desired site of
action. The determination of a suitable route of administration and
an effective dosage for a particular indication is within the level
of skill in the art. Preferably for wound treatment, one
administers the therapeutic compound directly to the site. Suitable
dosage ranges for the polypeptides of the invention can be
extrapolated from these dosages or from similar studies in
appropriate animal models. Dosages can then be adjusted as
necessary by the clinician to provide maximal therapeutic
benefit.
[0279] 4.9.2 Compositions/Formulations
[0280] Pharmaceutical compositions for use in accordance with the
present invention thus may be formulated in a conventional manner
using one or more physiologically acceptable carriers comprising
excipients and auxiliaries which facilitate processing of the
active compounds into preparations which can be used
pharmaceutically. These pharmaceutical compositions may be
manufactured in a manner that is itself known, e.g., by means of
conventional mixing, dissolving, granulating, dragee-making,
levigating, emulsifying, encapsulating, entrapping or lyophilizing
processes. Proper formulation is dependent upon the route of
administration chosen. When a therapeutically effective amount of
protein or other active ingredient of the present invention is
administered orally, protein or other active ingredient of the
present invention will be in the form of a tablet, capsule, powder,
solution or elixir. When administered in tablet form, the
pharmaceutical composition of the invention may additionally
contain a solid carrier such as a gelatin or an adjuvant. The
tablet, capsule, and powder contain from about 5 to 95% protein or
other active ingredient of the present invention, and preferably
from about 25 to 90% protein or other active ingredient of the
present invention. When administered in liquid form, a liquid
carrier such as water, petroleum, oils of animal or plant origin
such as peanut oil, mineral oil, soybean oil, or sesame oil, or
synthetic oils may be added. The liquid form of the pharmaceutical
composition may further contain physiological saline solution,
dextrose or other saccharide solution, or glycols such as ethylene
glycol, propylene glycol or polyethylene glycol. When administered
in liquid form, the pharmaceutical composition contains from about
0.5 to 90% by weight of protein or other active ingredient of the
present invention, and preferably from about 1 to 50% protein or
other active ingredient of the present invention.
[0281] When a therapeutically effective amount of protein or other
active ingredient of the present invention is administered by
intravenous, cutaneous or subcutaneous injection, protein or other
active ingredient of the present invention will be in the form of a
pyrogen-free, parenterally acceptable aqueous solution. The
preparation of such parenterally acceptable protein or other active
ingredient solutions, having due regard to pH, isotonicity,
stability, and the like, is within the skill in the art. A
preferred pharmaceutical composition for intravenous, cutaneous, or
subcutaneous injection should contain, in addition to protein or
other active ingredient of the present invention, an isotonic
vehicle such as Sodium Chloride Injection, Ringer's Injection,
Dextrose Injection, Dextrose and Sodium Chloride Injection,
Lactated Ringer's Injection, or other vehicle as known in the art.
The pharmaceutical composition of the present invention may also
contain stabilizers, preservatives, buffers, antioxidants, or other
additives known to those of skill in the art. For injection, the
agents of the invention may be formulated in aqueous solutions,
preferably in physiologically compatible buffers such as Hanks's
solution, Ringer's solution, or physiological saline buffer. For
transmucosal administration, penetrants appropriate to the barrier
to be permeated are used in the formulation. Such penetrants are
generally known in the art.
[0282] For oral administration, the compounds can be formulated
readily by combining the active compounds with pharmaceutically
acceptable carriers well known in the art. Such carriers enable the
compounds of the invention to be formulated as tablets, pills,
dragees, capsules, liquids, gels, syrups, slurries, suspensions and
the like, for oral ingestion by a patient to be treated.
Pharmaceutical preparations for oral use can be obtained from a
solid excipient, optionally grinding a resulting mixture, and
processing the mixture of granules, after adding suitable
auxiliaries, if desired, to obtain tablets or dragee cores.
Suitable excipients are, in particular, fillers such as sugars,
including lactose, sucrose, mannitol, or sorbitol; cellulose
preparations such as, for example, maize starch, wheat starch, rice
starch, potato starch, gelatin, gum tragacanth, methyl cellulose,
hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose,
and/or polyvinylpyrrolidone (PVP). If desired, disintegrating
agents may be added, such as the cross-linked polyvinyl
pyrrolidone, agar, or alginic acid or a salt thereof such as sodium
alginate. Dragee cores are provided with suitable coatings. For
this purpose, concentrated sugar solutions may be used, which may
optionally contain gum arabic, talc, polyvinyl pyrrolidone,
carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer
solutions, and suitable organic solvents or solvent mixtures.
Dyestuffs or pigments may be added to the tablets or dragee
coatings for identification or to characterize different
combinations of active compound doses.
[0283] Pharmaceutical preparations which can be used orally include
push-fit capsules made of gelatin, as well as soft, sealed capsules
made of gelatin and a plasticizer, such as glycerol or sorbitol.
The push-fit capsules can contain the active ingredients in
admixture with filler such as lactose, binders such as starches,
and/or lubricants such as talc or magnesium stearate and,
optionally, stabilizers. In soft capsules, the active compounds may
be dissolved or suspended in suitable liquids, such as fatty oils,
liquid paraffin, or liquid polyethylene glycols. In addition,
stabilizers may be added. All formulations for oral administration
should be in dosages suitable for such administration. For buccal
administration, the compositions may take the form of tablets or
lozenges formulated in conventional manner.
[0284] For administration by inhalation, the compounds for use
according to the present invention are conveniently delivered in
the form of an aerosol spray presentation from pressurized packs or
a nebuliser, with the use of a suitable propellant, e.g.,
dichlorodifluoromethane, trichlorofluoromethane,
dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In
the case of a pressurized aerosol the dosage unit may be determined
by providing a valve to deliver a metered amount. Capsules and
cartridges of, e.g., gelatin for use in an inhaler or insufflator
may be formulated containing a powder mix of the compound and a
suitable powder base such as lactose or starch. The compounds may
be formulated for parenteral administration by injection, e.g., by
bolus injection or continuous infusion. Formulations for injection
may be presented in unit dosage form, e.g., in ampules or in
multi-dose containers, with an added preservative. The compositions
may take such forms as suspensions, solutions or emulsions in oily
or aqueous vehicles, and may contain formulatory agents such as
suspending, stabilizing and/or dispersing agents.
[0285] Pharmaceutical formulations for parenteral administration
include aqueous solutions of the active compounds in water-soluble
form. Additionally, suspensions of the active compounds may be
prepared as appropriate oily injection suspensions. Suitable
lipophilic solvents or vehicles include fatty oils such as sesame
oil, or synthetic fatty acid esters, such as ethyl oleate or
triglycerides, or liposomes. Aqueous injection suspensions may
contain substances which increase the viscosity of the suspension,
such as sodium carboxymethyl cellulose, sorbitol, or dextran.
Optionally, the suspension may also contain suitable stabilizers or
agents which increase the solubility of the compounds to allow for
the preparation of highly concentrated solutions. Alternatively,
the active ingredient may be in powder form for constitution with a
suitable vehicle, e.g., sterile pyrogen-free water, before use.
[0286] The compounds may also be formulated in rectal compositions
such as suppositories or retention enemas, e.g., containing
conventional suppository bases such as cocoa butter or other
glycerides. In addition to the formulations described previously,
the compounds may also be formulated as a depot preparation. Such
long acting formulations may be administered by implantation (for
example subcutaneously or intramuscularly) or by intramuscular
injection. Thus, for example, the compounds may be formulated with
suitable polymeric or hydrophobic materials (for example as an
emulsion in an acceptable oil) or ion exchange resins, or as
sparingly soluble derivatives, for example, as a sparingly soluble
salt.
[0287] A pharmaceutical carrier for the hydrophobic compounds of
the invention is a co-solvent system comprising benzyl alcohol, a
nonpolar surfactant, a water-miscible organic polymer, and an
aqueous phase. The co-solvent system may be the VPD co-solvent
system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the
nonpolar surfactant polysorbate 80, and 65% w/v polyethylene glycol
300, made up to volume in absolute ethanol. The VPD co-solvent
system (VPD:5W) consists of VPD diluted 1:1 with a 5% dextrose in
water solution. This co-solvent system dissolves hydrophobic
compounds well, and itself produces low toxicity upon systemic
administration. Naturally, the proportions of a co-solvent system
may be varied considerably without destroying its solubility and
toxicity characteristics. Furthermore, the identity of the
co-solvent components may be varied: for example, other
low-toxicity nonpolar surfactants may be used instead of
polysorbate 80; the fraction size of polyethylene glycol may be
varied; other biocompatible polymers may replace polyethylene
glycol, e.g. polyvinyl pyrrolidone; and other sugars or
polysaccharides may substitute for dextrose. Alternatively, other
delivery systems for hydrophobic pharmaceutical compounds may be
employed. Liposomes and emulsions are well known examples of
delivery vehicles or carriers for hydrophobic drugs. Certain
organic solvents such as dimethylsulfoxide also may be employed,
although usually at the cost of greater toxicity. Additionally, the
compounds may be delivered using a sustained-release system, such
as semipermeable matrices of solid hydrophobic polymers containing
the therapeutic agent. Various types of sustained-release materials
have been established and are well known by those skilled in the
art. Sustained-release capsules may, depending on their chemical
nature, release the compounds for a few weeks up to over 100 days.
Depending on the chemical nature and the biological stability of
the therapeutic reagent, additional strategies for protein or other
active ingredient stabilization may be employed.
[0288] The pharmaceutical compositions also may comprise suitable
solid or gel phase carriers or excipients. Examples of such
carriers or excipients include but are not limited to calcium
carbonate, calcium phosphate, various sugars, starches, cellulose
derivatives, gelatin, and polymers such as polyethylene glycols.
Many of the active ingredients of the invention may be provided as
salts with pharmaceutically compatible counter ions. Such
pharmaceutically acceptable base addition salts are those salts
which retain the biological effectiveness and properties of the
free acids and which are obtained by reaction with inorganic or
organic bases such as sodium hydroxide, magnesium hydroxide,
ammonia, trialkylamine, dialkylamine, monoalkylamine, dibasic amino
acids, sodium acetate, potassium benzoate, triethanol amine and the
like.
[0289] The pharmaceutical composition of the invention may be in
the form of a complex of the protein(s) or other active
ingredient(s) of present invention along with protein or peptide
antigens. The protein and/or peptide antigen will deliver a
stimulatory signal to both B and T lymphocytes. B lymphocytes will
respond to antigen through their surface immunoglobulin receptor. T
lymphocytes will respond to antigen through the T cell receptor
(TCR) following presentation of the antigen by MHC proteins. MHC
and structurally related proteins including those encoded by class
I and class II MHC genes on host cells will serve to present the
peptide antigen(s) to T lymphocytes. The antigen components could
also be supplied as purified MHC-peptide complexes alone or with
co-stimulatory molecules that can directly signal T cells.
Alternatively antibodies able to bind surface immunoglobulin and
other molecules on B cells as well as antibodies able to bind the
TCR and other molecules on T cells can be combined with the
pharmaceutical composition of the invention.
[0290] The pharmaceutical composition of the invention may be in
the form of a liposome in which protein of the present invention is
combined, in addition to other pharmaceutically acceptable
carriers, with amphipathic agents such as lipids which exist in
aggregated form as micelles, insoluble monolayers, liquid crystals,
or lamellar layers in aqueous solution. Suitable lipids for
liposomal formulation include, without limitation, monoglycerides,
diglycerides, sulfatides, lysolecithins, phospholipids, saponin,
bile acids, and the like. Preparation of such liposomal
formulations is within the level of skill in the art, as disclosed,
for example, in U.S. Pat. Nos. 4,235,871; 4,501,728; 4,837,028; and
4,737,323, all of which are incorporated herein by reference.
[0291] The amount of protein or other active ingredient of the
present invention in the pharmaceutical composition of the present
invention will depend upon the nature and severity of the condition
being treated, and on the nature of prior treatments which the
patient has undergone. Ultimately, the attending physician will
decide the amount of protein or other active ingredient of the
present invention with which to treat each individual patient.
Initially, the attending physician will administer low doses of
protein or other active ingredient of the present invention and
observe the patient's response. Larger doses of protein or other
active ingredient of the present invention may be administered
until the optimal therapeutic effect is obtained for the patient,
and at that point the dosage is not increased further. It is
contemplated that the various pharmaceutical compositions used to
practice the method of the present invention should contain about
0.01 .mu.g to about 100 mg (preferably about 0.1 .mu.g to about 10
mg, more preferably about 0.1 .mu.g to about 1 mg) of protein or
other active ingredient of the present invention per kg body
weight. For compositions of the present invention which are useful
for bone, cartilage, tendon or ligament regeneration, the
therapeutic method includes administering the composition
topically, systematically, or locally as an implant or device. When
administered, the therapeutic composition for use in this invention
is, of course, in a pyrogen-free, physiologically acceptable form.
Further, the composition may desirably be encapsulated or injected
in a viscous form for delivery to the site of bone, cartilage or
tissue damage. Topical administration may be suitable for wound
healing and tissue repair. Therapeutically useful agents other than
a protein or other active ingredient of the invention which may
also optionally be included in the composition as described above,
may alternatively or additionally, be administered simultaneously
or sequentially with the composition in the methods of the
invention. Preferably for bone and/or cartilage formation, the
composition would include a matrix capable of delivering the
protein-containing or other active ingredient-containing
composition to the site of bone and/or cartilage damage, providing
a structure for the developing bone and cartilage and optimally
capable of being resorbed into the body. Such matrices may be
formed of materials presently in use for other implanted medical
applications.
[0292] The choice of matrix material is based on biocompatibility,
biodegradability, mechanical properties, cosmetic appearance and
interface properties. The particular application of the
compositions will define the appropriate formulation. Potential
matrices for the compositions may be biodegradable and chemically
defined calcium sulfate, tricalcium phosphate, hydroxyapatite,
polylactic acid, polyglycolic acid and polyanhydrides. Other
potential materials are biodegradable and biologically
well-defined, such as bone or dermal collagen. Further matrices are
comprised of pure proteins or extracellular matrix components.
Other potential matrices are nonbiodegradable and chemically
defined, such as sintered hydroxyapatite, bioglass, aluminates, or
other ceramics. Matrices may be comprised of combinations of any of
the above mentioned types of material, such as polylactic acid and
hydroxyapatite or collagen and tricalcium phosphate. The
bioceramics may be altered in composition, such as in
calcium-aluminate-phosphate and processing to alter pore size,
particle size, particle shape, and biodegradability. Presently
preferred is a 50:50 (mole weight) copolymer of lactic acid and
glycolic acid in the form of porous particles having diameters
ranging from 150 to 800 microns. In some applications, it will be
useful to utilize a sequestering agent, such as carboxymethyl
cellulose or autologous blood clot, to prevent the protein
compositions from disassociating from the matrix.
[0293] A preferred family of sequestering agents is cellulosic
materials such as alkylcelluloses (including
hydroxyalkylcelluloses), including methylcellulose, ethylcellulose,
hydroxyethylcellulose, hydroxypropylcellulose,
hydroxypropyl-methylcellulose, and carboxymethylcellulose, the most
preferred being cationic salts of carboxymethylcellulose (CMC).
Other preferred sequestering agents include hyaluronic acid, sodium
alginate, poly(ethylene glycol), polyoxyethylene oxide,
carboxyvinyl polymer and poly(vinyl alcohol). The amount of
sequestering agent useful herein is 0.5-20 wt %, preferably 1-10 wt
% based on total formulation weight, which represents the amount
necessary to prevent desorption of the protein from the polymer
matrix and to provide appropriate handling of the composition, yet
not so much that the progenitor cells are prevented from
infiltrating the matrix, thereby providing the protein the
opportunity to assist the osteogenic activity of the progenitor
cells. In further compositions, proteins or other active
ingredients of the invention may be combined with other agents
beneficial to the treatment of the bone and/or cartilage defect,
wound, or tissue in question. These agents include various growth
factors such as epidermal growth factor (EGF), platelet derived
growth factor (PDGF), transforming growth factors (TGF-.alpha. and
TGF-.beta.), and insulin-like growth factor (IGF).
[0294] The therapeutic compositions are also presently valuable for
veterinary applications. Particularly domestic animals and
thoroughbred horses, in addition to humans, are desired patients
for such treatment with proteins or other active ingredients of the
present invention. The dosage regimen of a protein-containing
pharmaceutical composition to be used in tissue regeneration will
be determined by the attending physician considering various
factors which modify the action of the proteins, e.g., amount of
tissue weight desired to be formed, the site of damage, the
condition of the damaged tissue, the size of a wound, type of
damaged tissue (e.g., bone), the patient's age, sex, and diet, the
severity of any infection, time of administration and other
clinical factors. The dosage may vary with the type of matrix used
in the reconstitution and with inclusion of other proteins in the
pharmaceutical composition. For example, the addition of other
known growth factors, such as IGF I (insulin like growth factor I),
to the final composition, may also effect the dosage. Progress can
be monitored by periodic assessment of tissue/bone growth and/or
repair, for example, X-rays, histomorphometric determinations and
tetracycline labeling.
[0295] Polynucleotides of the present invention can also be used
for gene therapy. Such polynucleotides can be introduced either in
vivo or ex vivo into cells for expression in a mammalian subject.
Polynucleotides of the invention may also be administered by other
known methods for introduction of nucleic acid into a cell or
organism (including, without limitation, in the form of viral
vectors or naked DNA). Cells may also be cultured ex vivo in the
presence of proteins of the present invention in order to
proliferate or to produce a desired effect on or activity in such
cells. Treated cells can then be introduced in vivo for therapeutic
purposes.
[0296] 4.9.3 Effective Dosage
[0297] Pharmaceutical compositions suitable for use in the present
invention include compositions wherein the active ingredients are
contained in an effective amount to achieve its intended purpose.
More specifically, a therapeutically effective amount means an
amount effective to prevent development of or to alleviate the
existing symptoms of the subject being treated. Determination of
the effective amount is well within the capability of those skilled
in the art, especially in light of the detailed disclosure provided
herein. For any compound used in the method of the invention, the
therapeutically effective dose can be estimated initially from
appropriate in vitro assays. For example, a dose can be formulated
in animal models to achieve a circulating concentration range that
can be used to more accurately determine useful doses in humans.
For example, a dose can be formulated in animal models to achieve a
circulating concentration range that includes the IC.sub.50 as
determined in cell culture (i.e., the concentration of the test
compound which achieves a half-maximal inhibition of the protein's
biological activity). Such information can be used to more
accurately determine useful doses in humans.
[0298] A therapeutically effective dose refers to that amount of
the compound that results in amelioration of symptoms or a
prolongation of survival in a patient. Toxicity and therapeutic
efficacy of such compounds can be determined by standard
pharmaceutical procedures in cell cultures or experimental animals,
e.g., for determining the LD.sub.50 (the dose lethal to 50% of the
population) and the ED.sub.50 (the dose therapeutically effective
in 50% of the population). The dose ratio between toxic and
therapeutic effects is the therapeutic index and it can be
expressed as the ratio between LD.sub.50 and ED.sub.50. Compounds
which exhibit high therapeutic indices are preferred. The data
obtained from these cell culture assays and animal studies can be
used in formulating a range of dosage for use in human. The dosage
of such compounds lies preferably within a range of circulating
concentrations that include the ED.sub.50 with little or no
toxicity. The dosage may vary within this range depending upon the
dosage form employed and the route of administration utilized. The
exact formulation, route of administration and dosage can be chosen
by the individual physician in view of the patient's condition.
See, e.g., Fingl et al., 1975, in "The Pharmacological Basis of
Therapeutics", Ch. 1 p. 1. Dosage amount and interval may be
adjusted individually to provide plasma levels of the active moiety
which are sufficient to maintain the desired effects, or minimal
effective concentration (MEC). The MEC will vary for each compound
but can be estimated from in vitro data. Dosages necessary to
achieve the MEC will depend on individual characteristics and route
of administration. However, HPLC assays or bioassays can be used to
determine plasma concentrations.
[0299] Dosage intervals can also be determined using MEC value.
Compounds should be administered using a regimen which maintains
plasma levels above the MEC for 10-90% of the time, preferably
between 30-90% and most preferably between 50-90%. In cases of
local administration or selective uptake, the effective local
concentration of the drug may not be related to plasma
concentration.
[0300] An exemplary dosage regimen for polypeptides or other
compositions of the invention will be in the range of about 0.01
.mu.g/kg to 100 mg/kg of body weight daily, with the preferred dose
being about 0.11 g/kg to 25 mg/kg of patient body weight daily,
varying in adults and children. Dosing may be once daily, or
equivalent doses may be delivered at longer or shorter
intervals.
[0301] The amount of composition administered will, of course, be
dependent on the subject being treated, on the subject's age and
weight, the severity of the affliction, the manner of
administration and the judgment of the prescribing physician.
[0302] 4.9.4 Packaging
[0303] The compositions may, if desired, be presented in a pack or
dispenser device which may contain one or more unit dosage forms
containing the active ingredient. The pack may, for example,
comprise metal or plastic foil, such as a blister pack. The pack or
dispenser device may be accompanied by instructions for
administration. Compositions comprising a compound of the invention
formulated in a compatible pharmaceutical carrier may also be
prepared, placed in an appropriate container, and labeled for
treatment of an indicated condition.
[0304] 4.10 Antibodies
[0305] Another aspect of the invention is an antibody that
specifically binds the polypeptide of the invention. Such
antibodies include monoclonal and polygonal antibodies, single
chain antibodies, chimeric antibodies, bifunctional/bispecific
antibodies, humanized antibodies, human antibodies, and
complementary determining region (CDR)-grafted antibodies,
including compounds which include CDR and/or antigen-binding
sequences, which specifically recognize a polypeptide of the
invention. Preferred antibodies of the invention are human
antibodies which are produced and identified according to methods
described in WO93/11236, published Jun. 20, 1993, which is
incorporated herein by reference in its entirety. Antibody
fragments, including Fab, Fab', F(ab').sub.2, and F.sub.v, are also
provided by the invention. The term "specific for" indicates that
the variable regions of the antibodies of the invention recognize
and bind polypeptides of the invention exclusively (i.e., able to
distinguish the polypeptide of the invention from other similar
polypeptides despite sequence identity, homology, or similarity
found in the family of polypeptides), but may also interact with
other proteins (for example, S. aureus protein A or other
antibodies in ELISA techniques) through interactions with sequences
outside the variable region of the antibodies, and in particular,
in the constant region of the molecule. Screening assays to
determine binding specificity of an antibody of the invention are
well known and routinely practiced in the art. For a comprehensive
discussion of such assays, see Harlow et al. (Eds), Antibodies A
Laboratory Manual; Cold Spring Harbor Laboratory; Cold Spring
Harbor, N.Y. (1988), Chapter 6. Antibodies that recognize and bind
fragments of the polypeptides of the invention are also
contemplated, provided that the antibodies are first and foremost
specific for, as defined above, full length polypeptides of the
invention. As with antibodies that are specific for full length
polypeptides of the invention, antibodies of the invention that
recognize fragments are those which can distinguish polypeptides
from the same family of polypeptides despite inherent sequence
identity, homology, or similarity found in the family of proteins.
Antibodies of the invention can be produced using any method well
known and routinely practiced in the art.
[0306] Non-human antibodies may be humanized by any methods known
in the art. In one method, the non-human CDRs are inserted into a
human antibody or consensus antibody framework sequence. Further
changes can then be introduced into the antibody framework to
modulate affinity or immunogenicity.
[0307] Antibodies of the invention are useful for, for example,
therapeutic purposes (by modulating activity of a polypeptide of
the invention), diagnostic purposes to detect or quantitate a
polypeptide of the invention, as well as purification of a
polypeptide of the invention. Kits comprising an antibody of the
invention for any of the purposes described herein are also
comprehended. In general, a kit of the invention also includes a
control antigen for which the antibody is immunospecific. The
invention further provides a hybridoma that produces an antibody
according to the invention. Antibodies of the invention are useful
for detection and/or purification of the polypeptides of the
invention.
[0308] Polypeptides of the invention may also be used to immunize
animals to obtain polyclonal and monoclonal antibodies which
specifically react with the protein. Such antibodies may be
obtained using either the entire protein or fragments thereof as an
immunogen. The peptide immunogens additionally may contain a
cysteine residue at the carboxyl terminus, and are conjugated to a
hapten such as keyhole limpet hemocyanin (KLH). Methods for
synthesizing such peptides are known in the art, for example, as in
R. P. Merrifield, J. Amer. Chem. Soc. 85, 2149-2154 (1963); J. L.
Krstenansky, et al., FEBS Lett. 211, 10 (1987).
[0309] Monoclonal antibodies binding to the protein of the
invention may be useful diagnostic agents for the immunodetection
of the protein. Neutralizing monoclonal antibodies binding to the
protein may also be useful therapeutics for both conditions
associated with the protein and also in the treatment of some forms
of cancer where abnormal expression of the protein is involved. In
the case of cancerous cells or leukemic cells, neutralizing
monoclonal antibodies against the protein may be useful in
detecting and preventing the metastatic spread of the cancerous
cells, which may be mediated by the protein. In general, techniques
for preparing polyclonal and monoclonal antibodies as well as
hybridomas capable of producing the desired antibody are well known
in the art (Campbell, A. M., Monoclonal Antibodies Technology:
Laboratory Techniques in Biochemistry and Molecular Biology,
Elsevier Science Publishers, Amsterdam, The Netherlands (1984); St.
Groth et al., J. Immunol. 35:1-21 (1990); Kohler and Milstein,
Nature 256:495-497 (1975)), the trioma technique, the human B-cell
hybridoma technique (Kozbor et al., Immunology Today 4:72 (1983);
Cole et al., in Monoclonal Antibodies and Cancer Therapy, Alan R.
Liss, Inc. (1985), pp. 77-96).
[0310] Any animal (mouse, rabbit, etc.) which is known to produce
antibodies can be immunized with a peptide or polypeptide of the
invention. Methods for immunization are well known in the art. Such
methods include subcutaneous or intraperitoneal injection of the
polypeptide. One skilled in the art will recognize that the amount
of the protein encoded by the ORF of the present invention used for
immunization will vary based on the animal which is immunized, the
antigenicity of the peptide and the site of injection. The protein
that is used as an immunogen may be modified or administered in an
adjuvant in order to increase the protein's antigenicity. Methods
of increasing the antigenicity of a protein are well known in the
art and include, but are not limited to, coupling the antigen with
a heterologous protein (such as globulin or .beta.-galactosidase)
or through the inclusion of an adjuvant during immunization.
[0311] For monoclonal antibodies, spleen cells from the immunized
animals are removed, fused with myeloma cells, such as SP2/0-Ag14
myeloma cells, and allowed to become monoclonal antibody producing
hybridoma cells. Any one of a number of methods well known in the
art can be used to identify the hybridoma cell which produces an
antibody with the desired characteristics. These include screening
the hybridomas with an ELISA assay, Western blot analysis, or
radioimmunoassay (Lutz et al., Exp. Cell Research. 175:109-124
(1988)). Hybridomas secreting the desired antibodies are cloned and
the class and subclass is determined using procedures known in the
art (Campbell, A. M., Monoclonal Antibody Technology: Laboratory
Techniques in Biochemistry and Molecular Biology, Elsevier Science
Publishers, Amsterdam, The Netherlands (1984)). Techniques
described for the production of single chain antibodies (U.S. Pat.
No. 4,946,778) can be adapted to produce single chain antibodies to
proteins of the present invention.
[0312] For polyclonal antibodies, antibody-containing antiserum is
isolated from the immunized animal and is screened for the presence
of antibodies with the desired specificity using one of the
above-described procedures. The present invention further provides
the above-described antibodies in delectably labeled form.
Antibodies can be delectably labeled through the use of
radioisotopes, affinity labels (such as biotin, avidin, etc.),
enzymatic labels (such as horseradish peroxidase, alkaline
phosphatase, etc.) fluorescent labels (such as FITC or rhodamine,
etc.), paramagnetic atoms, etc. Procedures for accomplishing such
labeling are well-known in the art, for example, see (Sternberger,
L. A. et al., J. Histochem. Cytochem. 18:315 (1970); Bayer, E. A.
et al., Meth. Enzym. 62:308 (1979); Engval, E. et al., Immunol.
109:129 (1972); Goding, J. W. J. Immunol. Meth. 13:215 (1976)).
[0313] The labeled antibodies of the present invention can be used
for in vitro, in vivo, and in situ assays to identify cells or
tissues in which a fragment of the polypeptide of interest is
expressed. The antibodies may also be used directly in therapies or
other diagnostics. The present invention further provides the
above-described antibodies immobilized on a solid support. Examples
of such solid supports include plastics such as polycarbonate,
complex carbohydrates such as agarose and Sepharose.RTM., acrylic
resins and such as polyacrylamide and latex beads. Techniques for
coupling antibodies to such solid supports are well known in the
art (Weir, D. M. et al., "Handbook of Experimental Immunology" 4th
Ed., Blackwell Scientific Publications, Oxford, England, Chapter 10
(1986); Jacoby, W. D. et al., Meth. Enzym. 34 Academic Press, N.Y.
(1974)). The immobilized antibodies of the present invention can be
used for in vitro, in vivo, and in situ assays as well as for
immuno-affinity purification of the proteins of the present
invention.
[0314] 4.11 Computer Readable Sequences
[0315] In one application of this embodiment, a nucleotide sequence
of the present invention can be recorded on computer readable
media. As used herein, "computer readable media" refers to any
medium which can be read and accessed directly by a computer. Such
media include, but are not limited to: magnetic storage media, such
as floppy discs, hard disc storage medium, and magnetic tape;
optical storage media such as CD-ROM; electrical storage media such
as RAM and ROM; and hybrids of these categories such as
magnetic/optical storage media. A skilled artisan can readily
appreciate how any of the presently known computer readable mediums
can be used to create a manufacture comprising computer readable
medium having recorded thereon a nucleotide sequence of the present
invention. As used herein, "recorded" refers to a process for
storing information on computer readable medium. A skilled artisan
can readily adopt any of the presently known methods for recording
information on computer readable medium to generate manufactures
comprising the nucleotide sequence information of the present
invention.
[0316] A variety of data storage structures are available to a
skilled artisan for creating a computer readable medium having
recorded thereon a nucleotide sequence of the present invention.
The choice of the data storage structure will generally be based on
the means chosen to access the stored information. In addition, a
variety of data processor programs and formats can be used to store
the nucleotide sequence information of the present invention on
computer readable medium. The sequence information can be
represented in a word processing text file, formatted in
commercially-available software such as WordPerfect and Microsoft
Word, or represented in the form of an ASCII file, stored in a
database application, such as DB2, Sybase, Oracle, or the like. A
skilled artisan can readily adapt any number of data processor
structuring formats (e.g. text file or database) in order to obtain
computer readable medium having recorded thereon the nucleotide
sequence information of the present invention.
[0317] By providing any of the nucleotide sequences SEQ ID NOs:
1-13 or a representative fragment thereof; or a nucleotide sequence
at least 95% identical to any of the nucleotide sequences of SEQ ID
NOs: 1-13 in computer readable form, a skilled artisan can
routinely access the sequence information for a variety of
purposes. Computer software is publicly available which allows a
skilled artisan to access sequence information provided in a
computer readable medium. The examples which follow demonstrate how
software which implements the BLAST (Altschul et al., J. Mol. Biol.
215:403-410 (1990)) and BLAZE (Brutlag et al., Comp. Chem.
17:203-207 (1993)) search algorithms on a Sybase system is used to
identify open reading frames (ORFs) within a nucleic acid sequence.
Such ORFs may be protein encoding fragments and may be useful in
producing commercially important proteins such as enzymes used in
fermentation reactions and in the production of commercially useful
metabolites.
[0318] As used herein, "a computer-based system" refers to the
hardware means, software means, and data storage means used to
analyze the nucleotide sequence information of the present
invention. The minimum hardware means of the computer-based systems
of the present invention comprises a central processing unit (CPU),
input means, output means, and data storage means. A skilled
artisan can readily appreciate that any one of the currently
available computer-based systems are suitable for use in the
present invention. As stated above, the computer-based systems of
the present invention comprise a data storage means having stored
therein a nucleotide sequence of the present invention and the
necessary hardware means and software means for supporting and
implementing a search means. As used herein, "data storage means"
refers to memory which can store nucleotide sequence information of
the present invention, or a memory access means which can access
manufactures having recorded thereon the nucleotide sequence
information of the present invention.
[0319] As used herein, "search means" refers to one or more
programs which are implemented on the computer-based system to
compare a target sequence or target structural motif with the
sequence information stored within the data storage means. Search
means are used to identify fragments or regions of a known sequence
which match a particular target sequence or target motif. A variety
of known algorithms are disclosed publicly and a variety of
commercially available software for conducting search means are and
can be used in the computer-based systems of the present invention.
Examples of such software includes, but is not limited to,
Smith-Waterman, MacPattern (EMBL), BLASTN and BLASTA
(NPOLYPEPTIDEIA). A skilled artisan can readily recognize that any
one of the available algorithms or implementing software packages
for conducting homology searches can be adapted for use in the
present computer-based systems. As used herein, a "target sequence"
can be any nucleic acid or amino acid sequence of six or more
nucleotides or two or more amino acids. A skilled artisan can
readily recognize that the longer a target sequence is, the less
likely a target sequence will be present as a random occurrence in
the database. The most preferred sequence length of a target
sequence is from about 10 to 300 amino acids, more preferably from
about 30 to 100 nucleotide residues. However, it is well recognized
that searches for commercially important fragments, such as
sequence fragments involved in gene expression and protein
processing, may be of shorter length.
[0320] As used herein, "a target structural motif," or "target
motif," refers to any rationally selected sequence or combination
of sequences in which the sequence(s) are chosen based on a
three-dimensional configuration which is formed upon the folding of
the target motif. There are a variety of target motifs known in the
art. Protein target motifs include, but are not limited to, enzyme
active sites and signal sequences. Nucleic acid target motifs
include, but are not limited to, promoter sequences, hairpin
structures and inducible expression elements (protein binding
sequences).
[0321] 4.12 Triple Helix Formation
[0322] In addition, the fragments of the present invention, as
broadly described, can be used to control gene expression through
triple helix formation or antisense DNA or RNA, both of which
methods are based on the binding of a polynucleotide sequence to
DNA or RNA. Polynucleotides suitable for use in these methods are
preferably 20 to 40 bases in length and are designed to be
complementary to a region of the gene involved in transcription
(triple helix--see Lee et al., Nucl. Acids Res. 6:3073 (1979);
Cooney et al., Science 15241:456 (1988); and Dervan et al., Science
251:1360 (1991)) or to the mRNA itself (antisense--Olmno, J.
Neurochem. 56:560 (1991); Oligodeoxynucleotides as Antisense
Inhibitors of Gene Expression, CRC Press, Boca Raton, Fla. (1988)).
Triple helix-formation optimally results in a shut-off of RNA
transcription from DNA, while antisense RNA hybridization blocks
translation of an mRNA molecule into polypeptide. Both techniques
have been demonstrated to be effective in model systems.
Information contained in the sequences of the present invention is
necessary for the design of an antisense or triple helix
oligonucleotide.
[0323] 4.13 Diagnostic Assays and Kits
[0324] The present invention further provides methods to identify
the presence or expression of one of the ORFs of the present
invention, or homolog thereof, in a test sample, using a nucleic
acid probe or antibodies of the present invention, optionally
conjugated or otherwise associated with a suitable label.
[0325] In general, methods for detecting a polynucleotide of the
invention can comprise contacting a sample with a compound that
binds to and forms a complex with the polynucleotide for a period
sufficient to form the complex, and detecting the complex, so that
if a complex is detected, a polynucleotide of the invention is
detected in the sample. Such methods can also comprise contacting a
sample under stringent hybridization conditions with nucleic acid
primers that anneal to a polynucleotide of the invention under such
conditions, and amplifying annealed polynucleotides, so that if a
polynucleotide is amplified, a polynucleotide of the invention is
detected in the sample.
[0326] In general, methods for detecting a polypeptide of the
invention can comprise contacting a sample with a compound that
binds to and forms a complex with the polypeptide for a period
sufficient to form the complex, and detecting the complex, so that
if a complex is detected, a polypeptide of the invention is
detected in the sample.
[0327] In detail, such methods comprise incubating a test sample
with one or more of the antibodies or one or more of the nucleic
acid probes of the present invention and assaying for binding of
the nucleic acid probes or antibodies to components within the test
sample.
[0328] Conditions for incubating a nucleic acid probe or antibody
with a test sample vary. Incubation conditions depend on the format
employed in the assay, the detection methods employed, and the type
and nature of the nucleic acid probe or antibody used in the assay.
One skilled in the art will recognize that any one of the commonly
available hybridization, amplification or immunological assay
formats can readily be adapted to employ the nucleic acid probes or
antibodies of the present invention. Examples of such assays can be
found in Chard, T., An Introduction to Radioimmunoassay and Related
Techniques, Elsevier Science Publishers, Amsterdam, The Netherlands
(1986); Bullock, G. R. et al., Techniques in Immunocytochemistry,
Academic Press, Orlando, Fla. Vol. 1 (1982), Vol. 2 (1983), Vol. 3
(1985); Tijssen, P., Practice and Theory of immunoassays:
Laboratory Techniques in Biochemistry and Molecular Biology,
Elsevier Science Publishers, Amsterdam, The Netherlands (1985). The
test samples of the present invention include cells, protein or
membrane extracts of cells, or biological fluids such as sputum,
blood, serum, plasma, or urine. The test sample used in the
above-described method will vary based on the assay format, nature
of the detection method and the tissues, cells or extracts used as
the sample to be assayed. Methods for preparing protein extracts or
membrane extracts of cells are well known in the art and can be
readily be adapted in order to obtain a sample which is compatible
with the system utilized.
[0329] In another embodiment of the present invention, kits are
provided which contain the necessary reagents to carry out the
assays of the present invention. Specifically, the invention
provides a compartment kit to receive, in close confinement, one or
more containers which comprises: (a) a first container comprising
one of the probes or antibodies of the present invention; and (b)
one or more other containers comprising one or more of the
following: wash reagents, reagents capable of detecting presence of
a bound probe or antibody.
[0330] In detail, a compartment kit includes any kit in which
reagents are contained in separate containers. Such containers
include small glass containers, plastic containers or strips of
plastic or paper. Such containers allows one to efficiently
transfer reagents from one compartment to another compartment such
that the samples and reagents are not cross-contaminated, and the
agents or solutions of each container can be added in a
quantitative fashion from one compartment to another. Such
containers will include a container which will accept the test
sample, a container which contains the antibodies used in the
assay, containers which contain wash reagents (such as phosphate
buffered saline, Tris-buffers, etc.), and containers which contain
the reagents used to detect the bound antibody or probe. Types of
detection reagents include labeled nucleic acid probes, labeled
secondary antibodies, or in the alternative, if the primary
antibody is labeled, the enzymatic, or antibody binding reagents
which are capable of reacting with the labeled antibody. One
skilled in the art will readily recognize that the disclosed probes
and antibodies of the present invention can be readily incorporated
into one of the established kit formats which are well known in the
art.
[0331] 4.14 Medical Imaging
[0332] The novel polypeptides and binding partners of the invention
are useful in medical imaging of sites expressing the molecules of
the invention (e.g., where the polypeptide of the invention is
involved in the immune response, for imaging sites of inflammation
or infection). See, e.g., Kunkel et al., U.S. Pat. No. 5,413,778.
Such methods involve chemical attachment of a labeling or imaging
agent, administration of the labeled polypeptide to a subject in a
pharmaceutically acceptable carrier, and imaging the labeled
polypeptide in vivo at the target site.
[0333] 4.15 Screening Assays
[0334] Using the isolated proteins and polynucleotides of the
invention, the present invention further provides methods of
obtaining and identifying agents which bind to a polypeptide
encoded by an ORF corresponding to any of the nucleotide sequences
set forth in SEQ ID NOs: 1-13, or bind to a specific domain of the
polypeptide encoded by the nucleic acid. In detail, said method
comprises the steps of:
[0335] (a) contacting an agent with an isolated protein encoded by
an ORF of the present invention, or nucleic acid of the invention;
and
[0336] (b) determining whether the agent binds to said protein or
said nucleic acid.
[0337] In general, therefore, such methods for identifying
compounds that bind to a polynucleotide of the invention can
comprise contacting a compound with a polynucleotide of the
invention for a time sufficient to form a polynucleotide/compound
complex, and detecting the complex, so that if a
polynucleotide/compound complex is detected, a compound that binds
to a polynucleotide of the invention is identified.
[0338] Likewise, in general, therefore, such methods for
identifying compounds that bind to a polypeptide of the invention
can comprise contacting a compound with a polypeptide of the
invention for a time sufficient to form a polypeptide/compound
complex, and detecting the complex, so that if a
polypeptide/compound complex is detected, a compound that binds to
a polynucleotide of the invention is identified.
[0339] Methods for identifying compounds that bind to a polypeptide
of the invention can also comprise contacting a compound with a
polypeptide of the invention in a cell for a time sufficient to
form a polypeptide/compound complex, wherein the complex drives
expression of a receptor gene sequence in the cell, and detecting
the complex by detecting reporter gene sequence expression, so that
if a polypeptide/compound complex is detected, a compound that
binds a polypeptide of the invention is identified.
[0340] Compounds identified via such methods can include compounds
which modulate the activity of a polypeptide of the invention (that
is, increase or decrease its activity, relative to activity
observed in the absence of the compound). Alternatively, compounds
identified via such methods can include compounds which modulate
the expression of a polynucleotide of the invention (that is,
increase or decrease expression relative to expression levels
observed in the absence of the compound). Compounds, such as
compounds identified via the methods of the invention, can be
tested using standard assays well known to those of skill in the
art for their ability to modulate activity/expression.
[0341] The agents screened in the above assay can be, but are not
limited to, peptides, carbohydrates, vitamin derivatives, or other
pharmaceutical agents. The agents can be selected and screened at
random or rationally selected or designed using protein modeling
techniques.
[0342] For random screening, agents such as peptides,
carbohydrates, pharmaceutical agents and the like are selected at
random and are assayed for their ability to bind to the protein
encoded by the ORF of the present invention. Alternatively, agents
may be rationally selected or designed. As used herein, an agent is
said to be "rationally selected or designed" when the agent is
chosen based on the configuration of the particular protein. For
example, one skilled in the art can readily adapt currently
available procedures to generate peptides, pharmaceutical agents
and the like, capable of binding to a specific peptide sequence, in
order to generate rationally designed antipeptide peptides, for
example see Hurby et al., Application of Synthetic Peptides:
Antisense Peptides," In Synthetic Peptides, A User's Guide, W. H.
Freeman, NY (1992), pp. 289-307, and Kaspczak et al., Biochemistry
28:9230-8 (1989), or pharmaceutical agents, or the like.
[0343] In addition to the foregoing, one class of agents of the
present invention, as broadly described, can be used to control
gene expression through binding to one of the ORFs or EMFs of the
present invention. As described above, such agents can be randomly
screened or rationally designed/selected. Targeting the ORF or EMF
allows a skilled artisan to design sequence specific or element
specific agents, modulating the expression of either a single ORF
or multiple ORFs which rely on the same EME for expression control.
One class of DNA binding agents are agents which contain base
residues which hybridize or form a triple helix formation by
binding to DNA or RNA. Such agents can be based on the classic
phosphodiester, ribonucleic acid backbone, or can be a variety of
sulfhydryl or polymeric derivatives which have base attachment
capacity.
[0344] Agents suitable for use in these methods preferably contain
20 to 40 bases and are designed to be complementary to a region of
the gene involved in transcription (triple helix--see Lee et al.,
Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456
(1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA
itself (antisense--Okano, J. Neurochem. 56:560 (1991);
Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression,
CRC Press, Boca Raton, Fla. (1988)). Triple helix-formation
optimally results in a shut-off of RNA transcription from DNA,
while antisense RNA hybridization blocks translation of an mRNA
molecule into polypeptide. Both techniques have been demonstrated
to be effective in model systems. Information contained in the
sequences of the present invention is necessary for the design of
an antisense or triple helix oligonucleotide and other DNA binding
agents.
[0345] Agents which bind to a protein encoded by one of the ORFs of
the present invention can be used as a diagnostic agent. Agents
which bind to a protein encoded by one of the ORFs of the present
invention can be formulated using known techniques to generate a
pharmaceutical composition.
[0346] 4.16 Use of Nucleic Acids as Probes
[0347] Another aspect of the subject invention is to provide for
polypeptide-specific nucleic acid hybridization probes capable of
hybridizing with naturally occurring nucleotide sequences. The
hybridization probes of the subject invention may be derived from
any of the nucleotide sequences SEQ ID NOs: 1-13. Because the
corresponding gene is only expressed in a limited number of
tissues, a hybridization probe derived from of any of the
nucleotide sequences SEQ ID NOs: 1-13 can be used as an indicator
of the presence of RNA of cell type of such a tissue in a
sample.
[0348] Any suitable hybridization technique can be employed, such
as, for example, in situ hybridization. PCR as described in U.S.
Pat. Nos. 4,683,195 and 4,965,188 provides additional uses for
oligonucleotides based upon the nucleotide sequences. Such probes
used in PCR may be of recombinant origin, may be chemically
synthesized, or a mixture of both. The probe will comprise a
discrete nucleotide sequence for the detection of identical
sequences or a degenerate pool of possible sequences for
identification of closely related genomic sequences.
[0349] Other means for producing specific hybridization probes for
nucleic acids include the cloning of nucleic acid sequences into
vectors for the production of mRNA probes. Such vectors are known
in the art and are commercially available and may be used to
synthesize RNA probes in vitro by means of the addition of the
appropriate RNA polymerase as T7 or SP6 RNA polymerase and the
appropriate radioactively labeled nucleotides. The nucleotide
sequences may be used to constrict hybridization probes for mapping
their respective genomic sequences. The nucleotide sequence
provided herein may be mapped to a chromosome or specific regions
of a chromosome using well known genetic and/or chromosomal mapping
techniques. These techniques include in situ hybridization, linkage
analysis against known chromosomal markers, hybridization screening
with libraries or flow-sorted chromosomal preparations specific to
known chromosomes, and the like. The technique of fluorescent in
situ hybridization of chromosome spreads has been described, among
other places, in Verma et al (1988) Human Chromosomes: A Manual of
Basic Techniques, Pergamon Press, New York N.Y.
[0350] Fluorescent in situ hybridization of chromosomal
preparations and other physical chromosome mapping techniques may
be correlated with additional genetic map data. Examples of genetic
map data can be found in the 1994 Genome Issue of Science
(265:1981f). Correlation between the location of a nucleic acid on
a physical chromosomal map and a specific disease (or
predisposition to a specific disease) may help delimit the region
of DNA associated with that genetic disease. The nucleotide
sequences of the subject invention may be used to detect
differences in gene sequences between normal, carrier or affected
individuals.
[0351] 4.17 Preparation of Support Bound Oligonucleotides
[0352] Oligonucleotides, i.e., small nucleic acid segments, may be
readily prepared by, for example, directly synthesizing the
oligonucleotide by chemical means, as is commonly practiced using
an automated oligonucleotide synthesizer.
[0353] Support bound oligonucleotides may be prepared by any of the
methods known to those of skill in the art using any suitable
support such as glass, polystyrene or Teflon. One strategy is to
precisely spot oligonucleotides synthesized by standard
synthesizers. Immobilization can be achieved using passive
adsorption (Inouye & Hondo, (1990) J. Clin. Microbiol. 28(6)
1469-72); using UV light (Nagata et al., 1985; Dahlen et al., 1987;
Morrissey & Collins, (1989) Mol. Cell Probes 3(2) 189-207) or
by covalent binding of base modified DNA (Keller et al., 1988;
1989); all references being specifically incorporated herein.
[0354] Another strategy that may be employed is the use of the
strong biotin-streptavidin interaction as a linker. For example,
Broude et al. (1994) Proc. Natl. Acad. Sci. USA 91(8) 3072-6,
describe the use of biotinylated probes, although these are duplex
probes, that are immobilized on streptavidin-coated magnetic beads.
Streptavidin-coated beads may be purchased from Dynal, Oslo. Of
course, this same linking chemistry is applicable to coating any
surface with streptavidin. Biotinylated probes may be purchased
from various sources, such as, e.g., Operon Technologies (Alameda,
Calif.).
[0355] Nunc Laboratories (Naperville, Ill.) is also selling
suitable material that could be used. Nunc Laboratories have
developed a method by which DNA can be covalently bound to the
microwell surface termed CovaLink NH. CovaLink NH is a polystyrene
surface grafted with secondary amino groups (>NH) that serve as
bridge-heads for further covalent coupling. CovaLink Modules may be
purchased from Nunc Laboratories. DNA molecules may be bound to
CovaLink exclusively at the 5'-end by a phosphoramidate bond,
allowing immobilization of more than 1 pmol of DNA (Rasmussen et
al., (1991) Anal. Biochem. 198(1) 138-42).
[0356] The use of CovaLink NH strips for covalent binding of DNA
molecules at the 5'-end has been described (Rasmussen et al.,
(1991). In this technology, a phosphoramidate bond is employed (Chu
et al., (1983) Nucleic Acids Res. 11(8) 6513-29). This is
beneficial as immobilization using only a single covalent bond is
preferred. The phosphoramidate bond joins the DNA to the CovaLink
NH secondary amino groups that are positioned at the end of spacer
arms covalently grafted onto the polystyrene surface through a 2 nm
long spacer arm. To link an oligonucleotide to CovaLink NH via an
phosphoramidate bond, the oligonucleotide terminus must have a
5'-end phosphate group. It is, perhaps, even possible for biotin to
be covalently bound to CovaLink and then streptavidin used to bind
the probes.
[0357] More specifically, the linkage method includes dissolving
DNA in water (7.5 ng/ul) and denaturing for 10 min. at 95.degree.
C. and cooling on ice for 10 min. Ice-cold 0.1 M 1-methylimidazole,
pH 7.0 (1-MeIm.sub.7), is then added to a final concentration of 10
mM 1 -MeIm.sub.7. A ss DNA solution is then dispensed into CovaLink
NH strips (75 ul/well) standing on ice.
[0358] Carbodiimide 0.2 M
1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC), dissolved in
10 mM 1-MeIM.sub.7, is made fresh and 25 ul added per well. The
strips are incubated for 5 hours at 50.degree. C. After incubation
the strips are washed using, e.g., Nunc-Immuno Wash; first the
wells are washed 3 times, then they are soaked with washing
solution for 5 min., and finally they are washed 3 times (where in
the washing solution is 0.4 N NaOH, 0.25% SDS heated to 50.degree.
C.).
[0359] It is contemplated that a further suitable method for use
with the present invention is that described in PCT Patent
Application WO 90/03382 (Southern & Maskos), incorporated
herein by reference. This method of preparing an oligonucleotide
bound to a support involves attaching a nucleoside 3'-reagent
through the phosphate group by a covalent phosphodiester link to
aliphatic hydroxyl groups carried by the support. The
oligonucleotide is then synthesized on the supported nucleoside and
protecting groups removed from the synthetic oligonucleotide chain
under standard conditions that do not cleave the oligonucleotide
from the support. Suitable reagents include nucleoside
phosphoramidite and nucleoside hydrogen phosphorate.
[0360] An on-chip strategy for the preparation of DNA probe for the
preparation of DNA probe arrays may be employed. For example,
addressable laser-activated photodeprotection may be employed in
the chemical synthesis of oligonucleotides directly on a glass
surface, as described by Fodor et al. (1991) Science 251(4995)
767-73, incorporated herein by reference. Probes may also be
immobilized on nylon supports as described by Van Ness et al.
(1991) Nucleic Acids Res. 19(12) 3345-50; or linked to Teflon using
the method of Duncan & Cavalier (1988) Anal. Biochem. 169(1)
104-8; all references being specifically incorporated herein.
[0361] To link an oligonucleotide to a nylon support, as described
by Van Ness et al. (1991), requires activation of the nylon surface
via alkylation and selective activation of the 5'-amine of
oligonucleotides with cyanuric chloride.
[0362] One particular way to prepare support bound oligonucleotides
is to utilize the light-generated synthesis described by Pease et
al., (1994) PNAS USA 91(11) 5022-6, incorporated herein by
reference). These authors used current photolithographic techniques
to generate arrays of immobilized oligonucleotide probes (DNA
chips). These methods, in which light is used to direct the
synthesis of oligonucleotide probes in high-density, miniaturized
arrays, utilize photolabile 5'-protected N-acyl-deoxynucleoside
phosphoramidites, surface linker chemistry and versatile
combinatorial synthesis strategies. A matrix of 256 spatially
defined oligonucleotide probes may be generated in this manner.
[0363] 4.18 Preparation of Nucleic Acid Fragments
[0364] The nucleic acids may be obtained from any appropriate
source, such as cDNAs, genomic DNA, chromosomal DNA, microdissected
chromosome bands, cosmid or YAC inserts, and RNA, including mRNA
without any amplification steps. For example, Sambrook et al.
(1989) describes three protocols for the isolation of high
molecular weight DNA from mammalian cells (p. 9.14-9.23).
[0365] DNA fragments may be prepared as clones in M13, plasmid or
lambda vectors and/or prepared directly from genomic DNA or cDNA by
PCR or other amplification methods. Samples may be prepared or
dispensed in multiwell plates. About 100-1000 ng of DNA samples may
be prepared in 2-500 ml of final volume.
[0366] The nucleic acids would then be fragmented by any of the
methods known to those of skill in the art including, for example,
using restriction enzymes as described at 9.24-9.28 of Sambrook et
al. (1989), shearing by ultrasound and NaOH treatment.
[0367] Low pressure shearing is also appropriate, as described by
Schriefer et al. (1990) Nucleic Acids Res. 18(24) 7455-6,
incorporated herein by reference). In this method, DNA samples are
passed through a small French pressure cell at a variety of low to
intermediate pressures. A lever device allows controlled
application of low to intermediate pressures to the cell. The
results of these studies indicate that low-pressure shearing is a
useful alternative to sonic and enzymatic DNA fragmentation
methods.
[0368] One particularly suitable way for fragmenting DNA is
contemplated to be that using the two base recognition
endonuclease, CviJI, described by Fitzgerald et al. (1992) Nucleic
Acids Res. 20(14) 3753-62. These authors described an approach for
the rapid fragmentation and fractionation of DNA into particular
sizes that they contemplated to be suitable for shotgun cloning and
sequencing.
[0369] The restriction endonuclease CviJI normally cleaves the
recognition sequence PuGCPy between the G and C to leave blunt
ends. Atypical reaction conditions, which alter the specificity of
this enzyme (CviJI**), yield a quasi-random distribution of DNA
fragments form the small molecule pUC19 (2688 base pairs).
Fitzgerald et al. (1992) quantitatively evaluated the randomness of
this fragmentation strategy, using a CviJI** digest of pUC19 that
was size fractionated by a rapid gel filtration method and directly
ligated, without end repair, to a lac Z minus M13 cloning vector.
Sequence analysis of 76 clones showed that CviJI** restricts pyGCPy
and PuGCPu, in addition to PuGCPy sites, and that new sequence data
is accumulated at a rate consistent with random fragmentation.
[0370] As reported in the literature, advantages of this approach
compared to sonication and agarose gel fractionation include:
smaller amounts of DNA are required (0.2-0.5 ug instead of 2-5 ug);
and fewer steps are involved (no preligation, end repair, chemical
extraction, or agarose gel electrophoresis and elution are
needed
[0371] Irrespective of the manner in which the nucleic acid
fragments are obtained or prepared, it is important to denature the
DNA to give single stranded pieces available for hybridization.
This is achieved by incubating the DNA solution for 2-5 minutes at
80-90.degree. C. The solution is then cooled quickly to 2.degree.
C. to prevent renaturation of the DNA fragments before they are
contacted with the chip. Phosphate groups must also be removed from
genomic DNA by methods known in the art.
[0372] 4.19 Preparation of DNA Arrays
[0373] Arrays may be prepared by spotting DNA samples on a support
such as a nylon membrane. Spotting may be performed by using arrays
of metal pins (the positions of which correspond to an array of
wells in a microtiter plate) to repeated by transfer of about 20 nl
of a DNA solution to a nylon membrane. By offset printing, a
density of dots higher than the density of the wells is achieved.
One to 25 dots may be accommodated in 1 mm.sup.2, depending on the
type of label used. By avoiding spotting in some preselected number
of rows and columns, separate subsets (subarrays) may be formed.
Samples in one subarray may be the same genomic segment of DNA (or
the same gene) from different individuals, or may be different,
overlapped genomic clones. Each of the subarrays may represent
replica spotting of the same samples. In one example, a selected
gene segment may be amplified from 64 patients. For each patient,
the amplified gene segment may be in one 96-well plate (all 96
wells containing the same sample). A plate for each of the 64
patients is prepared. By using a 96-pin device, all samples may be
spotted on one 8.times.12 cm membrane. Subarrays may contain 64
samples, one from each patient. Where the 96 subarrays are
identical, the dot span may be 1 mm.sup.2 and there may be a 1 mm
space between subarrays.
[0374] Another approach is to use membranes or plates (available
from NUNC, Naperville, Ill.) which may be partitioned by physical
spacers e.g. a plastic grid molded over the membrane, the grid
being similar to the sort of membrane applied to the bottom of
multiwell plates, or hydrophobic strips. A fixed physical spacer is
not preferred for imaging by exposure to flat phosphor-storage
screens or x-ray films.
[0375] The present invention is illustrated in the following
examples. Upon consideration of the present disclosure, one of
skill in the art will appreciate that many other embodiments and
variations may be made in the scope of the present invention.
Accordingly, it is intended that the broader aspects of the present
invention not be limited to the disclosure of the following
examples. The present invention is not to be limited in scope by
the exemplified embodiments which are intended as illustrations of
single aspects of the invention, and compositions and methods which
are functionally equivalent are within the scope of the invention.
Indeed, numerous modifications and variations in the practice of
the invention are expected to occur to those skilled in the art
upon consideration of the present preferred embodiments.
Consequently, the only limitations which should be placed upon the
scope of the invention are those which appear in the appended
claims.
[0376] All references cited within the body of the instant
specification are hereby incorporated by reference in their
entirety.
5.0 EXAMPLES
5.1 Example 1
[0377] Novel Nucleic Acid Sequences Obtained From Various
Libraries
[0378] A plurality of novel nucleic acids were obtained from cDNA
libraries prepared from various human tissues and in some cases
isolated from a genomic library derived from human chromosome using
standard PCR, SBH sequence signature analysis and Sanger sequencing
techniques. The inserts of the library were amplified with PCR
using primers specific for the vector sequences which flank the
inserts. Clones from cDNA libraries were spotted on nylon membrane
filters and screened with oligonucleotide probes (e.g., 7-mers) to
obtain signature sequences. The clones were clustered into groups
of similar or identical sequences. Representative clones were
selected for sequencing.
[0379] In some cases, the 5' sequence of the amplified inserts was
then deduced using a typical Sanger sequencing protocol. PCR
products were purified and subjected to fluorescent dye terminator
cycle sequencing. Single pass gel sequencing was done using a 377
Applied Biosystems (ABI) sequencer to obtain the novel nucleic acid
sequences. In some cases RACE (Random Amplification of cDNA Ends)
was performed to further extend the sequence in the 5'
direction.
5.2 Example 2
[0380] Novel Nucleic Acids
[0381] The novel nucleic acids of the present invention of the
invention were assembled from sequences that were obtained from a
cDNA library by methods described in Example 1 above, and in some
cases sequences obtained from one or more public databases. The
nucleic acids were assembled using an EST sequence as a seed. Then
a recursive algorithm was used to extend the seed EST into an
extended assemblage, by pulling additional sequences from different
databases (i.e., Hyseq's database containing EST sequences, dbEST
version 114, gb pri 114, and UniGene version 101) that belong to
this assemblage. The algorithm terminated when there was no
additional sequences from the above databases that would extend the
assemblage. Inclusion of component sequences into the assemblage
was based on a BLASTN hit to the extending assemblage with BLAST
score greater than 300 and percent identity greater than 95%.
[0382] Using PHRAP (Univ. of Washington) or CAP4 (Paracel), a full
length gene cDNA sequence and its corresponding protein sequence
were generated from the assemblage. Any frame shifts and incorrect
stop codons were corrected by hand editing. During editing, the
sequence was checked using FASTY and/or BLAST against Genbank
(i.e., dbEST version 118, gb pri 118, UniGene version 118, Genepet
release 118). Other computer programs which may have been used in
the editing process were phredPhrap and Consed (University of
Washington) and ed-ready, ed-ext and gc-zip-2 (Hyseq, Inc.). The
full-length nucleotide and amino acid sequences, including splice
variants resulting from these procedures are shown in the Sequence
Listing as SEQ ID NOS: 1-13.
[0383] Table 1 shows the various tissue sources of SEQ ID NO:
1-13.
[0384] The homology for SEQ ID NO: 1-13 were obtained by a BLASTP
version 2.0 al 19MP-WashU search against Genpept release 118, using
BLAST algorithm. The results showed homologues for SEQ ID NO: 1-13
from Genpept. The homologues with identifiable functions for SEQ ID
NO: 1-13 are shown in Table 2 below.
[0385] Using eMatrix software package (Stanford University,
Stanford, Calif.) (Wu et al., J. Comp. Biol., Vol. 6 pp. 219-235
(1999) herein incorporated by reference), all the sequences were
examined to determine whether they had identifiable signature
regions. Table 3 shows the signature region found in the indicated
polypeptide sequences, the description of the signature, the
eMatrix p-value(s) and the position(s) of the signature within the
polypeptide sequence.
[0386] Using the pFam software program (Sonnhammer et al., Nucleic
Acids Res., Vol. 26(1) pp. 320-322 (1998) herein incorporated by
reference) all the polypeptide sequences were examined for domains
with homology to certain peptide domains. Table 4 shows the name of
the domain found, the description, the p-value and the pFam score
for the identified domain within the sequence.
[0387] The nucleotide sequence within the sequences that codes for
signal peptide sequences and their cleavage sites can be determine
from using Neural Network SignalP V1.1 program (from Center for
Biological Sequence Analysis, The Technical University of Denmark).
The process for identifying prokaryotic and eukaryotic signal
peptides and their cleavage sites are also disclosed by Henrik
Nielson, Jacob Engelbrecht, Soren Brunak, and Gunnar von Heijne in
the publication "Identification of prokaryotic and eukaryotic
signal peptides and prediction of their cleavage sites" Protein
Engineering, Vol. 10, no. 1, pp. 1-6 (1997), incorporated herein by
reference. A maximum S score and a mean S score, as described in
the Nielson et as reference, was obtained for the polypeptide
sequences. Table 5 shows the position of the signal peptide in each
of the polypeptides and the maximum score and mean score associated
with that signal peptide.
1TABLE 1 HYSEQ LIBRARY TISSUE ORIGIN RNA, SOURCE NAME SEQ ID NOS:
adult brain GIBCO ABD003 2 6-8 adult brain Clontech ABR006 6-8
adult brain Clontech ABR008 2 5-8 10 adult brain Invitrogen ABT004
3 6-8 cultured Strategene ADP001 10 preadipocytes adrenal gland
Clontech ADR002 1 adult heart GIBCO AHR001 6-8 10 adult kidney
GIBCO AKD001 2 10 adult kidney Invitrogen AKT002 10 adult lung
GIBCO ALG001 8 10 young liver GIBCO ALV001 5 9 11 adult liver
Invitrogen ALV002 2 adult ovary Invitrogen AOV001 6-9 11 placenta
Invitrogen APL002 10 testis GIBCO ATS001 10 bone marrow Clontech
BMD001 2 10-11 adult colon Invitrogen CLN001 3-4 9 adult cervix
BioChain CVX001 2 endothelial cells Strategene EDT001 9-11 fetal
brain Clontech FBR004 6-8 fetal brain Clontech FBR006 1 4 10 fetal
brain Invitrogen FBT002 10 fetal heart Invitrogen FHR001 9 fetal
lung Invitrogen FLG003 6-8 fetal liver-spleen Columbia FLS001 2 5
9-11 University fetal liver-spleen Columbia FLS002 1 9-10
University fetal muscle Invitrogen FMS001 6-8 fetal skin Invitrogen
FSK001 1-2 6-8 fetal skin Invitrogen FSK002 6-8 fetal brain GIBCO
HFB001 3 6-8 infant brain Columbia IB2002 2 6-8 University infant
brain Columbia IB2003 6-8 University lung tumor Invitrogen LGT002 3
6-8 10-11 lymphocytes ATCC LPC001 leukocyte GIBCO LUC001 3 6-8 10
melanoma from cell Clontech MEL004 5-8 line ATCC # CRL 1424 mammary
gland Invitrogen MMG001 3-4 6-8 10 neuronal cells Strategene NTU001
4 13 rectum Invitrogen REC001 10 spinal cord Clontech SPC001 10
adult spleen Clontech SPLc01 6-8 thalamus Clontech THA002 6-8
thymus Clontech THMc02 1 thyroid gland Clontech THR001 1-2 9
trachea Clontech TRC001 6-8
[0388]
2TABLE 2 CORRESPONDING SEQ ID NO. IN SMITH- SEQ ID U.S.S.N.
ACCESSION WATERMAN % NO: 09/649,167 NUMBER DESCRIPTION SCORE
IDENTITY 1 1884 Z14016 Nicotiana tabacum 103 37 pistil extensin
like protein, partial CDS 2 5410 22854 D11466 Homo sapiens 2519 100
22855 22856 PIG-A protein 3 11528 AC002505 Arabidopsis thaliana 240
30 putative cyclin 4 14360 14361 AF159297 Zea mays extensin- 148 24
14362 like protein 5 16899 16900 AC002988 Homo sapiens 381 62 16901
OLF4 6 21007 21008 AF124490 Homo sapiens ARF 3912 99 21009 21010
GTPase-activating protein GIT1 7 21007 21008 AF124490 Homo sapiens
ARF 3887 98 21009 21010 GTPase-activating protein GIT1 8 21007
21008 AF124490 Homo sapiens ARF 2567 99 21009 21010
GTPase-activating protein GIT1 9 26173 26174 Y10529 Homo sapiens
969 71 26175 26176 olfactory receptor 26177 26178 10 27023 27024
AF127837 Hylobates lar 1082 95 27025 olfactory receptor 11 27169
27170 Y10529 Homo sapiens 1393 100 27171 27172 olfactory receptor
27173 27174 12 28495 AF044601 Homo sapiens orphan 2113 99 G
protein-coupled receptor; GPC-R 13 28544 AF121976 Mus musculus 1017
58 odorant receptor S19
[0389]
3TABLE 3 SEQ ACCES- ID SION DESCRIP- NO: NO. TION RESULTS* 1
DM01803 1 HERPES- DM01803C 7.00 8.800e-07 219-229 VIRUS GLY-
COPROTEIN H. 2 PF00534 Glycosyl trans- PF00534B 14.47 6.182e-15
312-336 ferases group 1. 3 PD02331 CYCLIN PD02331C 13.84 3.192e-09
128-155 CELL CYCLE DIVISION PROTE. 4 PR00513 5-HYDROXY- PR00513C
10.79 4.814e-06 5-22 TRYPT- AMINE 1B RECEPTOR SIGNATURE 5 PR00237
RHODOPSIN- PR00237A 11.48 2.742e-09 107-132 LIKE GPCR PR00237B
13.50 3.500e-09 140-162 SUPER- FAMILY SIGNATURE 6 PF00023 Ank
repeat PF00023B 14.20 5.091e-09 188-198 proteins. 7 PF00023 Ank
repeat PF00023B 14.20 5.091e-09 188-198 proteins. PF00023B 14.20
5.091e-09 970-980 8 PF00023 Ank repeat PF00023B 14.20 5.091e-09
188-198 proteins. PF00023B 14.20 5.091e-09 970-980 10 PR00237
RHODOPSIN- PR00237E 13.03 2.200e-10 240-264 LIKE GPCR PR00237B
13.50 9.500e-09 100-122 SUPER- PR00237C 15.69 1.000e-08 145-168
FAMILY SIGNATURE 11 BL00237 G-protein BL00237A 27.68 6.143e-13
57-97 coupled recep- BL00237D 11.23 5.091e-09 249-266 tors
proteins. 12 BL00237 G-protein BL00237A 27.68 3.250e-19 146-186
coupled recep- BL00237C 13.19 4.240e-14 309-336 tors proteins.
BL00237B 5.28 1.000e-09 259-271 BL00237D 11.23 5.636e-09 367-384 13
PR00237 RHODOPSIN- PR00237A 11.48 1.000e-08 180-205 LIKE GPCR
SUPER- FAMILY SIGNATURE *Results include in order: accession number
subtype; raw score; p-value; position of signature in amino acid
sequence.
[0390]
4TABLE 4 SEQ ID pFAM NO: pFAM NAME DESCRIPTION p-value SCORE 2
Glycos_transf_1 Glycosyl transferases 3.9e-15 56.9 group 1 5 7tm_1
7 transmembrane 3.4e-19 63.1 receptor (rhodopsin family) 6 ank Ank
repeat 4.7e-06 33.6 7 ank Ank repeat 4.7e-06 33.6 10 7tm_1 7
transmembrane 2.3e-45 146.2 receptor (rhodopsin family) 11 7tm_1 7
transmembrane 1.8e-41 133.9 receptor (rhodopsin family) 12 7tm_1 7
transmembrane 9.2e-63 201.5 receptor (rhodopsin family) 13 7tm_1 7
transmembrane 1.5e-16 54.8 receptor (rhodopsin family)
[0391]
5TABLE 5 POSITION OF SIGNAL IN AMINO ACID maxS meanS SEQ ID NO:
SEQUENCE (MAXIMUM SCORE) (MEAN SCORE) 9 1-18 0.958 0.889 11 1-22
0.966 0.767
[0392]
Sequence CWU 1
1
13 1 3134 DNA Homo sapiens CDS (189)..(1742) 1 aatgtcgacg
atttcgtgcc ggggattcgc cggcccacgc caggccccgg gcggagaatg 60
aaaggacaat ctgcttcatc ctgattctgc ggcattccaa actgtggtat ccttgggggt
120 tctcttaaca ttgctatggt gcagaagatt taaaatcagc tgatgttcac
aaggaataca 180 gtcacgtg atg tat gaa ggg aaa cat ata cac ttc tct gag
gtt gac aat 230 Met Tyr Glu Gly Lys His Ile His Phe Ser Glu Val Asp
Asn 1 5 10 aag ccc ttg tgc tca tat agc ccc aaa ctg tgc aag cag agg
cga ctc 278 Lys Pro Leu Cys Ser Tyr Ser Pro Lys Leu Cys Lys Gln Arg
Arg Leu 15 20 25 30 aac ggc tac gcc ttc tgt atc aga cac gtt ctg gag
gac aag act gcc 320 Asn Gly Tyr Ala Phe Cys Ile Arg His Val Leu Glu
Asp Lys Thr Ala 35 40 45 ccc ttc aag caa tgt gaa tat gtg gcc aag
tat aac agc caa cgc tgc 374 Pro Phe Lys Gln Cys Glu Tyr Val Ala Lys
Tyr Asn Ser Gln Arg Cys 50 55 60 acc aac ccc atc ccc aaa tca gag
gat cgt agg tac tgc aac agc cac 422 Thr Asn Pro Ile Pro Lys Ser Glu
Asp Arg Arg Tyr Cys Asn Ser His 65 70 75 ttg cag gta ctt ggc ttt
atc ccg aaa aaa gag agg aag aaa aag aat 470 Leu Gln Val Leu Gly Phe
Ile Pro Lys Lys Glu Arg Lys Lys Lys Asn 80 85 90 gat cct ata gat
gag gtg aag gtc agg cac cag atg gat acc atg gcc 518 Asp Pro Ile Asp
Glu Val Lys Val Arg His Gln Met Asp Thr Met Ala 95 100 105 110 ttt
agc ctg aca gtg ccc acg ttg gcc ttg aag atg ccc aac gga ctg 566 Phe
Ser Leu Thr Val Pro Thr Leu Ala Leu Lys Met Pro Asn Gly Leu 115 120
125 gat gga atg tcc ctc tct cca cct ggg gca agg gtc cct ctc cac tac
614 Asp Gly Met Ser Leu Ser Pro Pro Gly Ala Arg Val Pro Leu His Tyr
130 135 140 ctg gaa act gaa ttg gaa gac cca ttt gct ttc aat gag gaa
gat gat 662 Leu Glu Thr Glu Leu Glu Asp Pro Phe Ala Phe Asn Glu Glu
Asp Asp 145 150 155 gac cta aag aaa ggg gca act gtg aga aag aag ttg
cag agc aag ttg 710 Asp Leu Lys Lys Gly Ala Thr Val Arg Lys Lys Leu
Gln Ser Lys Leu 160 165 170 gcc cag aat cgg cag cgc cag aga gag aca
gag att tta aaa gtt cga 758 Ala Gln Asn Arg Gln Arg Gln Arg Glu Thr
Glu Ile Leu Lys Val Arg 175 180 185 190 caa gag cac ttt agt ccc cct
cct gca cct tca cag cag cag cct ccg 806 Gln Glu His Phe Ser Pro Pro
Pro Ala Pro Ser Gln Gln Gln Pro Pro 195 200 205 cag cag cac tcc cac
ctg tca cct tta tct act tct tta aaa cct cca 854 Gln Gln His Ser His
Leu Ser Pro Leu Ser Thr Ser Leu Lys Pro Pro 210 215 220 gcg cca ccg
cag ggt tca gtc tgc aag tca cct caa cct cag aac acc 902 Ala Pro Pro
Gln Gly Ser Val Cys Lys Ser Pro Gln Pro Gln Asn Thr 225 230 235 agc
cta cca atg cag ggg gtg gca ccc acc aca cac act ata gca caa 950 Ser
Leu Pro Met Gln Gly Val Ala Pro Thr Thr His Thr Ile Ala Gln 240 245
250 gca cgg cag ttg tct cac aag agg cct ctg ccc ctc ctg cca tcc agt
998 Ala Arg Gln Leu Ser His Lys Arg Pro Leu Pro Leu Leu Pro Ser Ser
255 260 265 270 agg gct ccc act gtg gac cca ccc agg act gac cgg atc
ctc atg aaa 1046 Arg Ala Pro Thr Val Asp Pro Pro Arg Thr Asp Arg
Ile Leu Met Lys 275 280 285 gcc aca gcc ttc tct cca cac ttc tca tgt
ata agc cga ctg cag aga 1094 Ala Thr Ala Phe Ser Pro His Phe Ser
Cys Ile Ser Arg Leu Gln Arg 290 295 300 ctg gtg aaa ctg tgc acc cag
aaa cat cag ttg gac act gat ctg ttt 1142 Leu Val Lys Leu Cys Thr
Gln Lys His Gln Leu Asp Thr Asp Leu Phe 305 310 315 ccc cat tta ggt
ttg gac tgg tct gaa gag agc gga gag gaa cca gag 1190 Pro His Leu
Gly Leu Asp Trp Ser Glu Glu Ser Gly Glu Glu Pro Glu 320 325 330 gac
tca gag cag gcc tcg ccc tac cag gtt gca tgg tcc atc cgg gaa 1238
Asp Ser Glu Gln Ala Ser Pro Tyr Gln Val Ala Trp Ser Ile Arg Glu 335
340 345 350 acc ctc aga tat caa aga cat gtg tca gat gat gat gat gcg
gag agt 1286 Thr Leu Arg Tyr Gln Arg His Val Ser Asp Asp Asp Asp
Ala Glu Ser 355 360 365 agg agc tcc agg gtg act caa ctt tgc act tac
ttt cag cag aaa tat 1334 Arg Ser Ser Arg Val Thr Gln Leu Cys Thr
Tyr Phe Gln Gln Lys Tyr 370 375 380 aag cac ctc tgc cgc ctg gag cgg
gca gaa tct cgt caa aag aaa tgc 1382 Lys His Leu Cys Arg Leu Glu
Arg Ala Glu Ser Arg Gln Lys Lys Cys 385 390 395 cgg cat acg ttt agg
aaa gct ttg ctg cag gcg gcc agt aaa gaa cca 1430 Arg His Thr Phe
Arg Lys Ala Leu Leu Gln Ala Ala Ser Lys Glu Pro 400 405 410 gaa tgc
act ggt cag tta ata caa gaa ctg cgg aga gct gca tgc agt 1478 Glu
Cys Thr Gly Gln Leu Ile Gln Glu Leu Arg Arg Ala Ala Cys Ser 415 420
425 430 cga acc agc ata agc cgg acc aag ctg agg gag gtg gaa cca gca
gca 1526 Arg Thr Ser Ile Ser Arg Thr Lys Leu Arg Glu Val Glu Pro
Ala Ala 435 440 445 tgc agt gga acc gtg aag ggt gaa cag tgc gct aac
aaa gcc ctt cca 1574 Cys Ser Gly Thr Val Lys Gly Glu Gln Cys Ala
Asn Lys Ala Leu Pro 450 455 460 ttc acc aga cat tgt ttc caa cat atc
ctc ttg aac cac tct cag cag 1622 Phe Thr Arg His Cys Phe Gln His
Ile Leu Leu Asn His Ser Gln Gln 465 470 475 ctc ttc tca agt tgc aca
gcc aag ttt gca gat gga cag cag tgc tct 1670 Leu Phe Ser Ser Cys
Thr Ala Lys Phe Ala Asp Gly Gln Gln Cys Ser 480 485 490 gtg cca gtt
ttt gac att aca cat cag aca cct ctg tgt gaa gaa cat 1718 Val Pro
Val Phe Asp Ile Thr His Gln Thr Pro Leu Cys Glu Glu His 495 500 505
510 gcc aaa aaa tgg ata att cct tga gaggagataa ctcccgtaaa
gttcagcacc 1772 Ala Lys Lys Trp Ile Ile Pro * 515 agcagcagag
gaaacccagg aaaaaaacca agcctcctgc actaaccaaa aaacacaaga 1832
agaagagaag gcgtggacct cgtcgacccc aaaaacccat tccacctgca gtcccccaag
1892 ggaacctcag catgcccgcc agcgtctcac tgccagtgga ggcctctcac
atccggagcc 1952 catccacgcc agagctgagt gctgatgagt tgccggatga
cattgccaat gagatcactg 2012 acattccaca tgacttggaa ttgaaccagg
aggacttttc agatgtcctg ccacggctac 2072 ctgatgactt acaagatttt
gatttttttg aagggaagaa tggagacctc ctcccaacta 2132 ccgaagaggc
tgaggagctt gaacgggcct tgcaggctgt aacttctctc gagtgcctga 2192
gtaccattgg ggtccttgcc cagtcagatg gtgtgccagt ccaggagttg tcagatagag
2252 gaataggggt gttctccaca ggtactggag cttcaggaat acaatccttg
agccgagagg 2312 tgaacacaga cctaggggag ctattgaatg ggcgtatagt
acatgataat ttttctagtc 2372 tagagctgga tgagaacctg ctccgttctg
ctaccttgtc aaacccacct acacccctgg 2432 cagggcagat ccaggggcag
ttctctgccc cagccaacgt tggccttact tctgccactc 2492 tgatcagcca
gagtgcactt ggggagagag ccttcccagg acagtttcat ggacttcatg 2552
acggcagcca tgcctcccag aggccacatc ctgcccagct gctgagcaag gcagatgacc
2612 taatcacctc acgacagcaa tacagcagtg atcactcaca ctcctcaccc
catggaagcc 2672 attatgatag tgagcatgtg ccgtctccct acagtgacca
tatcacctct ccccacacaa 2732 catcgtactc tggtgataat atggcagcta
ccttttcagc agagatgccc atcatggcgc 2792 agcacttgct cccaacccaa
cttgaggtgc cacttggagg cgtggtaaac cccagaactc 2852 actggggcaa
tctccctgtc aaccttggag acccctctcc atttagcaac cttctcggcg 2912
cagatggaca tcttctttcc acttccctat ccacgccacc caccacttcg aactcagaga
2972 ccacacagcc tgccttcgcc accgtgaccc ccagcagctc cagtgtgctt
ccggggttac 3032 cacagaccag cttcagtggc atggggcctt ctgctgaact
aatggcctcc acctctattg 3092 cggccgctct agaggatcca agcttacgta
cgcgtgcatg cg 3134 2 3601 DNA Homo sapiens CDS (86)..(1540) 2
actggcggcc atggaactca ccggtaatag aggacacatc tcttaactgg gttgctctaa
60 gaactgatgt ctaaaccgtc tcagc atg gcc tgt aga gga gga gct ggg aat
112 Met Ala Cys Arg Gly Gly Ala Gly Asn 1 5 ggc cac cgt gcc tca gct
aca ctc tct cgg gtt agc cct gga agt ctt 160 Gly His Arg Ala Ser Ala
Thr Leu Ser Arg Val Ser Pro Gly Ser Leu 10 15 20 25 tac aca tgt aga
acc cgt acc cat aat ata tgc atg gta tct gac ttt 208 Tyr Thr Cys Arg
Thr Arg Thr His Asn Ile Cys Met Val Ser Asp Phe 30 35 40 ttc tac
cca aat atg gga ggc gtg gaa agc cac att tac cag ctc tct 256 Phe Tyr
Pro Asn Met Gly Gly Val Glu Ser His Ile Tyr Gln Leu Ser 45 50 55
cag tgc ctg att gaa aga ggg cat aag gtt ata att gtc acc cat gct 304
Gln Cys Leu Ile Glu Arg Gly His Lys Val Ile Ile Val Thr His Ala 60
65 70 tat gga aat cga aaa ggc atc cgt tac ctc acc agt ggc ctc aaa
gtc 352 Tyr Gly Asn Arg Lys Gly Ile Arg Tyr Leu Thr Ser Gly Leu Lys
Val 75 80 85 tat tac ttg cct ctg aaa gtc atg tac aac cag tct aca
gcc acg acc 400 Tyr Tyr Leu Pro Leu Lys Val Met Tyr Asn Gln Ser Thr
Ala Thr Thr 90 95 100 105 ctc ttt cac agt ctg cca ttg ctc agg tac
ata ttt gtt cgg gag aga 448 Leu Phe His Ser Leu Pro Leu Leu Arg Tyr
Ile Phe Val Arg Glu Arg 110 115 120 gtc acg ata atc cat tca cat agt
tct ttt tct gct atg gcc cat gat 496 Val Thr Ile Ile His Ser His Ser
Ser Phe Ser Ala Met Ala His Asp 125 130 135 gct ctc ttc cac gcc aag
aca atg ggg ctt cag aca gtc ttc acg gac 544 Ala Leu Phe His Ala Lys
Thr Met Gly Leu Gln Thr Val Phe Thr Asp 140 145 150 cat tcc ctt ttt
gga ttt gct gat gtc agc tcg gtg ctt aca aac aag 592 His Ser Leu Phe
Gly Phe Ala Asp Val Ser Ser Val Leu Thr Asn Lys 155 160 165 ctt cta
acc gtg tct ctt tgt gat aca aac cac atc att tgt gtg tct 640 Leu Leu
Thr Val Ser Leu Cys Asp Thr Asn His Ile Ile Cys Val Ser 170 175 180
185 tat act agt aag gaa aat act gta cta aga gca gca ctg aat cct gaa
688 Tyr Thr Ser Lys Glu Asn Thr Val Leu Arg Ala Ala Leu Asn Pro Glu
190 195 200 ata gtg tcc gtc att cct aat gct gta gat cct act gac ttc
act cca 736 Ile Val Ser Val Ile Pro Asn Ala Val Asp Pro Thr Asp Phe
Thr Pro 205 210 215 gac cca ttt aga agg cat gat agt ata act att gtt
gtt gtc agc aga 784 Asp Pro Phe Arg Arg His Asp Ser Ile Thr Ile Val
Val Val Ser Arg 220 225 230 ctt gtt tac aga aaa ggg atc gat ttg ctt
agt ggt ata ata cct gaa 832 Leu Val Tyr Arg Lys Gly Ile Asp Leu Leu
Ser Gly Ile Ile Pro Glu 235 240 245 ctc tgt cag aaa tat cca gat tta
aat ttc ata att gga gga gag gga 880 Leu Cys Gln Lys Tyr Pro Asp Leu
Asn Phe Ile Ile Gly Gly Glu Gly 250 255 260 265 cca aag aga atc att
ttg gaa gaa gtt cgg gaa aga tac cag ctg cat 928 Pro Lys Arg Ile Ile
Leu Glu Glu Val Arg Glu Arg Tyr Gln Leu His 270 275 280 gac agg gtg
cgt ctt ttg gga gct tta gaa cac aag gat gtt aga aat 976 Asp Arg Val
Arg Leu Leu Gly Ala Leu Glu His Lys Asp Val Arg Asn 285 290 295 gtc
tta gtt caa gga cat att ttt ctg aat acc tcc ctt act gaa gca 1024
Val Leu Val Gln Gly His Ile Phe Leu Asn Thr Ser Leu Thr Glu Ala 300
305 310 ttc tgc atg gcg atc gtg gaa gca gcc agt tgt ggt tta cag gtt
gta 1072 Phe Cys Met Ala Ile Val Glu Ala Ala Ser Cys Gly Leu Gln
Val Val 315 320 325 agt acc aga gtt ggt gga att cct gag gtg ctt cca
gaa aac ctt att 1120 Ser Thr Arg Val Gly Gly Ile Pro Glu Val Leu
Pro Glu Asn Leu Ile 330 335 340 345 att tta tgt gag cct tca gta aaa
tct ttg tgt gaa gga ttg gaa aag 1168 Ile Leu Cys Glu Pro Ser Val
Lys Ser Leu Cys Glu Gly Leu Glu Lys 350 355 360 gct att ttc caa ctg
aag tca ggg aca ttg cca gct cca gaa aac atc 1216 Ala Ile Phe Gln
Leu Lys Ser Gly Thr Leu Pro Ala Pro Glu Asn Ile 365 370 375 cat aac
ata gta aag act ttc tac acc tgg agg aat gtt gca gaa aga 1264 His
Asn Ile Val Lys Thr Phe Tyr Thr Trp Arg Asn Val Ala Glu Arg 380 385
390 act gaa aag gta tat gac cgg gta tca gtg gaa gct gtg ttg cca atg
1312 Thr Glu Lys Val Tyr Asp Arg Val Ser Val Glu Ala Val Leu Pro
Met 395 400 405 gac aaa cga ctg gac aga ctt att tct cac tgc ggc cca
gta aca ggc 1360 Asp Lys Arg Leu Asp Arg Leu Ile Ser His Cys Gly
Pro Val Thr Gly 410 415 420 425 tac atc ttt gct ttg ttg gca gtt ttc
aac ttc ctc ttc ctc att ttc 1408 Tyr Ile Phe Ala Leu Leu Ala Val
Phe Asn Phe Leu Phe Leu Ile Phe 430 435 440 ttg aga tgg atg act cca
gat tct atc att gat gtt gca ata gat gcc 1456 Leu Arg Trp Met Thr
Pro Asp Ser Ile Ile Asp Val Ala Ile Asp Ala 445 450 455 act ggg cca
cgg ggt gcc tgg act aat aac tat tct cac agt aaa aga 1504 Thr Gly
Pro Arg Gly Ala Trp Thr Asn Asn Tyr Ser His Ser Lys Arg 460 465 470
ggg ggt gag aat aat gag ata tct gaa acc agg tag aagg aagcctagat
1554 Gly Gly Glu Asn Asn Glu Ile Ser Glu Thr Arg * 475 480 485
tgtaagattt taaacatttg taatagttct ataaagacta tggaaaataa ccttgctttt
1614 ggggggtttt tgttttttta gagttaattt agtaagttat gctacctcta
tatcattcaa 1674 tattttctgt tgaggaaaga taaaaatgta tgcaattcct
gagtgtagaa acttcttgca 1734 cttatttaaa atttaggaga gaacatttaa
gccactcagg tatgcaattt ttcagactac 1794 tgaaatccct gtagcagaga
tgttttaaca ttatattttg agagctttgg gtgctgaagg 1854 gccaaacgtt
ttctgggcat tttttggcca gtttttaatg taacaccatt agacactcac 1914
cagatgttta caagttttct ttaggggaac tacaacaatt atatgaactg ttttatatca
1974 tgttcatata catttattag gaatctaaat catgtctttg aacatttatt
aggttcactc 2034 agtaggtgtt acatgtaatt aacaggttcc ttgagtaaga
tagtccatca gttaccagca 2094 cattttgaac ccctgctctg tgtagaatgt
tgaactagat gcttcccgcc attaaggacc 2154 aggggtgcat tcactctttg
tttaccattc aaatggctta cttcatcata attgtggttg 2214 atatgagatc
aatatccaac atgccaaaaa tgctcatgcc agttaatgcc aggaaaaaaa 2274
tcaccgacac actactagta ctttgttcct gttgtatgca ttctcctagg tagagcctcc
2334 atcttcagtt gtgtttgtga aggtattttt tgctttttaa atactgggga
ccgatatcac 2394 tgttgatagt gcagagaaac cctccacatt tttcagtgca
taattgagtt ttctataaat 2454 gccttcgtgt tttctgagca gaatgtacga
ggtgtgccat cccaaaacca gctgctaccc 2514 tgtcctttta atgtaagtca
ctccccttca ctgtggcctc gctgatgtct gataagtatt 2574 gtcagtgtgc
aaaaggcttt acttcagaat ggtttattta tagcaaacta agttgaaaat 2634
tttagaaaca gtctttgtgg gtggatgtta ttaactgtca ttgttgttgc ccagagccat
2694 gggtttttta accccaaatt atccacatgg tgtgtattat gaattctttg
aactcttaag 2754 gtttttgtga gaaaaggact gtgaattcaa aacaataagg
cacttgtggg tgcactacat 2814 agattctgac agtgttgtga ttctgtatag
gatttttaaa aatgacaaca ttcacaaaat 2874 ttattacttt ttaaaaaata
acatgcctat taactggttg cactgatata aaagaaatat 2934 atttgtgttt
tgtttgtact aaaatgcaaa agcaagagtg caatttttaa aatctagaag 2994
ttaggggttt tgttggagaa aaatggactg atctttaaac tattcagtct tactgggatt
3054 tttatgcata gaaactcaca tataaacatg aaataaacag tgccagtatt
cataggaaag 3114 tgagaaactg taatatttgg ccattattct attcaacagg
ttttagaggc acgccaccat 3174 tttttcctta tatttttgct taattttttt
aaattgtcat ttaattctta aactgtcatt 3234 tatttgagat ggaaataaga
tctaaagtta gttgcctttg cctgtaaaac atgtgatttg 3294 caaattatta
ttttcctttt tttttaacaa atggaagtaa atttgtttca cgtaaatctt 3354
aattttcaac ctttctggat accttaattg taactgtcag tttgcactgg tcggtatatg
3414 gaaacacatt gctctaccct gctacttagt tgattttaaa gtgaatttac
agtgatgaga 3474 aatttgtgaa aaatatattg tatttctttt gatgtttcaa
aaggttgcct atgaaaaact 3534 gatttgttaa aacatgctac atgtccaaaa
ataaagacca gaatgacatt ttgataaaaa 3594 aaaaaaa 3601 3 1357 DNA Homo
sapiens CDS (284)..(904) 3 ttgtattgat acctctggac cattccgcct
atttaggtga cactatagaa caagtttgta 60 caaaaaagca ggctggtacc
ggtccggaat tcccgggata tcgtcgaccc acgcgtccgg 120 cgccggggcc
gcctctcctt ccgccggtgc cgcggcgcct catggaagcc ccggagggcg 180
gcggaggggg gcctgcagcg cggggcccgg aggggcagcc ggcgcccgaa gccagggtgc
240 acttccgagt ggcgaggttc atcatggagg tgtcaagcta ggg atg cgg tcc att
295 Met Arg Ser Ile 1 ccc att gcc act gct tgc acc att tac cat aag
ttc ttt tgc gag acc 343 Pro Ile Ala Thr Ala Cys Thr Ile Tyr His Lys
Phe Phe Cys Glu Thr 5 10 15 20 aac ctg gac gcc tat gac cct tac ctg
att gcc atg tct tca att tac 391 Asn Leu Asp Ala Tyr Asp Pro Tyr Leu
Ile Ala Met Ser Ser Ile Tyr 25 30 35 ttg gcc ggc aaa gtg gaa gag
cag cac ctg cgg act cgt gac atc atc 439 Leu Ala Gly Lys Val Glu Glu
Gln His Leu Arg Thr Arg Asp Ile Ile 40 45 50 aat gtg tcc aac agg
tac ttt aac cca agc ggt gag ccc ctg gaa ttg 487 Asn Val Ser Asn Arg
Tyr Phe Asn Pro Ser Gly Glu Pro Leu Glu Leu 55 60 65 gac tcc cgc
ttc tgg gaa ctc cgg gac agc atc gtg cag tgt gag ctt 535 Asp Ser Arg
Phe Trp Glu Leu Arg Asp Ser Ile Val Gln Cys Glu Leu 70
75 80 ctc atg ctg aga gtt ctg cgc ttc cag gtc tcc ttc cag cat cca
cac 583 Leu Met Leu Arg Val Leu Arg Phe Gln Val Ser Phe Gln His Pro
His 85 90 95 100 aag tac ctg ctc cac tac ctg gtt tcc ctc cag aac
tgg ctg aac cgc 631 Lys Tyr Leu Leu His Tyr Leu Val Ser Leu Gln Asn
Trp Leu Asn Arg 105 110 115 cac agc tgg cag cgg acc cct gtt gcc gtc
acc gcc tgg gcc ctg ctg 679 His Ser Trp Gln Arg Thr Pro Val Ala Val
Thr Ala Trp Ala Leu Leu 120 125 130 cgg gac agc tac cat ggg gcg ctg
tgc ctc cgc ttc cag gcc cag cac 727 Arg Asp Ser Tyr His Gly Ala Leu
Cys Leu Arg Phe Gln Ala Gln His 135 140 145 atc gcc gtg gcg gtg ctc
tac ctg gcc ctg cag gtc tac gga gtt gag 775 Ile Ala Val Ala Val Leu
Tyr Leu Ala Leu Gln Val Tyr Gly Val Glu 150 155 160 gtg ccc gcc gag
gtc gag gct gag aag ccg tgg tgg cag gtg ttt aat 823 Val Pro Ala Glu
Val Glu Ala Glu Lys Pro Trp Trp Gln Val Phe Asn 165 170 175 180 gac
gac ctt acc aag cca atc att gat aat att gtg tct gat ctc att 871 Asp
Asp Leu Thr Lys Pro Ile Ile Asp Asn Ile Val Ser Asp Leu Ile 185 190
195 cag att tat acc atg gac aca gag atc ccc taa ggtcctgg cccaggcctg
922 Gln Ile Tyr Thr Met Asp Thr Glu Ile Pro * 200 205 cccaaagaga
agcccaggat ggtcggctgc ctggggacat tgtcaccacg tcgccatgac 982
ggctggtccc cacaggacca gctgggagga ctggttgtgc tgctggagaa gggctggaga
1042 aggcaatggc atgctgccgc tttgccagtc cctagaagtc gcggtgcagg
tgatggtggg 1102 agccgcgcct ccagcgggca ggccgggagt gtactgtgtg
cagctgaccc aaggcagcca 1162 catctgcgtt tgtcctttga gaggactttg
actacaatac aggcatgaca tcaatgaaag 1222 gaaagtcatg aaatcgatga
gactgaatcc ctacggattt cttaaaagcc agatttgtag 1282 ggagaatgaa
tgtgcaacgt ggctgaaatc tattttgtgt aataaaaggt gatacaagtc 1342
aaaaaaaaaa aaaaa 1357 4 2353 DNA Homo sapiens CDS (386)..(1783) 4
atccgggccc ttccagaagc aacccaggag ccccgagacc tgcagggatg tgtgcaccct
60 gacccctgac gcatagccct gcacctgcag ccagctggcc tcgggcttga
aaacatggcg 120 ggtgcgctcc aattcacggt ggtttccaag cgcattctgg
aggagaaaac acatgagtgt 180 gtggtcaggg ttctctgccg acagacctac
cgtggggaag aaagagaagt tctgaagatg 240 gatcatggcc gtgactgcat
gtcaaggaga atctccatga tgacacggag gcctacgtcg 300 agatagagta
aatatggtcc aattaaaagg tgacccgaca atcaacccct gaaaaaggcg 360
gtcataaaac ccccaggaga cgaag atg atg gca cgt cgt gac ccc aaa cct 412
Met Met Ala Arg Arg Asp Pro Lys Pro 1 5 ggg gca aag aga ctg gtg aga
gcc cag acc ctc cag aag cag cgg agg 460 Gly Ala Lys Arg Leu Val Arg
Ala Gln Thr Leu Gln Lys Gln Arg Arg 10 15 20 25 gcc cca gtt ggg cca
agg gct ccc ccg ccc gat gaa gaa gat ccc agg 508 Ala Pro Val Gly Pro
Arg Ala Pro Pro Pro Asp Glu Glu Asp Pro Arg 30 35 40 ctc aag tgc
aaa aac tgt gag gcc ttt ggc cac acg gcc aga agt acc 556 Leu Lys Cys
Lys Asn Cys Glu Ala Phe Gly His Thr Ala Arg Ser Thr 45 50 55 agg
tgc ccc atg aag tgc tgg aag gca gcc ctg gtt cca ccg aac ttt 604 Arg
Cys Pro Met Lys Cys Trp Lys Ala Ala Leu Val Pro Pro Asn Phe 60 65
70 ggg gaa aag gaa ggg aag gaa aac ctg aaa cca tgg aag ccc cag gtt
652 Gly Glu Lys Glu Gly Lys Glu Asn Leu Lys Pro Trp Lys Pro Gln Val
75 80 85 gaa gcg aac cct ggg ccc ttg aac aag gat aag gga gag aag
gaa gag 700 Glu Ala Asn Pro Gly Pro Leu Asn Lys Asp Lys Gly Glu Lys
Glu Glu 90 95 100 105 aga cca agg cca caa gac ccg cag agg aag gct
ctc ctc cac ata ttt 748 Arg Pro Arg Pro Gln Asp Pro Gln Arg Lys Ala
Leu Leu His Ile Phe 110 115 120 tcc ggg aaa cct cca gag aag ccg ctg
cca aat caa aaa gga tcc acg 796 Ser Gly Lys Pro Pro Glu Lys Pro Leu
Pro Asn Gln Lys Gly Ser Thr 125 130 135 gaa tct tct gat tat ctg agg
gtt gca agc ggg cca atg ccg gtc cac 844 Glu Ser Ser Asp Tyr Leu Arg
Val Ala Ser Gly Pro Met Pro Val His 140 145 150 aca acc agt aag agg
ccg cgt gtg gac cct gtc ctc tct gat cgc tca 892 Thr Thr Ser Lys Arg
Pro Arg Val Asp Pro Val Leu Ser Asp Arg Ser 155 160 165 gct acc gaa
atg tct gac agg ggc tcc gtc tta gct tca ctg tct ccc 940 Ala Thr Glu
Met Ser Asp Arg Gly Ser Val Leu Ala Ser Leu Ser Pro 170 175 180 185
ctc aga aaa gcc agt ctg agc tcc tcc tca agt ctt gga cca aag gaa 988
Leu Arg Lys Ala Ser Leu Ser Ser Ser Ser Ser Leu Gly Pro Lys Glu 190
195 200 aga cag aca ggg gct gcg gcc gac atc cct cag act gca gtc agg
cac 1036 Arg Gln Thr Gly Ala Ala Ala Asp Ile Pro Gln Thr Ala Val
Arg His 205 210 215 cag ggc ccc gag cct ctc ctc gtg gtg aag ccg aca
cac agc agc cct 1084 Gln Gly Pro Glu Pro Leu Leu Val Val Lys Pro
Thr His Ser Ser Pro 220 225 230 gag ggt ggc tgt cga gaa gtt ccc cag
gct gcc tcc aaa acc cac ggc 1132 Glu Gly Gly Cys Arg Glu Val Pro
Gln Ala Ala Ser Lys Thr His Gly 235 240 245 ctg ctc cag gcc gtc aga
ccc cag gca caa gac aaa cgt cct gcg gtg 1180 Leu Leu Gln Ala Val
Arg Pro Gln Ala Gln Asp Lys Arg Pro Ala Val 250 255 260 265 acc tca
cag ccc tgc cca cca gcc gcc aca cac agc ttg ggc cta ggc 1228 Thr
Ser Gln Pro Cys Pro Pro Ala Ala Thr His Ser Leu Gly Leu Gly 270 275
280 tcc aat ctc agc ttc ggg cca gga gcc aag aga tct gcc ccg gct ccg
1276 Ser Asn Leu Ser Phe Gly Pro Gly Ala Lys Arg Ser Ala Pro Ala
Pro 285 290 295 att cag gct tgc ctg aac ttc ccc aag aaa ccg aga ctg
ggt ccc ttc 1324 Ile Gln Ala Cys Leu Asn Phe Pro Lys Lys Pro Arg
Leu Gly Pro Phe 300 305 310 cag atc ccc gaa agc gcc atc cag gga ggt
gag ctg ggg gcc ccg gag 1372 Gln Ile Pro Glu Ser Ala Ile Gln Gly
Gly Glu Leu Gly Ala Pro Glu 315 320 325 aat ctc caa cct ccg cca gcc
gca acc gaa ctt gga cca cgt acc gtg 1420 Asn Leu Gln Pro Pro Pro
Ala Ala Thr Glu Leu Gly Pro Arg Thr Val 330 335 340 345 tca ccc cag
ata ggc acg agg aca ccc gcc cag gtg ctt agc ggc gac 1468 Ser Pro
Gln Ile Gly Thr Arg Thr Pro Ala Gln Val Leu Ser Gly Asp 350 355 360
cgg cag cct ccg cac agc aga cct tgc ctg cct act gcc cag gcc tgc
1516 Arg Gln Pro Pro His Ser Arg Pro Cys Leu Pro Thr Ala Gln Ala
Cys 365 370 375 acc atg tcc cat cac cca gcg gcc agc cat gat ggg gcc
cag cct ctc 1564 Thr Met Ser His His Pro Ala Ala Ser His Asp Gly
Ala Gln Pro Leu 380 385 390 aga gtg ctc ttt cgg aga ctg gaa aac gga
cgc tgg agc tcc agc ctg 1612 Arg Val Leu Phe Arg Arg Leu Glu Asn
Gly Arg Trp Ser Ser Ser Leu 395 400 405 ctg acg gcc ccc tca ttt cac
tct cct gag aag ccg gga gcc ttc ctc 1660 Leu Thr Ala Pro Ser Phe
His Ser Pro Glu Lys Pro Gly Ala Phe Leu 410 415 420 425 gct cag agc
cct cat gtc tca gag aag tct gag ggt ccc tgt gtt cgt 1708 Ala Gln
Ser Pro His Val Ser Glu Lys Ser Glu Gly Pro Cys Val Arg 430 435 440
gtc cca cca agc gtc ctc tat gag gac ctt cag gtt ccc tcc tcc tca
1756 Val Pro Pro Ser Val Leu Tyr Glu Asp Leu Gln Val Pro Ser Ser
Ser 445 450 455 gag gac agc gat tct gac ctg gag tga gactg
caggtggcag gggctccttg 1808 Glu Asp Ser Asp Ser Asp Leu Glu * 460
465 gcctccagct cccgtgactt ggaggggact gtgggactga ggagcacaga
gcagagagca 1868 gactctgtgc ggtgactccg aagctccccg gctgtggccc
ttctgtggat gtgggagccc 1928 aggccaggca gggagcagat gcagggactc
tgccccgttg aattctggtg agggacattg 1988 tagttcgcat ggttctctgg
aaacgcgcca ggaaaagctt ccgtgccagt gattcgttgc 2048 ctcagaaact
gcatgacgcg caggagtcag acttccgctg ggacgtcaat aggaaacggg 2108
ggaattactg tgtatttgct ctctagacga ctgaataagg gaaaagttag ggaaccctga
2168 gaggtgcagc ccttccgctg tgccccgccc tgagagcagt gtttccgacg
ctgggaagcg 2228 cgctgtgcaa agcgctctcg gggtctttcc tcagcctcga
aaagtgggct ctggaatccc 2288 tttgtaaata ggtgtgttga atttgttttg
aagtgaataa aattctcaaa aagaaaaaaa 2348 aaaaa 2353 5 897 DNA Homo
sapiens CDS (1)..(897) 5 atg gag gga tat tcc aac aag aaa ttg gat
aat atg tct ttg gat gat 48 Met Glu Gly Tyr Ser Asn Lys Lys Leu Asp
Asn Met Ser Leu Asp Asp 1 5 10 15 gct gtt tgc caa ggc act gcg ggc
agg aaa ggc aaa cga aga atg agg 96 Ala Val Cys Gln Gly Thr Ala Gly
Arg Lys Gly Lys Arg Arg Met Arg 20 25 30 tac gca ggc aac tgg agg
gtg aac aag atg aag agg agc ttt att gag 144 Tyr Ala Gly Asn Trp Arg
Val Asn Lys Met Lys Arg Ser Phe Ile Glu 35 40 45 tgt tac aac agc
tta gag gag acc cac agg agg acg gcg gac ctg ctc 192 Cys Tyr Asn Ser
Leu Glu Glu Thr His Arg Arg Thr Ala Asp Leu Leu 50 55 60 tcc gtg
gtc atg gcc cag cag agg gga agc gca gct cag tgt cca agt 240 Ser Val
Val Met Ala Gln Gln Arg Gly Ser Ala Ala Gln Cys Pro Ser 65 70 75 80
tac aca gac tcg cag aat ctc aca ggt gtc tta gaa ttt ctc ttc ctg 288
Tyr Thr Asp Ser Gln Asn Leu Thr Gly Val Leu Glu Phe Leu Phe Leu 85
90 95 gga ctc tca gag gat cca gaa ctg cag ccc gtc ctc gtt ggg ctg
ttc 336 Gly Leu Ser Glu Asp Pro Glu Leu Gln Pro Val Leu Val Gly Leu
Phe 100 105 110 ctg tcc atg tac ctg atc acg gtg ctg ggg aac ctg ctc
atc atc ctg 384 Leu Ser Met Tyr Leu Ile Thr Val Leu Gly Asn Leu Leu
Ile Ile Leu 115 120 125 gcc gtc agc tgt gac tcc cac ctc cac acc ccc
atg tac ttc ttc ctc 432 Ala Val Ser Cys Asp Ser His Leu His Thr Pro
Met Tyr Phe Phe Leu 130 135 140 tcc aac ttg tcc ttg gct gac atc gga
ctc acc tct gcc acc atc cct 480 Ser Asn Leu Ser Leu Ala Asp Ile Gly
Leu Thr Ser Ala Thr Ile Pro 145 150 155 160 aag atg att gtt gat atg
caa tct cac agc aga atc atc tcc tat gag 528 Lys Met Ile Val Asp Met
Gln Ser His Ser Arg Ile Ile Ser Tyr Glu 165 170 175 ggc tgc ctg atg
cag atg tct tta tct att ttg aag ggt gcg gtc acc 576 Gly Cys Leu Met
Gln Met Ser Leu Ser Ile Leu Lys Gly Ala Val Thr 180 185 190 tca gtg
atg tac act gtg gtc atc cct atg ctg aac ccc ttc atc tac 624 Ser Val
Met Tyr Thr Val Val Ile Pro Met Leu Asn Pro Phe Ile Tyr 195 200 205
agc ctg aga aac agg gac att aaa atc tcc aag atg att gtg gac atc 672
Ser Leu Arg Asn Arg Asp Ile Lys Ile Ser Lys Met Ile Val Asp Ile 210
215 220 cag tct cac agc aga gtc atc tcc tat gcg ggc tgc ctg act cag
gta 720 Gln Ser His Ser Arg Val Ile Ser Tyr Ala Gly Cys Leu Thr Gln
Val 225 230 235 240 tct ctt ttt gcc gtt ttt gga tgc atg gaa gac atg
ctt ctg agt gtg 768 Ser Leu Phe Ala Val Phe Gly Cys Met Glu Asp Met
Leu Leu Ser Val 245 250 255 atg gct tat gac cga aaa ggt gca gtg gcc
tca gtg atg tac acg gtg 816 Met Ala Tyr Asp Arg Lys Gly Ala Val Ala
Ser Val Met Tyr Thr Val 260 265 270 gtt act ccc atg ctg aac ccc ttc
atc tac agc cta aca ggg aaa tta 864 Val Thr Pro Met Leu Asn Pro Phe
Ile Tyr Ser Leu Thr Gly Lys Leu 275 280 285 aaa gtg ccc tgc ggc agc
tgc act gca gaa tag 897 Lys Val Pro Cys Gly Ser Cys Thr Ala Glu *
290 295 6 3396 DNA Homo sapiens CDS (27)..(2375) 6 aatttaggtg
acactataga agagct atg acg tcg cat gca cgc gta cgt aag 53 Met Thr
Ser His Ala Arg Val Arg Lys 1 5 ctt gga tcc tct aga gcg gcc gcg tcg
ccg ctg agg atg tcc cga aag 101 Leu Gly Ser Ser Arg Ala Ala Ala Ser
Pro Leu Arg Met Ser Arg Lys 10 15 20 25 ggg ccg cga gcg gag gtg tgt
gcg gac tgc agc gcc ccg gac cct ggc 149 Gly Pro Arg Ala Glu Val Cys
Ala Asp Cys Ser Ala Pro Asp Pro Gly 30 35 40 tgg gca tcc atc agc
agg ggt gtg ctg gtg tgt gac gag tgc tgc agc 197 Trp Ala Ser Ile Ser
Arg Gly Val Leu Val Cys Asp Glu Cys Cys Ser 45 50 55 gtg cac cgg
agc ctg gga cgc cac atc tcc att gtc aag cac ctt cgc 245 Val His Arg
Ser Leu Gly Arg His Ile Ser Ile Val Lys His Leu Arg 60 65 70 cac
agc gcc tgg cct ccc acg ctg ctg cag atg gtg cac acg ctt gcc 293 His
Ser Ala Trp Pro Pro Thr Leu Leu Gln Met Val His Thr Leu Ala 75 80
85 agc aac ggg gcc aac tcc atc tgg gag cac tcc ctg ctg gac ccc gca
341 Ser Asn Gly Ala Asn Ser Ile Trp Glu His Ser Leu Leu Asp Pro Ala
90 95 100 105 caa gtg cag agc ggc cgg cgt aaa gcc aac ccc caa gac
aaa gtc cac 389 Gln Val Gln Ser Gly Arg Arg Lys Ala Asn Pro Gln Asp
Lys Val His 110 115 120 ccc atc aag tca gag ttc atc agg gcc aag tac
cag atg ctg gca ttt 437 Pro Ile Lys Ser Glu Phe Ile Arg Ala Lys Tyr
Gln Met Leu Ala Phe 125 130 135 gtg cac aag ctt ccc tgc cgg gac gat
gat gga gtc acc gcc aaa gac 485 Val His Lys Leu Pro Cys Arg Asp Asp
Asp Gly Val Thr Ala Lys Asp 140 145 150 ctc agc aag caa cta cac tcg
agc gtg cgg aca ggc aac ctg gag aca 533 Leu Ser Lys Gln Leu His Ser
Ser Val Arg Thr Gly Asn Leu Glu Thr 155 160 165 tgt ctg cgc ctg ctc
tcc ctg ggt gcc cag gcc aac ttc ttc cac cca 581 Cys Leu Arg Leu Leu
Ser Leu Gly Ala Gln Ala Asn Phe Phe His Pro 170 175 180 185 gag aag
ggc acc aca cct ctg cac gtg gct gcc aag gca gga cag aca 629 Glu Lys
Gly Thr Thr Pro Leu His Val Ala Ala Lys Ala Gly Gln Thr 190 195 200
ctg cag gcc gag ctg ctt gta gtg tat ggg gct gac cct ggc tcc cct 677
Leu Gln Ala Glu Leu Leu Val Val Tyr Gly Ala Asp Pro Gly Ser Pro 205
210 215 gat gtt aat ggc cgc aca ccc att gac tat gcc agg cag gcg ggg
cac 725 Asp Val Asn Gly Arg Thr Pro Ile Asp Tyr Ala Arg Gln Ala Gly
His 220 225 230 cat gag ctg gcg gaa agg ctg gtt gag tgc caa tat gag
ctc act gac 773 His Glu Leu Ala Glu Arg Leu Val Glu Cys Gln Tyr Glu
Leu Thr Asp 235 240 245 cgg ctg gcc ttc tac ctc tgt gga cgc aag ccg
gat cac aag aat ggg 821 Arg Leu Ala Phe Tyr Leu Cys Gly Arg Lys Pro
Asp His Lys Asn Gly 250 255 260 265 cat tac atc atc cca cag atg gct
gac agc ctt gac tta tcc gaa ttg 869 His Tyr Ile Ile Pro Gln Met Ala
Asp Ser Leu Asp Leu Ser Glu Leu 270 275 280 gcc aaa gct gct aag aag
aag ctg cag gcg ctc agc aac cgg ctt ttt 917 Ala Lys Ala Ala Lys Lys
Lys Leu Gln Ala Leu Ser Asn Arg Leu Phe 285 290 295 gag gaa ctc gcc
atg gac gtg tat gac gag gtg gat cga aga gaa aat 965 Glu Glu Leu Ala
Met Asp Val Tyr Asp Glu Val Asp Arg Arg Glu Asn 300 305 310 gat gca
gtg tgg ctg gct acc caa aac cac agc act ctg gtg aca gag 1013 Asp
Ala Val Trp Leu Ala Thr Gln Asn His Ser Thr Leu Val Thr Glu 315 320
325 cgc agt gct gtg ccc ttc ctg cct gtt aac ccg gaa tac tca gcc acg
1061 Arg Ser Ala Val Pro Phe Leu Pro Val Asn Pro Glu Tyr Ser Ala
Thr 330 335 340 345 cgg aat cag ggg cga caa aag ctg gcc cgc ttt aat
gcc cga gag ttt 1109 Arg Asn Gln Gly Arg Gln Lys Leu Ala Arg Phe
Asn Ala Arg Glu Phe 350 355 360 gcc acc ttg atc atc gac att ctc agt
gag gcc aag cgg aga cag cag 1157 Ala Thr Leu Ile Ile Asp Ile Leu
Ser Glu Ala Lys Arg Arg Gln Gln 365 370 375 ggc aag agc ctg agc agc
ccc aca gac aac ctc gag ctg tct ctg cgg 1205 Gly Lys Ser Leu Ser
Ser Pro Thr Asp Asn Leu Glu Leu Ser Leu Arg 380 385 390 agc cag agt
gac ctc gac gac caa cac gac tac gac agc gtg gcc tct 1253 Ser Gln
Ser Asp Leu Asp Asp Gln His Asp Tyr Asp Ser Val Ala Ser 395 400 405
gac gag gac aca gac cag gag ccc ctg cgc agc acc ggc gcc act cgg
1301 Asp Glu Asp Thr Asp Gln Glu Pro Leu Arg Ser Thr Gly Ala Thr
Arg 410 415 420 425 agc aac cgg gcc cgg agc atg gac tcc tcg gac ttg
tct gac ggg gct 1349 Ser Asn Arg Ala Arg Ser Met Asp Ser Ser Asp
Leu Ser Asp Gly Ala 430 435 440 gtg acg ctg cag gag tac ctg gag ctg
aag aag gcc ctg gct aca tcg 1397 Val Thr Leu Gln Glu Tyr Leu Glu
Leu Lys Lys Ala Leu Ala Thr Ser
445 450 455 gag gca aag gtg cag cag ctc atg aag gtc aac agt agc ctg
agc gac 1445 Glu Ala Lys Val Gln Gln Leu Met Lys Val Asn Ser Ser
Leu Ser Asp 460 465 470 gag ctc cgg agg ctg cag cga gag atc cac aag
ctg cag gcg gag aac 1493 Glu Leu Arg Arg Leu Gln Arg Glu Ile His
Lys Leu Gln Ala Glu Asn 475 480 485 ctg cag ctc cgg cag cct cca ggg
ccg gtg ccc aca cct cca ctc ccc 1541 Leu Gln Leu Arg Gln Pro Pro
Gly Pro Val Pro Thr Pro Pro Leu Pro 490 495 500 505 agt gaa cgg gcg
gaa cac aca ccc atg gcg cca ggc ggg agc aca cac 1589 Ser Glu Arg
Ala Glu His Thr Pro Met Ala Pro Gly Gly Ser Thr His 510 515 520 cgc
agg gat cgc cag gcc ttt tcc atg tat gaa cct ggc tct gcc ctg 1637
Arg Arg Asp Arg Gln Ala Phe Ser Met Tyr Glu Pro Gly Ser Ala Leu 525
530 535 aag ccc ttt ggg ggc cac ctt ggg gac gag ctc act acg cgg ctg
cag 1685 Lys Pro Phe Gly Gly His Leu Gly Asp Glu Leu Thr Thr Arg
Leu Gln 540 545 550 cct ttc cac agc act gag cta gag gac gac gcc atc
tat tca gtg cac 1733 Pro Phe His Ser Thr Glu Leu Glu Asp Asp Ala
Ile Tyr Ser Val His 555 560 565 gtc cct gct ggc ctt tac cgg atc cgg
aaa ggg gtg tct gcc tca gct 1781 Val Pro Ala Gly Leu Tyr Arg Ile
Arg Lys Gly Val Ser Ala Ser Ala 570 575 580 585 gtg ccc ttc act ccc
tcc tcc ccg ctg ctg tcc tgc tcc cag gag gga 1829 Val Pro Phe Thr
Pro Ser Ser Pro Leu Leu Ser Cys Ser Gln Glu Gly 590 595 600 agc cgc
cac acg agc aag ctt tcc cgc cac ggc agt gga gcc gac agt 1877 Ser
Arg His Thr Ser Lys Leu Ser Arg His Gly Ser Gly Ala Asp Ser 605 610
615 gac tat gag aac acg caa agt ggg gac cca ctg ctg ggg ctg gaa ggg
1925 Asp Tyr Glu Asn Thr Gln Ser Gly Asp Pro Leu Leu Gly Leu Glu
Gly 620 625 630 aag agg ttt cta gag ctg ggc aaa gag gaa gac ttc cac
cca gag ctg 1973 Lys Arg Phe Leu Glu Leu Gly Lys Glu Glu Asp Phe
His Pro Glu Leu 635 640 645 gaa agc ctg gat gga gac cta gat cct ggg
ctt ccc agc aca gag gat 2021 Glu Ser Leu Asp Gly Asp Leu Asp Pro
Gly Leu Pro Ser Thr Glu Asp 650 655 660 665 gtc atc ttg aag aca gag
cag gtc acc aag aac att cag gaa ctg ttg 2069 Val Ile Leu Lys Thr
Glu Gln Val Thr Lys Asn Ile Gln Glu Leu Leu 670 675 680 cgg gca gcc
cag gag ttc aag cat gac agc ttc gtg ccc tgc tca gag 2117 Arg Ala
Ala Gln Glu Phe Lys His Asp Ser Phe Val Pro Cys Ser Glu 685 690 695
aag atc cat ttg gct gtg acc gag atg gcc tcc ctc ttc cca aag agg
2165 Lys Ile His Leu Ala Val Thr Glu Met Ala Ser Leu Phe Pro Lys
Arg 700 705 710 cca gcc ctg gag cca gtg cgg agc tca ctg cgg ctg ctc
aac gcc agc 2213 Pro Ala Leu Glu Pro Val Arg Ser Ser Leu Arg Leu
Leu Asn Ala Ser 715 720 725 gcc tac cgg ctg cag agt gag tgc cgg aag
aca gtg ccc cca gag ccc 2261 Ala Tyr Arg Leu Gln Ser Glu Cys Arg
Lys Thr Val Pro Pro Glu Pro 730 735 740 745 ggc gcc cca gtg gac ttc
cag ctg ctg act cag cag gtg atc cag tgc 2309 Gly Ala Pro Val Asp
Phe Gln Leu Leu Thr Gln Gln Val Ile Gln Cys 750 755 760 gcc tat gac
atc gcc aag gct gcc aag cag ctg gtc acc atc acc acc 2357 Ala Tyr
Asp Ile Ala Lys Ala Ala Lys Gln Leu Val Thr Ile Thr Thr 765 770 775
cga gag aag aag cag tga cctctc tccccacacc ctcacctgca ccctaggacc
2411 Arg Glu Lys Lys Gln * 780 tcactggcca taggagctgg gccactccag
acattaatcc ccaccccaac agagccactg 2471 gcacaagtgc ccttagtgct
gccacactcc ctggcagcca ggtgccctgg tgcccacccc 2531 tgtcgagccc
ctaaggatgg ggaggtgggg gggcaggagc ttctgtcccc cacattccat 2591
gcacctcccc tctgtatata gcatctcccc cctcctagtg agcaggggcc tgcaaggcat
2651 cactcccagc ccctcgcctt ctagggcacc ctcagcaaag gggcaggtgg
ggacactcca 2711 agtggggcag ctctccgtac atgcgcccca cccccatgag
ccagttcagc cctactgggg 2771 gctgagcggg ggcatcccct cctttgtaca
tagtctccat ggatgtccct gccctgtagc 2831 caccagcccc ttgctgctct
ccctttaatg ccatatggcc cctgcctagg gcacaggccc 2891 caacctgtgt
gctggggtcc ccagcagcaa acactggaaa gtctgttttt tttttttctt 2951
tcttcttccc caccccttaa ttttaacttt gtggtaactg agtgcccccg cgtgcctgcg
3011 tgttgagtgt gtggggcggc agtgccgttc cggaggcctg gtccatctgg
agttttgagg 3071 ggtgagggga ccagagcagt gggaccagca tggggatcag
cttcccttcc ccacctggga 3131 gccagggact gtccgggtag ccagttttgg
tcctgccagc tgcctccctg atccctcccc 3191 actctcgccc cttctctatg
aacttaaatc aaaaaccact tccctccatc tcctcctgct 3251 cctgcgtgga
gggggaatgt gtgctggcta aggtggagga ctgagcagct gagcctgggg 3311
ctggctcccc gggggtctcg actcagctgg tggcttttga actgagtccc tcccgtaaac
3371 tcttcaagcc agcaccacca taatt 3396 7 3423 DNA Homo sapiens CDS
(27)..(2402) 7 aatttaggtg acactataga agagct atg acg tcg cat gca cgc
gta cgt aag 53 Met Thr Ser His Ala Arg Val Arg Lys 1 5 ctt gga tcc
tct aga gcg gcc gcg tcg ccg ctg agg atg tcc cga aag 101 Leu Gly Ser
Ser Arg Ala Ala Ala Ser Pro Leu Arg Met Ser Arg Lys 10 15 20 25 ggg
ccg cga gcg gag gtg tgt gcg gac tgc agc gcc ccg gac cct ggc 149 Gly
Pro Arg Ala Glu Val Cys Ala Asp Cys Ser Ala Pro Asp Pro Gly 30 35
40 tgg gca tcc atc agc agg ggt gtg ctg gtg tgt gac gag tgc tgc agc
197 Trp Ala Ser Ile Ser Arg Gly Val Leu Val Cys Asp Glu Cys Cys Ser
45 50 55 gtg cac cgg agc ctg gga cgc cac atc tcc att gtc aag cac
ctt cgc 245 Val His Arg Ser Leu Gly Arg His Ile Ser Ile Val Lys His
Leu Arg 60 65 70 cac agc gcc tgg cct ccc acg ctg ctg cag atg gtg
cac acg ctt gcc 293 His Ser Ala Trp Pro Pro Thr Leu Leu Gln Met Val
His Thr Leu Ala 75 80 85 agc aac ggg gcc aac tcc atc tgg gag cac
tcc ctg ctg gac ccc gca 341 Ser Asn Gly Ala Asn Ser Ile Trp Glu His
Ser Leu Leu Asp Pro Ala 90 95 100 105 caa gtg cag agc ggc cgg cgt
aaa gcc aac ccc caa gac aaa gtc cac 389 Gln Val Gln Ser Gly Arg Arg
Lys Ala Asn Pro Gln Asp Lys Val His 110 115 120 ccc atc aag tca gag
ttc atc agg gcc aag tac cag atg ctg gca ttt 437 Pro Ile Lys Ser Glu
Phe Ile Arg Ala Lys Tyr Gln Met Leu Ala Phe 125 130 135 gtg cac aag
ctt ccc tgc cgg gac gat gat gga gtc acc gcc aaa gac 485 Val His Lys
Leu Pro Cys Arg Asp Asp Asp Gly Val Thr Ala Lys Asp 140 145 150 ctc
agc aag caa cta cac tcg agc gtg cgg aca ggc aac ctg gag aca 533 Leu
Ser Lys Gln Leu His Ser Ser Val Arg Thr Gly Asn Leu Glu Thr 155 160
165 tgt ctg cgc ctg ctc tcc ctg ggt gcc cag gcc aac ttc ttc cac cca
581 Cys Leu Arg Leu Leu Ser Leu Gly Ala Gln Ala Asn Phe Phe His Pro
170 175 180 185 gag aag ggc acc aca cct ctg cac gtg gct gcc aag gca
gga cag aca 629 Glu Lys Gly Thr Thr Pro Leu His Val Ala Ala Lys Ala
Gly Gln Thr 190 195 200 ctg cag gcc gag ctg ctt gta gtg tat ggg gct
gac cct ggc tcc cct 677 Leu Gln Ala Glu Leu Leu Val Val Tyr Gly Ala
Asp Pro Gly Ser Pro 205 210 215 gat gtt aat ggc cgc aca ccc att gac
tat gcc agg cag gcg ggg cac 725 Asp Val Asn Gly Arg Thr Pro Ile Asp
Tyr Ala Arg Gln Ala Gly His 220 225 230 cat gag ctg gcg gaa agg ctg
gtt gag tgc caa tat gag ctc act gac 773 His Glu Leu Ala Glu Arg Leu
Val Glu Cys Gln Tyr Glu Leu Thr Asp 235 240 245 cgg ctg gcc ttc tac
ctc tgt gga cgc aag ccg gat cac aag aat ggg 821 Arg Leu Ala Phe Tyr
Leu Cys Gly Arg Lys Pro Asp His Lys Asn Gly 250 255 260 265 cat tac
atc atc cca cag atg gct gac aga tct cgg caa aag tgc atg 869 His Tyr
Ile Ile Pro Gln Met Ala Asp Arg Ser Arg Gln Lys Cys Met 270 275 280
tct cag agc ctt gac tta tcc gaa ttg gcc aaa gct gct aag aag aag 917
Ser Gln Ser Leu Asp Leu Ser Glu Leu Ala Lys Ala Ala Lys Lys Lys 285
290 295 ctg cag gcg ctc agc aac cgg ctt ttt gag gaa ctc gcc atg gac
gtg 965 Leu Gln Ala Leu Ser Asn Arg Leu Phe Glu Glu Leu Ala Met Asp
Val 300 305 310 tat gac gag gtg gat cga aga gaa aat gat gca gtg tgg
ctg gct acc 1013 Tyr Asp Glu Val Asp Arg Arg Glu Asn Asp Ala Val
Trp Leu Ala Thr 315 320 325 caa aac cac agc act ctg gtg aca gag cgc
agt gct gtg ccc ttc ctg 1061 Gln Asn His Ser Thr Leu Val Thr Glu
Arg Ser Ala Val Pro Phe Leu 330 335 340 345 cct gtt aac ccg gaa tac
tca gcc acg cgg aat cag ggg cga caa aag 1109 Pro Val Asn Pro Glu
Tyr Ser Ala Thr Arg Asn Gln Gly Arg Gln Lys 350 355 360 ctg gcc cgc
ttt aat gcc cga gag ttt gcc acc ttg atc atc gac att 1157 Leu Ala
Arg Phe Asn Ala Arg Glu Phe Ala Thr Leu Ile Ile Asp Ile 365 370 375
ctc agt gag gcc aag cgg aga cag cag ggc aag agc ctg agc agc ccc
1205 Leu Ser Glu Ala Lys Arg Arg Gln Gln Gly Lys Ser Leu Ser Ser
Pro 380 385 390 aca gac aac ctc gag ctg tct ctg cgg agc cag agt gac
ctc gac gac 1253 Thr Asp Asn Leu Glu Leu Ser Leu Arg Ser Gln Ser
Asp Leu Asp Asp 395 400 405 caa cac gac tac gac agc gtg gcc tct gac
gag gac aca gac cag gag 1301 Gln His Asp Tyr Asp Ser Val Ala Ser
Asp Glu Asp Thr Asp Gln Glu 410 415 420 425 ccc ctg cgc agc acc ggc
gcc act cgg agc aac cgg gcc cgg agc atg 1349 Pro Leu Arg Ser Thr
Gly Ala Thr Arg Ser Asn Arg Ala Arg Ser Met 430 435 440 gac tcc tcg
gac ttg tct gac ggg gct gtg acg ctg cag gag tac ctg 1397 Asp Ser
Ser Asp Leu Ser Asp Gly Ala Val Thr Leu Gln Glu Tyr Leu 445 450 455
gag ctg aag aag gcc ctg gct aca tcg gag gca aag gtg cag cag ctc
1445 Glu Leu Lys Lys Ala Leu Ala Thr Ser Glu Ala Lys Val Gln Gln
Leu 460 465 470 atg aag gtc aac agt agc ctg agc gac gag ctc cgg agg
ctg cag cga 1493 Met Lys Val Asn Ser Ser Leu Ser Asp Glu Leu Arg
Arg Leu Gln Arg 475 480 485 gag atc cac aag ctg cag gcg gag aac ctg
cag ctc cgg cag cct cca 1541 Glu Ile His Lys Leu Gln Ala Glu Asn
Leu Gln Leu Arg Gln Pro Pro 490 495 500 505 ggg ccg gtg ccc aca cct
cca ctc ccc agt gaa cgg gcg gaa cac aca 1589 Gly Pro Val Pro Thr
Pro Pro Leu Pro Ser Glu Arg Ala Glu His Thr 510 515 520 ccc atg gcg
cca ggc ggg agc aca cac cgc agg gat cgc cag gcc ttt 1637 Pro Met
Ala Pro Gly Gly Ser Thr His Arg Arg Asp Arg Gln Ala Phe 525 530 535
tcc atg tat gaa cct ggc tct gcc ctg aag ccc ttt ggg ggc cac ctt
1685 Ser Met Tyr Glu Pro Gly Ser Ala Leu Lys Pro Phe Gly Gly His
Leu 540 545 550 ggg gac gag ctc act acg cgg ctg cag cct ttc cac agc
act gag cta 1733 Gly Asp Glu Leu Thr Thr Arg Leu Gln Pro Phe His
Ser Thr Glu Leu 555 560 565 gag gac gac gcc atc tat tca gtg cac gtc
cct gct ggc ctt tac cgg 1781 Glu Asp Asp Ala Ile Tyr Ser Val His
Val Pro Ala Gly Leu Tyr Arg 570 575 580 585 atc cgg aaa ggg gtg tct
gcc tca gct gtg ccc ttc act ccc tcc tcc 1829 Ile Arg Lys Gly Val
Ser Ala Ser Ala Val Pro Phe Thr Pro Ser Ser 590 595 600 ccg ctg ctg
tcc tgc tcc cag gag gga agc cgc cac acg agc aag ctt 1877 Pro Leu
Leu Ser Cys Ser Gln Glu Gly Ser Arg His Thr Ser Lys Leu 605 610 615
tcc cgc cac ggc agt gga gcc gac agt gac tat gag aac acg caa agt
1925 Ser Arg His Gly Ser Gly Ala Asp Ser Asp Tyr Glu Asn Thr Gln
Ser 620 625 630 ggg gac cca ctg ctg ggg ctg gaa ggg aag agg ttt cta
gag ctg ggc 1973 Gly Asp Pro Leu Leu Gly Leu Glu Gly Lys Arg Phe
Leu Glu Leu Gly 635 640 645 aaa gag gaa gac ttc cac cca gag ctg gaa
agc ctg gat gga gac cta 2021 Lys Glu Glu Asp Phe His Pro Glu Leu
Glu Ser Leu Asp Gly Asp Leu 650 655 660 665 gat cct ggg ctt ccc agc
aca gag gat gtc atc ttg aag aca gag cag 2069 Asp Pro Gly Leu Pro
Ser Thr Glu Asp Val Ile Leu Lys Thr Glu Gln 670 675 680 gtc acc aag
aac att cag gaa ctg ttg cgg gca gcc cag gag ttc aag 2117 Val Thr
Lys Asn Ile Gln Glu Leu Leu Arg Ala Ala Gln Glu Phe Lys 685 690 695
cat gac agc ttc gtg ccc tgc tca gag aag atc cat ttg gct gtg acc
2165 His Asp Ser Phe Val Pro Cys Ser Glu Lys Ile His Leu Ala Val
Thr 700 705 710 gag atg gcc tcc ctc ttc cca aag agg cca gcc ctg gag
cca gtg cgg 2213 Glu Met Ala Ser Leu Phe Pro Lys Arg Pro Ala Leu
Glu Pro Val Arg 715 720 725 agc tca ctg cgg ctg ctc aac gcc agc gcc
tac cgg ctg cag agt gag 2261 Ser Ser Leu Arg Leu Leu Asn Ala Ser
Ala Tyr Arg Leu Gln Ser Glu 730 735 740 745 tgc cgg aag aca gtg ccc
cca gag ccc ggc gcc cca gtg gac ttc cag 2309 Cys Arg Lys Thr Val
Pro Pro Glu Pro Gly Ala Pro Val Asp Phe Gln 750 755 760 ctg ctg act
cag cag gtg atc cag tgc gcc tat gac atc gcc aag gct 2357 Leu Leu
Thr Gln Gln Val Ile Gln Cys Ala Tyr Asp Ile Ala Lys Ala 765 770 775
gcc aag cag ctg gtc acc atc acc acc cga gag aag aag cag tga cct
2405 Ala Lys Gln Leu Val Thr Ile Thr Thr Arg Glu Lys Lys Gln * 780
785 790 ctctccccac accctcacct gcaccctagg acctcactgg ccataggagc
tgggccactc 2465 cagacattaa tccccacccc aacagagcca ctggcacaag
tgcccttagt gctgccacac 2525 tccctggcag ccaggtgccc tggtgcccac
ccctgtcgag cccctaagga tggggaggtg 2585 ggggggcagg agcttctgtc
ccccacattc catgcacctc ccctctgtat atagcatctc 2645 ccccctccta
gtgagcaggg gcctgcaagg catcactccc agcccctcgc cttctagggc 2705
accctcagca aaggggcagg tggggacact ccaagtgggg cagctctccg tacatgcgcc
2765 ccacccccat gagccagttc agccctactg ggggctgagc gggggcatcc
cctcctttgt 2825 acatagtctc catggatgtc cctgccctgt agccaccagc
cccttgctgc tctcccttta 2885 atgccatatg gcccctgcct agggcacagg
ccccaacctg tgtgctgggg tccccagcag 2945 caaacactgg aaagtctgtt
tttttttttt ctttcttctt ccccacccct taattttaac 3005 tttgtggtaa
ctgagtgccc ccgcgtgcct gcgtgttgag tgtgtggggc ggcagtgccg 3065
ttccggaggc ctggtccatc tggagttttg aggggtgagg ggaccagagc agtgggacca
3125 gcatggggat cagcttccct tccccacctg ggagccaggg actgtccggg
tagccagttt 3185 tggtcctgcc agctgcctcc ctgatccctc cccactctcg
ccccttctct atgaacttaa 3245 atcaaaaacc acttccctcc atctcctcct
gctcctgcgt ggagggggaa tgtgtgctgg 3305 ctaaggtgga ggactgagca
gctgagcctg gggctggctc cccgggggtc tcgactcagc 3365 tggtggcttt
tgaactgagt ccctcccgta aactcttcaa gccagcacca ccataatt 3423 8 2763
DNA Homo sapiens CDS (180)..(1742) 8 atcgacgact tgaacgcctg
cggtaccggt ccggaattcc cgggtcgacg atttcgtccg 60 agccctgctc
atggcagtga ggtgggctcc cagctgctga ggccacccag cactagtgag 120
tgacttggca tttttatttt tgttcagatc acaagaatgg gcattacatc atcccacag
179 atg gct gac aga tct cgg caa aag tgc atg tct cag agc ctt gac tta
227 Met Ala Asp Arg Ser Arg Gln Lys Cys Met Ser Gln Ser Leu Asp Leu
1 5 10 15 tcc gaa ttg gcc aaa gct gct aag aag aag ctg cag gcg ctc
agc aac 275 Ser Glu Leu Ala Lys Ala Ala Lys Lys Lys Leu Gln Ala Leu
Ser Asn 20 25 30 cgg ctt ttt gag gaa ctc gcc atg gac gtg tat gac
gag gtg gat cga 323 Arg Leu Phe Glu Glu Leu Ala Met Asp Val Tyr Asp
Glu Val Asp Arg 35 40 45 aga gaa aat gat gca gtg tgg ctg gct acc
caa aac cac agc act ctg 371 Arg Glu Asn Asp Ala Val Trp Leu Ala Thr
Gln Asn His Ser Thr Leu 50 55 60 gtg aca gag cgc agt gct gtg ccc
ttc ctg cct gtt aac ccg gaa tac 419 Val Thr Glu Arg Ser Ala Val Pro
Phe Leu Pro Val Asn Pro Glu Tyr 65 70 75 80 tca gcc acg cgg aat cag
ggg cga caa aag ctg gcc cgc ttt aat gcc 467 Ser Ala Thr Arg Asn Gln
Gly Arg Gln Lys Leu Ala Arg Phe Asn Ala 85 90 95 cga gag ttt gcc
acc ttg atc atc gac att ctc agt gag gcc aag cgg 515 Arg Glu Phe Ala
Thr Leu Ile Ile Asp Ile Leu Ser Glu Ala Lys Arg 100 105 110 aga cag
cag ggc aag agc ctg agc agc ccc aca gac aac ctc gag ctg 563 Arg Gln
Gln Gly Lys Ser Leu Ser Ser Pro Thr Asp Asn Leu Glu Leu 115 120 125
tct ctg cgg agc cag agt gac ctc gac gac caa cac gac tac gac agc 611
Ser Leu Arg Ser Gln Ser Asp Leu Asp Asp Gln His Asp Tyr Asp Ser 130
135 140 gtg gcc tct gac gag gac aca gac cag gag ccc ctg cgc agc acc
ggc 659 Val Ala Ser Asp Glu Asp Thr Asp Gln Glu Pro Leu Arg Ser Thr
Gly 145
150 155 160 gcc act cgg agc aac cgg gcc cgg agc atg gac tcc tcg gac
ttg tct 707 Ala Thr Arg Ser Asn Arg Ala Arg Ser Met Asp Ser Ser Asp
Leu Ser 165 170 175 gac ggg gct gtg acg ctg cag gag tac ctg gag ctg
aag aag gcc ctg 755 Asp Gly Ala Val Thr Leu Gln Glu Tyr Leu Glu Leu
Lys Lys Ala Leu 180 185 190 gct aca tcg gag gca aag gtg cag cag ctc
atg aag gtc aac agt agc 803 Ala Thr Ser Glu Ala Lys Val Gln Gln Leu
Met Lys Val Asn Ser Ser 195 200 205 ctg agc gac gag ctc cgg agg ctg
cag cga gag atc cac aag ctg cag 851 Leu Ser Asp Glu Leu Arg Arg Leu
Gln Arg Glu Ile His Lys Leu Gln 210 215 220 gcg gag aac ctg cag ctc
cgg cag cct cca ggg ccg gtg ccc aca cct 899 Ala Glu Asn Leu Gln Leu
Arg Gln Pro Pro Gly Pro Val Pro Thr Pro 225 230 235 240 cca ctc ccc
agt gaa cgg gcg gaa cac aca ccc atg gcg cca ggc ggg 947 Pro Leu Pro
Ser Glu Arg Ala Glu His Thr Pro Met Ala Pro Gly Gly 245 250 255 agc
aca cac cgc agg gat cgc cag gcc ttt tcc atg tat gaa cct ggc 995 Ser
Thr His Arg Arg Asp Arg Gln Ala Phe Ser Met Tyr Glu Pro Gly 260 265
270 tct gcc ctg aag ccc ttt ggg ggc cac ctt ggg gac gag ctc act acg
1043 Ser Ala Leu Lys Pro Phe Gly Gly His Leu Gly Asp Glu Leu Thr
Thr 275 280 285 cgg ctg cag cct ttc cac agc act gag cta gag gac gac
gcc atc tat 1091 Arg Leu Gln Pro Phe His Ser Thr Glu Leu Glu Asp
Asp Ala Ile Tyr 290 295 300 tca gtg cac gtc cct gct ggc ctt tac cgg
atc cgg aaa ggg gtg tct 1139 Ser Val His Val Pro Ala Gly Leu Tyr
Arg Ile Arg Lys Gly Val Ser 305 310 315 320 gcc tca gct gtg ccc ttc
act ccc tcc tcc ccg ctg ctg tcc tgc tcc 1187 Ala Ser Ala Val Pro
Phe Thr Pro Ser Ser Pro Leu Leu Ser Cys Ser 325 330 335 cag gag gga
agc cgc cac acg agc aag ctt tcc cgc cac ggc agt gga 1235 Gln Glu
Gly Ser Arg His Thr Ser Lys Leu Ser Arg His Gly Ser Gly 340 345 350
gcc gac agt gac tat gag aac acg caa agt ggg gac cca ctg ctg ggg
1283 Ala Asp Ser Asp Tyr Glu Asn Thr Gln Ser Gly Asp Pro Leu Leu
Gly 355 360 365 ctg gaa ggg aag agg ttt cta gag ctg ggc aaa gag gaa
gac ttc cac 1331 Leu Glu Gly Lys Arg Phe Leu Glu Leu Gly Lys Glu
Glu Asp Phe His 370 375 380 cca gag ctg gaa agc ctg gat gga gac cta
gat cct ggg ctt ccc agc 1379 Pro Glu Leu Glu Ser Leu Asp Gly Asp
Leu Asp Pro Gly Leu Pro Ser 385 390 395 400 aca gag gat gtc atc ttg
aag aca gag cag gtc acc aag aac att cag 1427 Thr Glu Asp Val Ile
Leu Lys Thr Glu Gln Val Thr Lys Asn Ile Gln 405 410 415 gaa ctg ttg
cgg gca gcc cag gag ttc aag cat gac agc ttc gtg ccc 1475 Glu Leu
Leu Arg Ala Ala Gln Glu Phe Lys His Asp Ser Phe Val Pro 420 425 430
tgc tca gag aag atc cat ttg gct gtg acc gag atg gcc tcc ctc ttc
1523 Cys Ser Glu Lys Ile His Leu Ala Val Thr Glu Met Ala Ser Leu
Phe 435 440 445 cca aag agg cca gcc ctg gag cca gtg cgg agc tca ctg
cgg ctg ctc 1571 Pro Lys Arg Pro Ala Leu Glu Pro Val Arg Ser Ser
Leu Arg Leu Leu 450 455 460 aac gcc agc gcc tac cgg ctg cag agt gag
tgc cgg aag aca gtg ccc 1619 Asn Ala Ser Ala Tyr Arg Leu Gln Ser
Glu Cys Arg Lys Thr Val Pro 465 470 475 480 cca gag ccc ggc gcc cca
gtg gac ttc cag ctg ctg act cag cag gtg 1667 Pro Glu Pro Gly Ala
Pro Val Asp Phe Gln Leu Leu Thr Gln Gln Val 485 490 495 atc cag tgc
gcc tat gac atc gcc aag gct gcc aag cag ctg gtc acc 1715 Ile Gln
Cys Ala Tyr Asp Ile Ala Lys Ala Ala Lys Gln Leu Val Thr 500 505 510
atc acc acc cga gag aag aag cag tga cctct ctccccacac cctcacctgc
1767 Ile Thr Thr Arg Glu Lys Lys Gln * 515 520 accctaggac
ctcactggcc ataggagctg ggccactcca gacattaatc cccaccccaa 1827
cagagccact ggcacaagtg cccttagtgc tgccacactc cctggcagcc aggtgccctg
1887 gtgcccaccc ctgtcgagcc cctaaggatg gggaggtggg ggggcaggag
cttctgtccc 1947 ccacattcca tgcacctccc ctctgtatat agcatctccc
ccctcctagt gagcaggggc 2007 ctgcaaggca tcactcccag cccctcgcct
tctagggcac cctcagcaaa ggggcaggtg 2067 gggacactcc aagtggggca
gctctccgta catgcgcccc acccccatga gccagttcag 2127 ccctactggg
ggctgagcgg gggcatcccc tcctttgtac atagtctcca tggatgtccc 2187
tgccctgtag ccaccagccc cttgctgctc tccctttaat gccatatggc ccctgcctag
2247 ggcacaggcc ccaacctgtg tgctggggtc cccagcagca aacactggaa
agtctgtttt 2307 ttttttttct ttcttcttcc ccacccctta attttaactt
tgtggtaact gagtgccccc 2367 gcgtgcctgc gtgttgagtg tgtggggcgg
cagtgccgtt ccggaggcct ggtccatctg 2427 gagttttgag gggtgagggg
accagagcag tgggaccagc atggggatca gcttcccttc 2487 cccacctggg
agccagggac tgtccgggta gccagttttg gtcctgccag ctgcctccct 2547
gatccctccc cactctcgcc ccttctctat gaacttaaat caaaaaccac ttccctccat
2607 ctcctcctgc tcctgcgtgg agggggaatg tgtgctggct aaggtggagg
actgagcagc 2667 tgagcctggg gctggctccc cgggggtctc gactcagctg
gtggcttttg aactgagtcc 2727 ctcccgtaaa ctcttcaagc cagcaccacc ataatt
2763 9 1080 DNA Homo sapiens CDS (178)..(1080) 9 atgttcaaag
ccatccttgg ccatgtgtgg cccaaagacc atgggttgga caagcttgtt 60
gtaaggtgtc caagacacac agagccatgg aatctcacag gtatctcaga attcctcctc
120 ctgggactct cagaggatcc agaactgcag cccgtcctcc ctgggctgtc cctgtcc
177 atg tac ctg gtc acg gtg ctg agg aac ctg ctc atc atc ctg gct gtc
225 Met Tyr Leu Val Thr Val Leu Arg Asn Leu Leu Ile Ile Leu Ala Val
1 5 10 15 agc tct gac tcc cac ctc cac acc ccc atg tgc ttc ttc ctc
tcc aac 273 Ser Ser Asp Ser His Leu His Thr Pro Met Cys Phe Phe Leu
Ser Asn 20 25 30 ctg tgc tgg gct gac atc ggt ttc acc tcg gcc atg
gtt ccc aag atg 321 Leu Cys Trp Ala Asp Ile Gly Phe Thr Ser Ala Met
Val Pro Lys Met 35 40 45 att gtg gac atg cag tcg cat agc aga gtc
atc tct tat gcg ggc tgc 369 Ile Val Asp Met Gln Ser His Ser Arg Val
Ile Ser Tyr Ala Gly Cys 50 55 60 ctg aca cag atg tct ttc ttt gtc
ctt ttt gca tgt ata gaa gac atg 417 Leu Thr Gln Met Ser Phe Phe Val
Leu Phe Ala Cys Ile Glu Asp Met 65 70 75 80 ctc ctg aca gtg atg gcc
tat gac cga ttt gtg gcc atc tgt cac ccc 465 Leu Leu Thr Val Met Ala
Tyr Asp Arg Phe Val Ala Ile Cys His Pro 85 90 95 ctg cac tac cca
gtc atc atg aat cct cac ctt ggt gtc ttc tta gtt 513 Leu His Tyr Pro
Val Ile Met Asn Pro His Leu Gly Val Phe Leu Val 100 105 110 ttg gtg
tcc ttt ttc ctc agc ctg ttg gat tcc cag ctg cac agt tgg 561 Leu Val
Ser Phe Phe Leu Ser Leu Leu Asp Ser Gln Leu His Ser Trp 115 120 125
att gtg tta caa ttc acc ttc ttc aag aat gtg gaa atc tcc aat ttt 609
Ile Val Leu Gln Phe Thr Phe Phe Lys Asn Val Glu Ile Ser Asn Phe 130
135 140 gtc tgt gac cca tct caa ctt ctc aac ctt gcc tgt tct gac agt
gtc 657 Val Cys Asp Pro Ser Gln Leu Leu Asn Leu Ala Cys Ser Asp Ser
Val 145 150 155 160 atc aat agc ata ttc ata tat tta gat agt att atg
ttt ggt ttt ctt 705 Ile Asn Ser Ile Phe Ile Tyr Leu Asp Ser Ile Met
Phe Gly Phe Leu 165 170 175 ccc att tca ggg atc ctt ttg tct tac gct
aac aat gtc ccc tcc att 753 Pro Ile Ser Gly Ile Leu Leu Ser Tyr Ala
Asn Asn Val Pro Ser Ile 180 185 190 cta aga att tca tca tca gat agg
aag tct aaa gcc ttc tcc acc tgt 801 Leu Arg Ile Ser Ser Ser Asp Arg
Lys Ser Lys Ala Phe Ser Thr Cys 195 200 205 ggc tct cac ctg gca gtt
gtt tgc tta ttt tat gga aca ggc att ggc 849 Gly Ser His Leu Ala Val
Val Cys Leu Phe Tyr Gly Thr Gly Ile Gly 210 215 220 gtg tac ctg act
tca gct gtg tca cca ccc ccc agg aat ggt gtg gtg 897 Val Tyr Leu Thr
Ser Ala Val Ser Pro Pro Pro Arg Asn Gly Val Val 225 230 235 240 gca
tca gtg atg tac gct gtg gtc acc ccc atg ctg aac cct ttc atc 945 Ala
Ser Val Met Tyr Ala Val Val Thr Pro Met Leu Asn Pro Phe Ile 245 250
255 tac agc ctg aga aat agg gac att caa agt gcc ctg tgg agg ctg cgc
993 Tyr Ser Leu Arg Asn Arg Asp Ile Gln Ser Ala Leu Trp Arg Leu Arg
260 265 270 agc aga aca gtc gaa tct cat gat ctg tta tct caa gat ctg
ctc cat 1041 Ser Arg Thr Val Glu Ser His Asp Leu Leu Ser Gln Asp
Leu Leu His 275 280 285 cct ttt tct tgt gtg ggt gag aaa ggt caa cca
cat taa 1080 Pro Phe Ser Cys Val Gly Glu Lys Gly Gln Pro His * 290
295 300 10 1062 DNA Homo sapiens CDS (1)..(1062) 10 atg gct ttt atc
gtg ccc gat gtt aat gca cgt tct ttt ttg aca ata 48 Met Ala Phe Ile
Val Pro Asp Val Asn Ala Arg Ser Phe Leu Thr Ile 1 5 10 15 aat tca
tgg cca tca gat aat atc aat ttg aca tac acg gca tca ggg 96 Asn Ser
Trp Pro Ser Asp Asn Ile Asn Leu Thr Tyr Thr Ala Ser Gly 20 25 30
cct tca cag cca cca tac atc agc tac atg gaa gca gga aac caa aca 144
Pro Ser Gln Pro Pro Tyr Ile Ser Tyr Met Glu Ala Gly Asn Gln Thr 35
40 45 gga ttt tta gag ttt atc ctt ctc gga ctc tct gag gat cca gaa
cta 192 Gly Phe Leu Glu Phe Ile Leu Leu Gly Leu Ser Glu Asp Pro Glu
Leu 50 55 60 cag ccg ttc ata ttt ggg ctg ttc ctg tcc atg tac ctg
ggg acg gtg 240 Gln Pro Phe Ile Phe Gly Leu Phe Leu Ser Met Tyr Leu
Gly Thr Val 65 70 75 80 ctg gga aac ctg ctc atc atc ctg gcc atc agc
tct gac tcc cac ctc 288 Leu Gly Asn Leu Leu Ile Ile Leu Ala Ile Ser
Ser Asp Ser His Leu 85 90 95 cac acc ccc atg tac ttc ttc ctc tcc
aac ctg tcc tgg gtt gac atc 336 His Thr Pro Met Tyr Phe Phe Leu Ser
Asn Leu Ser Trp Val Asp Ile 100 105 110 tgt ttc agc act tgc atc gtc
ccc aag atg ctg gtg aac atc cag acc 384 Cys Phe Ser Thr Cys Ile Val
Pro Lys Met Leu Val Asn Ile Gln Thr 115 120 125 gag aac aaa gcc atc
tcc tac atg gac tgc ctc aca cag gtc tat ttc 432 Glu Asn Lys Ala Ile
Ser Tyr Met Asp Cys Leu Thr Gln Val Tyr Phe 130 135 140 tcc atg ttt
ttt cct att ctg gac acg cta ctc ctg acc gtg atg gcc 480 Ser Met Phe
Phe Pro Ile Leu Asp Thr Leu Leu Leu Thr Val Met Ala 145 150 155 160
tat gac cgg ttt gtg gct gtc tgc cac cct ctg cac tat atg atc atc 528
Tyr Asp Arg Phe Val Ala Val Cys His Pro Leu His Tyr Met Ile Ile 165
170 175 atg aac ccc cac ctc tgt ggc ctc ctg gtt ttt gtc acc tgg ctc
att 576 Met Asn Pro His Leu Cys Gly Leu Leu Val Phe Val Thr Trp Leu
Ile 180 185 190 ggt gtc atg aca tcc ctc ctc cat att tct ctg atg atg
cat cta atc 624 Gly Val Met Thr Ser Leu Leu His Ile Ser Leu Met Met
His Leu Ile 195 200 205 ttc tgt aaa gat ttt gaa att cca cat ttt ttc
tgc gaa ctg acg tac 672 Phe Cys Lys Asp Phe Glu Ile Pro His Phe Phe
Cys Glu Leu Thr Tyr 210 215 220 atc ctc cag ctg gcc tgc tct gat acc
ttc ctg aac agc acg ttg ata 720 Ile Leu Gln Leu Ala Cys Ser Asp Thr
Phe Leu Asn Ser Thr Leu Ile 225 230 235 240 tac ttt atg acg ggt gtg
ctg ggc gtt ttt ccc ctc ctt ggg atc att 768 Tyr Phe Met Thr Gly Val
Leu Gly Val Phe Pro Leu Leu Gly Ile Ile 245 250 255 ttc tct tat tca
cga att gct tca tcc ata agg aag atg tcc tca tct 816 Phe Ser Tyr Ser
Arg Ile Ala Ser Ser Ile Arg Lys Met Ser Ser Ser 260 265 270 ggg gga
aaa caa aaa gca ctt tcc acc tgt ggg tct cac ctc tcc gtc 864 Gly Gly
Lys Gln Lys Ala Leu Ser Thr Cys Gly Ser His Leu Ser Val 275 280 285
gtt tct tta ttt tat ggg aca ggc att ggg gtc cac ttc act tct gcg 912
Val Ser Leu Phe Tyr Gly Thr Gly Ile Gly Val His Phe Thr Ser Ala 290
295 300 gtg act cac tct tcc cag aaa atc tcc gtg gcc tcg gtg atg tac
act 960 Val Thr His Ser Ser Gln Lys Ile Ser Val Ala Ser Val Met Tyr
Thr 305 310 315 320 gtg gtc acc ccc atg ttg aac ccc ttc atc tac agc
ctg agg aac aag 1008 Val Val Thr Pro Met Leu Asn Pro Phe Ile Tyr
Ser Leu Arg Asn Lys 325 330 335 gat gtg aag gga gcc ctg ggg agt ctc
ctc agc agg gca gcc tct tgt 1056 Asp Val Lys Gly Ala Leu Gly Ser
Leu Leu Ser Arg Ala Ala Ser Cys 340 345 350 ttg tga 1062 Leu * 11
1297 DNA Homo sapiens CDS (225)..(1091) 11 gaactcggca cgaggcggcc
caggagaagc agttcctgcc ggcgctgctg agtttcttca 60 tctacaaccc
gcgcttctgg ccgcgggaag gagaggttgt tcggaatcct ataattgaaa 120
aacagtaaag atggaaaacc agttattgaa tatcaagagg aggagttgtt gaagtctcag
180 gggatccaga actgcagcca gtccttgctg ggctgttcct gtcc atg tgc ctg
gtc 236 Met Cys Leu Val 1 acg gtg ctg ggg aac ctg ctc atc atc ctg
gcc atc agc cct gac tcc 284 Thr Val Leu Gly Asn Leu Leu Ile Ile Leu
Ala Ile Ser Pro Asp Ser 5 10 15 20 cac ctc cac acc ccc atg tac ttc
ttc ctc tcc aac ctg tcc ttg gct 332 His Leu His Thr Pro Met Tyr Phe
Phe Leu Ser Asn Leu Ser Leu Ala 25 30 35 gac atc ggt ttc acc tcc
acc acg gtc ccc aag atg att gtg gac atg 380 Asp Ile Gly Phe Thr Ser
Thr Thr Val Pro Lys Met Ile Val Asp Met 40 45 50 caa act cac agc
aga gtc atc tcc tat gaa ggc tgc ctg act cag atg 428 Gln Thr His Ser
Arg Val Ile Ser Tyr Glu Gly Cys Leu Thr Gln Met 55 60 65 tct ttt
ttt gtc ctt ttt gca tgt atg gat gac atg ctc ctg agt gtg 476 Ser Phe
Phe Val Leu Phe Ala Cys Met Asp Asp Met Leu Leu Ser Val 70 75 80
atg gcc tat gac cgg ttt gtg gcc atc tgt cac ccc ctg cac tac cga 524
Met Ala Tyr Asp Arg Phe Val Ala Ile Cys His Pro Leu His Tyr Arg 85
90 95 100 atc atc atg aac cca cgc ctc tgt ggc ttc tta atc ttg ttg
tct ttt 572 Ile Ile Met Asn Pro Arg Leu Cys Gly Phe Leu Ile Leu Leu
Ser Phe 105 110 115 ttt att agt ctt ttg gac tcc cag ttg cac aat ttg
att atg tta cag 620 Phe Ile Ser Leu Leu Asp Ser Gln Leu His Asn Leu
Ile Met Leu Gln 120 125 130 ctc acc tgc ttc aag gat gtg gac att tct
aat ttc ttc tgt gac cct 668 Leu Thr Cys Phe Lys Asp Val Asp Ile Ser
Asn Phe Phe Cys Asp Pro 135 140 145 tct caa ctc ctc cac ctt agg tgt
tcc gac acc ttc atc aat gaa atg 716 Ser Gln Leu Leu His Leu Arg Cys
Ser Asp Thr Phe Ile Asn Glu Met 150 155 160 gtc ata tat ttc atg ggt
gcc ata ttt ggc tgt ctc cct atc tca ggg 764 Val Ile Tyr Phe Met Gly
Ala Ile Phe Gly Cys Leu Pro Ile Ser Gly 165 170 175 180 atc ctt ttc
tct tac tat aaa att gtt tcc ccc att ctg aga gtt cca 812 Ile Leu Phe
Ser Tyr Tyr Lys Ile Val Ser Pro Ile Leu Arg Val Pro 185 190 195 aca
tca gat ggg aag tat aaa gcc ttc tcc acc tgt ggc tct cac ctg 860 Thr
Ser Asp Gly Lys Tyr Lys Ala Phe Ser Thr Cys Gly Ser His Leu 200 205
210 gca gtt gtt tgc tta ttt tat gga aca ggg ctt gta ggg tac ctc agt
908 Ala Val Val Cys Leu Phe Tyr Gly Thr Gly Leu Val Gly Tyr Leu Ser
215 220 225 tca gct gtg tta cca tcc ccc agg aag agt atg gtg gct tca
gtg atg 956 Ser Ala Val Leu Pro Ser Pro Arg Lys Ser Met Val Ala Ser
Val Met 230 235 240 tac act gtg gtc acc ccc atg ctg aac ccc ttc atc
tac agc ctg agg 1004 Tyr Thr Val Val Thr Pro Met Leu Asn Pro Phe
Ile Tyr Ser Leu Arg 245 250 255 260 aac aag gac att caa agt gcc ctg
tgc agg ctg cat ggc aga atc atc 1052 Asn Lys Asp Ile Gln Ser Ala
Leu Cys Arg Leu His Gly Arg Ile Ile 265 270 275 aaa tct cat cat ctc
cat cct ttt tgt tat atg gga tag aaatggcagc 1101 Lys Ser His His Leu
His Pro Phe Cys Tyr Met Gly * 280 285 aaaatttaac acctaggcct
gcaaattctg cctccttggt cacattattt tggttgcttg 1161 atggctttca
ttcctctctg ggtttcgtat gtgaatattg cttgctttgt tttgtcttta 1221
attgcaatgg gtgagtattc tggtatcctt tgttcatcat acacatcatg aatgattcca
1281 atataaaaaa aaaaaa 1297 12 1535 DNA Homo sapiens CDS
(1)..(1338) 12 atg aac cgc acc ggg gca tgt cga ctt caa ggg gct ggt
ggg ccg tcc 48 Met Asn Arg Thr Gly Ala Cys Arg Leu Gln Gly Ala Gly
Gly
Pro Ser 1 5 10 15 ctg tcc ttg gag act cct ctc tgc ctc aat tgc tct
gtc ctc cct gga 96 Leu Ser Leu Glu Thr Pro Leu Cys Leu Asn Cys Ser
Val Leu Pro Gly 20 25 30 gac ctg tac cca ggg ggt gca agg aac ccc
atg gct tgc aat ggc agt 144 Asp Leu Tyr Pro Gly Gly Ala Arg Asn Pro
Met Ala Cys Asn Gly Ser 35 40 45 gcg gcc agg ggg cac ttt gac cct
gag gac ttg aac ctg act gac gag 192 Ala Ala Arg Gly His Phe Asp Pro
Glu Asp Leu Asn Leu Thr Asp Glu 50 55 60 gca ctg aga ctc aag tac
ctg ggg ccc cag cag aca gag ctg ttc atg 240 Ala Leu Arg Leu Lys Tyr
Leu Gly Pro Gln Gln Thr Glu Leu Phe Met 65 70 75 80 ccc atc tgt gcc
aca tac ctg ctg atc ttc gtg gtg ggc gct gtg ggc 288 Pro Ile Cys Ala
Thr Tyr Leu Leu Ile Phe Val Val Gly Ala Val Gly 85 90 95 aat ggg
ctg acc tgt ctg gtc atc ctg cgc cac aag gcc atg cgc acg 336 Asn Gly
Leu Thr Cys Leu Val Ile Leu Arg His Lys Ala Met Arg Thr 100 105 110
cct acc aac tac tac ctc ttc agc ctg gcc gtg tcg gac ctg ctg gtg 384
Pro Thr Asn Tyr Tyr Leu Phe Ser Leu Ala Val Ser Asp Leu Leu Val 115
120 125 ctg ctg gtg ggc ctg ccc ctg gag ctc tat gag atg tgg cac aac
tac 432 Leu Leu Val Gly Leu Pro Leu Glu Leu Tyr Glu Met Trp His Asn
Tyr 130 135 140 ccc ttc ctg ctg ggc gtt ggt ggc tgc tat ttc cgc acg
cta ctg ttt 480 Pro Phe Leu Leu Gly Val Gly Gly Cys Tyr Phe Arg Thr
Leu Leu Phe 145 150 155 160 gag atg gtc tgc ctg gcc tca gtg ctc aac
gtc act gcc ctg agc gtg 528 Glu Met Val Cys Leu Ala Ser Val Leu Asn
Val Thr Ala Leu Ser Val 165 170 175 gaa cgc tat gtg gcc gtg gtg cac
cca ctc cag gcc agg tcc atg gtg 576 Glu Arg Tyr Val Ala Val Val His
Pro Leu Gln Ala Arg Ser Met Val 180 185 190 acg cgg gcc cat gtg cgc
cga gtg ctt ggg gcc gtc tgg ggt ctt gcc 624 Thr Arg Ala His Val Arg
Arg Val Leu Gly Ala Val Trp Gly Leu Ala 195 200 205 atg ctc tgc tcc
ctg ccc aac acc agc ctg cac ggc atc cgg cag ctg 672 Met Leu Cys Ser
Leu Pro Asn Thr Ser Leu His Gly Ile Arg Gln Leu 210 215 220 cac gtg
ccc tgc cgg ggc cca gtg cca gac tca gct gtt tgc atg ctg 720 His Val
Pro Cys Arg Gly Pro Val Pro Asp Ser Ala Val Cys Met Leu 225 230 235
240 gtc ccg cca cgg gcc ctc tac aac atg gta gtg cag acc acc gcg ctg
768 Val Pro Pro Arg Ala Leu Tyr Asn Met Val Val Gln Thr Thr Ala Leu
245 250 255 ctc ttc ttc tgc ctg ccc atg gcc atc atg agc gtg ctc tac
ctg ctc 816 Leu Phe Phe Cys Leu Pro Met Ala Ile Met Ser Val Leu Tyr
Leu Leu 260 265 270 att ggg ctg cga ctg cgg cgg gag agg ctg ctg ctc
atg cag gag gcc 864 Ile Gly Leu Arg Leu Arg Arg Glu Arg Leu Leu Leu
Met Gln Glu Ala 275 280 285 aag ggc agg ggc tct gca gca gcc agg tcc
aga tac acc tgc agg ctc 912 Lys Gly Arg Gly Ser Ala Ala Ala Arg Ser
Arg Tyr Thr Cys Arg Leu 290 295 300 cag cag cac gat cgg ggc cgg aga
caa gtg acc aag atg ctg ttt gtc 960 Gln Gln His Asp Arg Gly Arg Arg
Gln Val Thr Lys Met Leu Phe Val 305 310 315 320 ctg gtc gtg gtg ttt
ggc atc tgc tgg gcc ccg ttc cac gcc gac cgc 1008 Leu Val Val Val
Phe Gly Ile Cys Trp Ala Pro Phe His Ala Asp Arg 325 330 335 gtc atg
tgg agc gtc gtg tca cag tgg aca gat ggc ctg cac ctg gcc 1056 Val
Met Trp Ser Val Val Ser Gln Trp Thr Asp Gly Leu His Leu Ala 340 345
350 ttc cag cac gtg cac gtc atc tcc ggc atc ttc ttc tac ctg ggc tcg
1104 Phe Gln His Val His Val Ile Ser Gly Ile Phe Phe Tyr Leu Gly
Ser 355 360 365 gcg gcc aac ccc gtg ctc tat agc ctc atg tcc agc cgc
ttc cga gag 1152 Ala Ala Asn Pro Val Leu Tyr Ser Leu Met Ser Ser
Arg Phe Arg Glu 370 375 380 acc ttc cag gag gcc ctg tgc ctc ggg gcc
tgc tgc cat cgc ctc aga 1200 Thr Phe Gln Glu Ala Leu Cys Leu Gly
Ala Cys Cys His Arg Leu Arg 385 390 395 400 ccc cgc cac agc tcc cac
agc ctc agc agg atg acc aca ggc agc acc 1248 Pro Arg His Ser Ser
His Ser Leu Ser Arg Met Thr Thr Gly Ser Thr 405 410 415 ctg tgt gat
gtg ggc tcc ctg ggc agc tgg gtc cac ccc ctg gct ggg 1296 Leu Cys
Asp Val Gly Ser Leu Gly Ser Trp Val His Pro Leu Ala Gly 420 425 430
aac gat ggc cca gag gcg cag caa gag acc gat cca tcc tga gtggagc
1345 Asn Asp Gly Pro Glu Ala Gln Gln Glu Thr Asp Pro Ser * 435 440
445 cttaaagtgg cttcacctgg aggggccaga gggtcacctg gagctgggga
gacacatctg 1405 ccttcctctg cagggatgcc ttcacgtact gtccctagtt
cagcctagaa attctgacca 1465 gcacctcagt ttccctcaga gggaaacagc
aggaggaggg atccctgact gctgaggact 1525 cacactgacc 1535 13 1539 DNA
Homo sapiens CDS (130)..(1539) 13 gcacgaggtg gaggacgcgg ctgcttcaag
tccttggctc tgatccaggc cacagattcc 60 aggattctac aggcaggaaa
catcttagaa atcagggttg ggcaggcagg agccaggaga 120 gtagctaca atg act
tca cca gta ctg gtg gac ata cga gaa gag gtg 168 Met Thr Ser Pro Val
Leu Val Asp Ile Arg Glu Glu Val 1 5 10 acc tgc cct atc tgc ctg gag
ctc cta aca gaa ccc ctg agc ata gac 216 Thr Cys Pro Ile Cys Leu Glu
Leu Leu Thr Glu Pro Leu Ser Ile Asp 15 20 25 tgt ggc cac agc ttc
tgc caa gcc tgc atc aca cca aat ggc agg gaa 264 Cys Gly His Ser Phe
Cys Gln Ala Cys Ile Thr Pro Asn Gly Arg Glu 30 35 40 45 tca gtg att
ggt caa gaa ggg gaa aga agc tgc cct gtg tgc cag acc 312 Ser Val Ile
Gly Gln Glu Gly Glu Arg Ser Cys Pro Val Cys Gln Thr 50 55 60 agc
tac cag cca ggg aac ctg cgg cct aat cgg cat ctg gcc aac ata 360 Ser
Tyr Gln Pro Gly Asn Leu Arg Pro Asn Arg His Leu Ala Asn Ile 65 70
75 gtg agg cgg ctc aga gag gta gtg ttg ggc cct ggg aag cag ctg aaa
408 Val Arg Arg Leu Arg Glu Val Val Leu Gly Pro Gly Lys Gln Leu Lys
80 85 90 gca gtt ctt tgt gca gac cat gga gaa aaa ctg cag ctc ttc
tgt cag 456 Ala Val Leu Cys Ala Asp His Gly Glu Lys Leu Gln Leu Phe
Cys Gln 95 100 105 gag gat ggg aag gag aag ttt cag gag tct cta aag
aag ctg aag aac 504 Glu Asp Gly Lys Glu Lys Phe Gln Glu Ser Leu Lys
Lys Leu Lys Asn 110 115 120 125 gag gag cag gaa gct gag aag cta aca
gct ttt atc aga gag aag aag 552 Glu Glu Gln Glu Ala Glu Lys Leu Thr
Ala Phe Ile Arg Glu Lys Lys 130 135 140 aca tcc tgg aag gca agg gag
act ttt tct gaa gat gtc ctg ggg cag 600 Thr Ser Trp Lys Ala Arg Glu
Thr Phe Ser Glu Asp Val Leu Gly Gln 145 150 155 gaa tca tgg cag agt
aca aat gca agg gaa aat gca ggg atc cca ggg 648 Glu Ser Trp Gln Ser
Thr Asn Ala Arg Glu Asn Ala Gly Ile Pro Gly 160 165 170 ctg gag gct
gcc cac ttc tgg att gcc atc cct ttc tgt gcc atg tat 696 Leu Glu Ala
Ala His Phe Trp Ile Ala Ile Pro Phe Cys Ala Met Tyr 175 180 185 ctt
gta gca ctg gtt gga aat gct gcc ctc atc ctg gtc att gcc atg 744 Leu
Val Ala Leu Val Gly Asn Ala Ala Leu Ile Leu Val Ile Ala Met 190 195
200 205 gac aat gct ctt cat gca cct atg tac ctc ttc ctc tgc ctt ctc
tca 792 Asp Asn Ala Leu His Ala Pro Met Tyr Leu Phe Leu Cys Leu Leu
Ser 210 215 220 ctc aca gac ctg gct ctc agt tct acc act gtg ccc aag
atg ctg gcc 840 Leu Thr Asp Leu Ala Leu Ser Ser Thr Thr Val Pro Lys
Met Leu Ala 225 230 235 att ttg tgg ctc cat gct ggt gag att tcc ttt
ggt gga tgc ctg gcc 888 Ile Leu Trp Leu His Ala Gly Glu Ile Ser Phe
Gly Gly Cys Leu Ala 240 245 250 cag atg ttt tgt gtc cat tct atc tat
gct ctg gag tcc tcg att cta 936 Gln Met Phe Cys Val His Ser Ile Tyr
Ala Leu Glu Ser Ser Ile Leu 255 260 265 ctt gcc atg gcc ttt gat agg
tat gtg gct atc tgt aac cca tta agg 984 Leu Ala Met Ala Phe Asp Arg
Tyr Val Ala Ile Cys Asn Pro Leu Arg 270 275 280 285 tat aca acc att
ctc aac cat gct gtc ata ggc aga att ggc ttt gtt 1032 Tyr Thr Thr
Ile Leu Asn His Ala Val Ile Gly Arg Ile Gly Phe Val 290 295 300 ggg
cta ttc cgt agt gtg gct att gtc tcc ccc ttc atc ttc ttg ctg 1080
Gly Leu Phe Arg Ser Val Ala Ile Val Ser Pro Phe Ile Phe Leu Leu 305
310 315 agg cga ctc ccc tac tgt ggt cac cgt gtc atg aca cac aca tac
tgt 1128 Arg Arg Leu Pro Tyr Cys Gly His Arg Val Met Thr His Thr
Tyr Cys 320 325 330 gag cat atg ggc atc gcc cga ctg gcc tgt gcc aac
atc act gtc aat 1176 Glu His Met Gly Ile Ala Arg Leu Ala Cys Ala
Asn Ile Thr Val Asn 335 340 345 att gtc tat ggg cta act gtg gct ctg
ctg gcc atg gga ctg gat tcc 1224 Ile Val Tyr Gly Leu Thr Val Ala
Leu Leu Ala Met Gly Leu Asp Ser 350 355 360 365 att ctc att gcc att
tcc tat ggc ttt atc ctc cat gca gtc ttt cac 1272 Ile Leu Ile Ala
Ile Ser Tyr Gly Phe Ile Leu His Ala Val Phe His 370 375 380 ctt cca
tct cat gat gcc cag cac aaa gct ctg agt acc tgt ggc tcc 1320 Leu
Pro Ser His Asp Ala Gln His Lys Ala Leu Ser Thr Cys Gly Ser 385 390
395 cac att ggc atc atc ctg gtt ttc tac atc cct gcc ttc ttc tcc ttc
1368 His Ile Gly Ile Ile Leu Val Phe Tyr Ile Pro Ala Phe Phe Ser
Phe 400 405 410 ctc acc cac cgc ttt ggt cac cac gaa gtc ccc aag cat
gtg cac atc 1416 Leu Thr His Arg Phe Gly His His Glu Val Pro Lys
His Val His Ile 415 420 425 ttt ctg gct aat ctc tat gtg ctg gtg cct
cct gta ctc aat cct att 1464 Phe Leu Ala Asn Leu Tyr Val Leu Val
Pro Pro Val Leu Asn Pro Ile 430 435 440 445 ctc tat gga gct aga acc
aag gag att cgg agt cga ctt cta aaa ctg 1512 Leu Tyr Gly Ala Arg
Thr Lys Glu Ile Arg Ser Arg Leu Leu Lys Leu 450 455 460 ctt cac ctg
ggg aag act tca ata tga 1539 Leu His Leu Gly Lys Thr Ser Ile * 465
470
* * * * *